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Investigating T cell responses in HIV infection has revealed several correlates of viral 
control, but their importance is not fully understood. Further studies to understand the 
relationship between HIV and the immune system are warranted. The advent of 
polychromatic flow cytometry has allowed for in depth analysis of T cell functions and 
phenotypes in HIV infection, including the measurement of T cells that can produce 
multiple immune molecules simultaneously. The aim of this study was to develop a 
polychromatic flow cytometry panel to measure multiple functional markers, and 
optimise a stimulation and staining protocol for use in the laboratory. A flow cytometry 
panel measuring IFN-γ, IL-2, TNF-α and the degranulation marker CD107a was 
established. It was found that a stimulation time of 16 h and the use of both monensin and 
BFA protein transport inhibitors were required for optimal detection of the four 
functions. HIV-specific T cell responses were investigated in 20 chronically-infected 
individuals and 7 individuals with acute infection that were followed longitudinally over 
the first year of infection. HIV-specific CD8+ T cell responses were detectable in chronic 
infection, with CD8+ responses greater in magnitude and frequency than CD4+ responses. 
HIV-specific CD8+ T cells predominantly produced IFN-γ and degranulated, with a near 
complete absence of IL-2 and TNF-α production in chronic infection.  In contrast, HIV-
specific CD4+ T cells showed a broader cytokine repertoire, producing IFN-γ, TNF-α and 
IL-2, but rarely degranulating.  There were poor polyfunctional CD8+ and CD4+ T cell 
responses in chronic infection. In the acute cohort, a decline in polyfunctionality over the 
first year of infection was observed, consistent with observations from the chronic cohort.  
There was a greater magnitude of CD4+ T cell responses in acute infection compared to 
chronic infection, and a greater magnitude of CD8+ T cell responses in chronic infection 
compared to acute infection. In summary, it appears that HIV-specific T cell 
polyfunctional responses are lost early in infection, and this is most striking in the CD4+ 
T cell compartment. These results emphasize the importance of acute and longitudinal 
HIV studies to understand better the relationship between HIV and the immune system, 
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It has been more than 25 years since the human immunodeficiency virus (HIV) was 
discovered, yet there is still much that is unknown about the interactions between the 
virus and the human immune system. This interaction is important to understand for 
applying the knowledge to vaccine development, since vaccination may be the only 
hope for long-term control of the epidemic (as reviewed in Letvin, 2005). The 
unknown immunological factors involved in viral control impact both on effective 
vaccine development as well as vaccine evaluation.  
 
The interaction between HIV and the immune system has been extensively studied in 
order to determine which immune features correlate with HIV control. There are a 
number of immunological techniques available and as technology advances, more 
techniques are becoming accessible to researchers, thereby increasing our knowledge 
about HIV and the immune system. This review will discuss some of the 
immunological techniques used to measure immune responses to HIV and features of 
cellular immunity that have been implicated in the control of HIV. 
 
1.1 Techniques to measur  T cell responses 
 
A wide variety of immunological methods have been applied to measure T cell 
responses in HIV infection.  These techniques are reviewed briefly in this section and 
both the advantages and limitations of the assays are considered.  
 
The enzyme-linked immunospot (ELISPOT) assay has been widely applied to 
measure the frequencies of HIV-specific T cells (Edwards et al, 2002; Addo et al., 
2003; Kaufmann et al., 2004, Masemola, et al., 2004, Zuniga et al., 2006; 
Geldmacher et al., 2007a, 2007b; Gray et al., 2008). It is a sensitive and robust 
technique for the quantification of IFN-γ and has a high throughput as many peptides, 
or pools of peptides, can be screened at once and specific reactive peptides can be 











cell is unknown and the assay measures only a single function. Dual ELISPOTs that 
can measure IL-2 and IFN-γ simultaneously have been developed (Boulet et al., 
2007), although these are not in common use.  
 
Flow cytometry, similar to the ELISPOT assay, has been used to quantify HIV-
specific T cells (Betts et al., 2001, Ramduth et al., 2005). The power of flow 
cytometry is the fact that specific T cell phenotypic subsets can be identified in 
addition to measuring cytokine production. With the advent of polychromatic flow 
cytometry, allowing more than four markers to be measured, up to 17 markers can be 
evaluated (Perfetto et al., 2004), depending on the configuration and lasers of the 
cytometer utilised to acquire samples. Polychromatic flow cytometry has been used to 
quantify combinations of cytokines expressed from single cells (Betts et al., 2006), as 
well as identifying complex differentiation phenotypes of T cells (Duvall et al., 2008). 
One limitation of flow cytometry is that a large number of cells are required to 
measure combinations of cytokines reliably.   
 
Immune assays have been developed to measure cell functions such as proliferation 
and cytotoxicity (as reviewed by Hickling, 1998).  The advantage of these techniques 
is that rather than measuring surrogates of immunity, such as IFN-γ or CD107a, they 
measure functions of cells directly. Traditional assays used radioactive materials, such 
as the 51Cr-release assay, measuring cytotoxicity, and the 3H incorporation assay, 
measuring proliferation. Proliferation can also be assessed by flow cytometry using 
fluorescent dyes such as carboxyfluorescein succinimidyl ester (CFSE) (Younes et al., 
2003) and oregon green.  The nuclear protein Ki67 has also been used as an indication 
of cell division (Starr et al., 2002).  
 
For measuring cytotoxicity, several flow cytometry-based assays have been 
developed. Cytotoxic T lymphocytes (CTLs) are capable of mediating apoptosis of 
infected cells via cytotoxic molecules (as reviewed by Suni et al., 2005) and the 
Fas/Fas ligand-killing pathway (Bossi and Griffths 1999). These cytotoxic molecules 
can then be used as surrogate markers for the assessment of cytotoxicity. CTLs have 
lytic granules containing perforin and granzymes, which induce apoptosis (as 











granules also consist of granulysin, which is involved in lysis of cells. During 
cytolysis, the granule membrane fuses with the cell membrane and releases perforin 
and granzymes into target cells (Figure 1.1). Within the inner membrane of the 
granule are the proteins CD107 and CD63, and during the fusion process, CD107 is 
transiently expressed on the cell surface. CD107 is used as a marker for degranulation 
and hence an indirect measure of cytotoxic activity (Betts et al., 2003). The lysosomal 
membrane protein, CD63 (LAMP-3), is also expressed on the cell surface during the 
degranulation process (Peters et al., 1991). However, the expression of CD63 was 
either negative or low compared to CD107a and CD107b in SEB-stimulated CD8+ T 
cells, and the background for CD63 was greater compared to CD107a and CD107b 
(Betts et al., 2003). Thus, it appears that CD107a and CD107b are more reliable 
markers for degranulation compared to CD63. CD107a, perforin and granzymes have 




Figure 1.1: The cytolytic molecules expressed during degranulation (taken from Suni 
et al., 2005). 
 
Another recent technique that has now become more widely available is the 
measurement of a vast array of analytes by cytokine bead array (CBA) and the 
Luminex system (duPont et al., 2005). Traditionally, soluble analytes secreted from 
stimulated cells were measured using enzyme-linked immunosorbent assays 











volume and single analytes are measured (Aziz et al., 1999). The Luminex system, 
however, allows for a greater throughput using a small sample volume, by using 
antibody-conjugated beads that are specific for each analyte in the Luminex system, 
and a secondary enzyme conjugated to a fluorophore, which fluoresces at different 
intensities to distinguish between the analytes. The samples are read on a bio-plex 
suspension array reader. Standards are also run in conjunction with samples so 
analytes of interest can be quantified. The advantage of this technique is that up to 42 
analytes (Millipore, Multiplex Kit) can be measured per sample, and may include 
those rarely measured in other assays, such as Eotaxin, FGF-2 (Fibroblast Growth 
Fatcor-2), IP-10 (Interferon-Inducible Protein), MCP-1 (Monocyte Chemotactic 
Protein-1), and VEGF (Vascular Endothelial Growth Factor).  The Luminex system 
has been used to evaluate twenty analytes in lymph nodes of HIV-infected individuals 
(Biancotto et al., 2007). A limitation of this procedure is that the analytes quantified 
may be produced by any cell type in the population, i.e. not necessarily T cells, thus 
the disadvantage is that the phenotype of the responding cells can not be identified.  
 
The viral inhibition assay is another technique which measures the ability of CTLs to 
inhibit viral replication (Kimberlin et al., 1995). It is an even more direct measure of 
antiviral function than the cytotoxicity assay. Briefly, cells infected with viral 
particles are incubated with effector cells, and the viral RNA is quantitated from the 
supernatant. It has been observed that epitope-specific CD8+ T cell clones from SIV 
elite controllers were able to suppress SIV replication, and this suppression was not 
always linked to the production of cytokines (IL-2, TNF-α and IFN-γ) that are 
commonly measured (Chung et al., 2007). Therefore, measuring these cytokines may 
not reveal antiviral functioning, thus emphasizing the importance of using assays that 
measure functions directly. 
 
A number of factors in immunological assays may influence assay outcome. These 
include sample choice (peripheral blood mononuclear cells or other tissues), 
cryopreserved materials, and type of stimuli. Human T cell studies are performed in 
vitro in defined experimental conditions and results obtained might not accurately 












Measurement of HIV-specific T cell responses have been extensively studied using 
peripheral blood mononuclear cells (PBMCs). PBMCs can easily be extracted from 
blood samples and obtaining blood samples from participants is less invasive than 
many other tissues. Thus, PBMCs allow for the characterisation of circulating T cells, 
but may not be an accurate description of what is happening in other compartments of 
the body that may be important in HIV pathogenesis, such as the gut (Brenchley et al., 
2004). PBMCs may be cryopreserved, and multiple samples can then be thawed and 
assayed simultaneously.  However, cryopreservation can lead to loss of CD4+ T cell 
responses with samples cyropreserved for more than a year (Owen et al., 2007). 
Therefore, investigating CD4+ T cell responses from samples frozen for more than a 
year may underestimate responses.  
 
In the HIV immunology field, synthetic overlapping peptides are commonly used as 
antigen to stimulate T cells. Overlapping peptides of 15-18 amino acids are generally 
used, with each peptide overlapping the adjacent one by 10-12 amino acids, to ensure 
that no epitopes are lost. Peptides of longer lengths tended to detect more CD4+ T cell 
responses, but this was not significantly different compared to shorter peptides 
(Draenert et al., 2003). It is also important to note that these peptides are synthesized 
primarily based on consensus sequences. A study by Altfeld et al (2003) showed that 
using autologous peptides increased the likelihood of detecting responses by 29 %, 
and this was especially true for more variable proteins such as Tat and Vpr (Altfeld et 
al., 2003). Thus, it is likely that consensus peptides may underestimate the breadth 
and total magnitude of responses to HIV.  
 
In summary, since the discovery of HIV in the early 1980’s, there have been many 
advances in understanding the immune response to HIV. This knowledge has been 
greatly enhanced with new technologies being developed as well as improvements on 
existing assays.    
 
1.2 The characteristics of HIV-specific T cell responses  
 
Studies have investigated the nature of HIV-specific T cell responses that may play a 
role in viral control, by determining phenotypic and functional characteristics of these 











do persist in HIV infection, however immunity is either insufficient or impaired, 
leading to AIDS in the majority of cases if left untreated. It is however relevant to 
investigate T cell functioning in HIV infection due to two significant early findings. 
Firstly, depletion of CD8+ T cells in SIV-infected macaques during acute infection 
resulted in uncontrolled viremia and rapid progression of disease (Schmitz et al., 
1999) and secondly, the initial decline in viremia in acute infection is associated with 
a concomitant increase in T cell responses (Koup et al., 1994).  What we know about 
the immune T cell features that do (and do not) correlate with viral control will be the 
focus of this review.  
 
1.2.1 The magnitude and breadth of IFN-γ HIV-specific T cell responses 
 
Initial studies to elucidate correlates of viral control focused on defining the 
magnitude and breadth of IFN-γ  T cell responses.  IFN-γ  is a TH 1 cytokine that is 
key for cell-mediated immunity (as reviewed in Schroder et al., 2004).  It is an 
antiviral cytokine that induces a number of anti-viral proteins (such as Mx, dsRNA 
protein kinase, ribonucleic acid nuclease, and nitric oxide), which in turn inhibit viral 
replication, degrade single stranded RNA, and inhibit protein synthesis (as reviewed 
in Chesler et al., 2002). IFN-γ has been implicated in the control of viral infections, 
such as herpes simplex virus (HSV), measles virus, vesticular stomatitis virus and 
LCMV (Lymphocytic Choriomeningitis virus; Cantin et al., 1999; Chesler et al., 
2002). Due to the vital role it plays in controlling these viral infections, its role in HIV 
infection has been investigated.  
 
Characterising HIV-specific T cell responses using the IFN-γ ELISPOT assay has 
been the focus of numerous studies (Edwards et al, 2002; Addo et al., 2003; 
Kaufmann et al., 2004, Masemola, et al., 2004, Zuniga et al., 2006; Geldmacher et 
al., 2007a, 2007b; Gray et al., 2008). HIV-specific T cell responses have also been 
evaluated by intracellular cytokine staining (ICS) and flow cytometry (Betts et al., 
2001; Boaz et al., 2002; Ramduth et al., 2005). HIV-specific T cells can accumulate 
to high numbers in chronic infection, ranging from 280 to 25,860 spot-forming cells 
(SFC)/106 (median = 4245 SFC/106), where each spot represents an HIV-specific T 











different HIV proteins in a whole genome analysis, with an average of about 15 
epitopes (range of 2 to 42 epitopes; Addo et al., 2003). 
 
Flow cytometry studies have revealed that both CD4+ and CD8+ T cells are capable of 
producing IFN-γ in response to HIV proteins (Betts et al., 2001; Ramduth et al., 2005; 
Boaz et al., 2002), and that the magnitudes of HIV-specific CD4+ and CD8+ T cells 
positively correlated (Ramduth et al., 2005). However, the magnitude and frequency 
of HIV-specific CD8+ T cells were greater compared to HIV-specific CD4+ T cells 
(Betts et al., 2001; Ramduth et al., 2005). Whole HIV genome analysis illustrated that 
all HIV proteins are targeted, although Gag and Nef are the most commonly 
recognized for both T cell compartments (Betts et al., 2001; Ramduth et al., 2005, 
Addo et al., 2003; Kaufmann et al., 2004; Zuniga et al., 2006; Masemola et al., 2003).  
 
Correlations of viral load and CD4+ counts with the magnitude and breadth of IFN-γ 
T cell responses have given conflicting results. No corr lation was observed between 
the magnitude (Addo et al., 2003; Kaufmann et al., 2004, Ramduth et al., 2005) and 
breadth (Addo et al., 2003; Kaufmann et al., 2004; Masemola et al., 2004) of total 
HIV-specific T cell responses in both CD8+ and CD4+ T cells and viral load, when the 
entire HIV genome was analysed. In contrast, a positive correlation was found 
between the total HIV-specific CD8+ T cell frequency and viral control, which was 
determined by flow cytomet y, in which the IFN-γ responses were evaluated in 
untreated HIV-infected individuals (Betts et al., 2001). The authors concluded that 
this was a result of viral load driving T cell responses. Similarly, a positive correlation 
between total magnitude of HIV-specific CD8+ T cell responses and viral load was 
also observed in untreated HIV-infected individuals by an IFN-γ ELISPOT assay 
(Masemola et al., 2004). Thus, magnitude or breadth of total HIV-specific T cells 
does not appear to control viral replication, but merely reflect the high antigen burden. 
 
Important insights have been revealed when examining the specificity of T cell 
responses. Studies have shown the importance of Gag-specific T cell IFN-γ responses 
in the control of viral load in chronic infection. A greater breadth of Gag-specific T 
cell IFN-γ responses inversely associated with decreasing viremia (Kiepiela et al., 











IFN-γ responses positively correlated with CD4+ counts (Edwards et al, 2002; 
Geldmacher et al., 2007a). In addition to this, it has been revealed that the preferential 
targeting of Gag (i.e. when the Gag protein is the dominant T cell target) inversely 
correlates with viral control  (Ramduth et al., 2005; Masemola et al., 2004; Zuniga et 
al., 2006), in particular Gag protein p24 (Zuniga et al., 2006).  Thus, when Gag is the 
preferred target of CD8+ T cells, as measured by IFN-γ production, there is a 
significant association with viral control.  
 
HIV-specific T cell responses evaluated in the above-mentioned studies consisted of 
cross-sectional studies in chronic infection. A recent study followed chronically HIV-
infected untreated individuals for nine months and evaluated the dynamics of Gag-
specific IFN-γ T cell responses using the ELISPOT assay (Geldmacher et al., 2007b). 
This study revealed that the magnitude and breadth of HIV-specific T cell responses 
was influenced by time post infection, with longer time of infection correlating with a 
loss in Gag responses.  Furthermore, high baseline viral loads and sustained viral 
replication led to a loss of responses.  Thus, previous cross-sectional studies 
indicating that Gag responses are important for viral control may merely have 
reflected the duration of infection and persisting viremia, leading to escape and 
exhaustion and therefore loss of Gag responses in individuals with higher viral loads.  
Examining HIV-specific T cell functioning during acute infection can also give 
valuable insights into the interaction between the immune response and HIV. The 
magnitude and breadth of early HIV-specific T cell IFN-γ responses, at 3 months post 
infection, did not correlate with viral load at 12 months post infection (Gray et al., 
2008). Thus, it was concluded that early HIV-specific T cell IFN-γ  responses were 
also not playing a role in viral control. 
 
In summary, the numerous studies indicate that control of HIV infection cannot be 
explained merely by measuring HIV-specific CD4+ or CD8+ T cell IFN-γ responses, 
and that neither the breadth nor magnitude of IFN-γ production alone is associated 
with viral control, and thus may not be involved in the control of viral replication. An 













1.2.2 The influence of host genetics in HIV infection 
 
As discussed in previous section, HIV-specific T cell responses were shown to lack 
the ability to control viral replication and hence clear infection. One reason for the 
lack of viral control may be because HIV continually mutates and evolves, due to 
significant pressure from the immune system (Leslie et al., 2004), thereby allowing it 
to evade the immune system (Goulder et al., 2001). Certain human leukocyte antigens 
(HLAs) have been identified to be associated with either good or poor outcome of 
HIV disease (Table 1.1).  However, viral immune escape may be at a fitness cost to 
the virus, which has been observed in the Gag-epitope TW10 (Leslie et al., 2004). 
Gag is a highly conserved protein and forms the viral capsid. Integrity of the capsid is 
vital for viral productivity and when certain regions are targeted by epitope responses, 
viral replication may be negatively influenced, resulting in low viral loads, or viral 
escape that exacts a fitness cost. There are also HLA alleles in which escape rarely 
occurs, as in the case of HLA-B27 restricting the Gag epitope, KK10, in which escape 
resulted only after 9 years of infection, followed by progression to AIDS occurred 
(Goulder et al., 1997).  
 
Table 1.1: HLA Class I and II alleles associated with HIV disease outcome 
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1.2.3 Interleukin 2 (IL-2) and proliferation of HIV-specific T cells 
 
T cells produce a variety of cytokines and effector molecules besides IFN-γ, such as 
IL-2, IL-6, MIP-1β and TNF-α, IL-17, IL-15 and perforin, just to name few, which 
play a role in immune function (as reviewed in Ma et al., 2006). IL-2 is one of the 
primary cytokines that CD4+ T cells secrete upon antigen recognition (Lichterfeld et 
al., 2004). It is a growth factor for antigen-specific cells, and is responsible for their 
proliferation. In mouse studies, CD4+ T cells are crucial for the development of 
memory CD8+ T cells (Janssen et al., 2003; Shedlock et al., 2003; Sun et al., 2004), 
and this has also been observed in HIV infection (Lichterfeld et al., 2004).  
 
The ability of CD4+ T cells to secrete IL-2 or both IL-2 and IFN-γ has been shown to 
inversely correlate with viral control in chronic HIV infection (Harari et al., 2004).  In 
these individuals, the frequency of Gag-specific IL-2+, IL-2+ IFN-γ+ and total IL-2+ 
secreting CD4+ T cells all inversely correlated with viral control, as detected by ICS 
and flow cytometry.  Individuals that had progressive infection were shown to have a 
dominant CD4+ IFN-γ+ response compared to individuals with non-progressive 
disease, who produced IL-2. Similar results have been obtained in long term non-
progressors (LTNPs) (Rosenberg et al., 1997; Boaz et al., 2002). LTNPs are 
individuals that control HIV replication in the absence of treatment and are able to 
sustain normal CD4+ counts and maintain low viral loads for long periods (Rosenberg 
et al., 1997). These studies have shown that Gag-specific CD4+ T cells producing 
IFN-γ and IL-2 inversely correlated with viral load in LTNPs. The presence of SIV-
specific T cells secreting both IFN-γ and IL-2 was also associated with long term 
control of infection in vaccinated and SHIV-challenged macaques, demonstrating that 
this type of immune response is also important in viral control in a vaccine setting 
(Sadagopal et al., 2005). 
 
IL-2 can be used as a surrogate marker for proliferation, since a direct correlation 
between IL-2 secretion and HIV-specific proliferation was observed (Harari et al., 
2004). The ability of both HIV-specific CD4+ and CD8+ T cells to proliferate has been 
implicated in the control of viral replication (Rosenberg et al., 1997; Kalams et al., 











CD4+ T cell proliferative responses have not only been observed in LTNPs 
(Rosenberg et al., 1997), where viral loads are low to undetectable, but also in chronic 
HIV infection (Kalams et a., 1999; Boritz et al., 2004). These studies illustrated that 
there was an inverse correlation between viral load and Gag-specific CD4+ T cell 
proliferative responses. HIV-specific CD8+ T cell proliferative responses have also 
been shown to inversely correlate with viral load in a large cohort of chronically 
infected, untreated individuals (Day et al., 2007). This highlights the importance of 
HIV-specific T cell proliferation HIV viral control.  
 
Several investigations have revealed that viremic subjects show proliferative 
impairment (McNeil et al., 2001; Palmer et al., 2002; Younes et al., 2003; Iyasere et 
al., 2003). Viral load appears to play an important role in immune function and 
influencing proliferation in a negative manner. HIV-infected, treated individuals had 
detectable HIV-specific CD4+ T cell proliferation, however, when treatment was 
interrupted and viral load increased, these HIV-specific proliferative responses 
decreased, even in the presence of sustained IFN-γ responses (McNeil et al., 2001) 
which was also observed for HIV-specific CD8+ T cells (Younes et al., 2003). This 
loss of proliferation in response to HIV could then be restored when viral replication 
was controlled again due to treatment (McNeil et al., 2001; Palmer et al., 2002). 
Besides antiviral therapy, defects in proliferation can be corrected in vitro by the 
addition of exogenous IL-2 (Iyasere et al., 2003) or autologous IL-2 secreting CD4+ T 
cells (Lichterfeld et al., 2004).   
 
Thus, studies have shown the importance of IL-2 production and HIV-specific 
proliferation of T cells with viral control in HIV infection, however during chronic 
infection, high viral loads appear to impair the proliferative function of T cells.  
 
1.2.4 Cytotoxic activity of T cells 
 
As discussed earlier, CD8+ T cells have the ability to kill infected cells. Thus, this 
function in HIV infection has been investigated. Cytotoxic CD8+ T cells have been 
measured in several studies in HIV infection (Appay et al., 2000; Kuerten et al., 2008; 











perforin and granzymes, however, the cytolytic response appears to be impaired, as 
HIV-specific CD8+ T cells produce significantly lower levels of perforin in chronic 
infection compared to CMV-specific CD8+ T cells (Appay et al., 2000). This may be 
due to constant exposure to antigen during chronic infection, leading to impairment in 
cytotoxic function. In the same study, lower levels of perforin were also found in 
ARV-naïve individuals who controlled viral load and chronically infected subjects on 
HAART (highly active antiretroviral therapy) who suppressed viral load, compared to 
higher Cytomegalovirus (CMV)-specific CD8+ T cell perforin levels (Appay et al., 
2000). Thus, regardless of viral loads, in HIV-infected individuals CD8+ T cells 
appear to produce lower levels of perforin, which cannot be restored with HAART. In 
contrast, HIV-specific CD8+ T cell proliferation in LTNPs was related to greater 
expression of perforin, compared to progressors (Migueles et al., 2002). However, 
this may have been the result of stimulating these samples with autologous CD4+ T 
cells, resulting in expansion of cells and an increase in perforin expression. The 
increase in perforin expression was not observed in HIV-infected progressors in 
which only a small portion of cells were capable of proliferating. In terms of viral 
control, cytotoxic function in chronically -infected and untreated individuals was 
shown to have no correlation with viral load (Day et al., 2007). In this study, 
cytotoxic function was measured by CD107a expression on antigen-stimulated CD8+ 
T cells, and may not necessarily be an accurate measurement of cytotoxic function as 
compared to measuring perforin and granzymes.    
 
Interestingly, CD4+ T cell cytotoxicity has been documented in several infections, 
such as hepatitis B, C and D and Cryptococcus neoformans infections (Aslan et al., 
2006; Zheng et al., 2007).  Cytotoxic CD4+ T cells were shown to be the major subset 
for killing Cryptococcus neoformans infected cells. In HIV infection, it was observed 
that CD4+ cytotoxic T cells produce perforin (Appay et al., 2002a). However, HIV-
specific CD4+ cytotoxicity was impaired in terms of perforin and granulysin 
expression (Zheng et al., 2007). In a single LTNP, perforin-mediated CD4+ T cell 
cytolysis exerted potent viral suppression (Norris et al., 2004). Although there are a 
limited number of studies, it appears that HIV-specific CD4+ cytotoxicity is perforin 












These studies provide insight into cytotoxic function and suggest that it too, like 
proliferative ability, is impaired in HIV infection.  Further studies investigating CTL 
functioning for both CD8+ and CD4+ T cells are still required for a complete analysis 
of markers that are expressed during cytotoxicity, such as perforin, granzymes, 
granulysin, and CD107a. 
  
1.2.5 Polyfunctional T cell responses 
 
T cells are capable of secreting a broad range of cytokines and chemokines. Cells that 
produce multiple cytokines simultaneously have been termed ‘polyfunctional’. 
Increasingly, immune studies are investigating polyfunctional T cell responses to a 
variety of diseases, including Leishmania, hepatitis C, tuberculosis, CMV, SARS 
coronavirus (Darrah et al., 2007; Ciufredda et al., 2008; Day et al., 2008; Fuhrmann 
et al., 2008; Arens et al., 2008; Li et al., 2008), as well as in vaccine evaluation 
(Darrah et al., 2007; Genesca et al., 2007; Sun et al., 2008; Beveridge et al, 2007; 
Bansal et al., 2008). Gradually more evidence is accumulating that illustrates that the 
presence of these cells is associated with HIV non-progression (Betts et al., 2006; 
Kannanganat et al., 2007b; Duvall et al., 2008). It is important to note how vital the 
development of polychromatic flow cytometry is for allowing measurement of 
polyfunctional T cells. 
 
1.2.5.1 Polyfunctional T cells as a correlate of protection  
 
Recently, T cell polyfunctionality has been implicated in viral control. However it is 
still not known whether the presence of polyfunctionality is a result of low viremia, or 
the cause of control of viral replication. A study conducted by Betts et al. (2006) 
evaluated whether polyfunctionality correlated with viral control. Chronically-
infected and elite HIV controllers were characterized for their HIV-specific CD8+ T 
cell responses, by measuring five T cell functions, namely degranulation (CD107a 
expression), IL-2, IFN-γ, TNF-α and MIP-1β. It was found that the frequency of 
HIV-specific CD8+ T cells with the greatest amount of polyfunctionality (CD8+ T 
cells producing all five functions) inversely correlated with viral control in the elite 











specific CD4+ T cells secreting three cytokines (IL-2, IFN-γ and TNF-α) were shown 
to correlate inversely with viral control in subjects that controlled infection compared 
to non-controllers (Kannanganat et al., 2007b).  This highlights the importance of not 
only CD8+ but also CD4+ polyfunctional T cells in the control of HIV infection. There 
is also evidence that suggests that the presence of polyfunctional memory T cells is 
associated with HIV-2 infection, which is characterised by low viral loads and slow or 
no progression to AIDS (Duvall et al., 2008). It was observed that both HIV-2 
specific memory CD4+ and CD8+ T cells were more polyfunctional compared to both 
HIV-1 specific memory CD4+ and CD8+ T cells. However, it is crucial to note that in 
the above-mentioned studies, cohorts in which polyfunctionality was associated with 
HIV nonprogression consisted of individuals that were characterised by low to 
undetectable viral loads, thus the results obtained could be a consequence of low viral 
loads rather than a correlate of control.  
 
Two studies have performed longitudinal analyses to evaluate T cell functionality as 
the cause or consequence of viral load. Chronically-infected individuals that had 
started ARVs were followed for 3 months (Rehr et al., 2008). Initially plasma viral 
loads were high and CD8+ T cell cytokine production was limited to IFN-γ. However, 
after 3 months on therapy, plasma viral loads decreased significantly and IL-2 and 
TNF-α production significantly increased. It was also shown that polyfunctional T 
cells were present more frequently 3 months after initiation of therapy compared to 
baseline. Further evidence to support this comes from a study in which individuals 
that received ARVs and then reduced antigen loads were shown to either partially 
restore or maintain functionality (Streeck et al., 2008). Here, HIV-specific CD8+ T 
cells had diverse functions, such as the ability to degranulate and produce IL-2, IFN-γ, 
TNF-α and MIP-1β during primary infection. However, monofunctionality increased 
after primary infection in untreated HIV infection. This loss in functionality was not 
observed for CMV, EBV (Epstein Barr virus) and influenza-specific CD8+ T cells in 
the same individuals. This suggests that the impairment in T cell function may be a 
consequence of ongoing viral replication from acute to chronic HIV infection.  
 
Vaccine-induced polyfunctional T cells have been shown to correlate with protection 











al., 2008). Smallpox has been eradicated due to immunization with vaccinia virus. 
What made this vaccine so successful? One reason could be the fact that this vaccine 
induces highly polyfunctional CD8+ T cells which are capable of degranulation and 
secreting IL-2, IFN-γ, MIP-1β and TNF-α after antigenic stimulation (Precopio et al., 
2007). Leishmania species are protozoans, which cause skin and mucosal diseases in 
humans as well as other vertebrates (as reviewed in Melby, 2002). In mouse studies, 
immunization with leishmania polyprotein induced polyfunctional CD4+ T cells that 
were capable of producing IL-2, IFN-γ and TNF-α simultaneously (Darrah et al., 
2007). The frequency of the triple-producing CD4+ T cells inversely correlated with 
lesion size, indicating that these cells were involved in the reduction of lesions, whilst 
single cytokine producing cells were not involved with protection. 
 
Similarly, a protective role of vaccine-induced polyfunctional T cells has been 
observed in SHIV (Sun et al., 2008) and SIV (Genesca et al., 2008) vaccine studies. 
Rhesus macaques vaccinated with live attenuated SHIV 89.6 and challenged with 
SIVmac239 who controlled virus replication compared to those that were unable to 
control viral replication had polyfunctional SIV-specific CD8+ T cells (Genesca et al., 
2008). Additionally, rhesus macaques vaccinated with various vectors and challenged 
with pathogenic SHIV-89.6 were shown to have a better disease outcome due to 
vaccine-induced polyfunctional CD8+ T cell responses compared to non-vaccinated 
macaques (Sun et al., 2008). Thus, vaccine-induced polyfunctional T cells appear to 
play a role in disease progression.  Some candidate HIV vaccines are also capable of 
eliciting polyfunctional CD4+ and CD8+ T cells, such as a DNA prime/poxvirus boost 
vaccination strategy (Harari et al., 2008) and similarly, an HIV DNA prime/Env 
protein boost vaccine strategy, that elicited polyfunctional HIV-specific CD4+ T cell 
responses in seronegative individuals (Bansal et al., 2008). While these candidate 
vaccines appear promising since they elicit polyfunctional T cells, only efficacy 
studies will reveal whether they do indeed provide protection from HIV infection or 
better disease outcome.   
 
It therefore appears that polyfunctional T cell responses may be impaired in HIV 











function. Polyfunctional T cells can be induced by vaccination, however their 
protective function has yet to be determined.  
 
1.2.5.2 Presence of polyfunctional T cells in different compartments 
 
As mentioned earlier, HIV-specific T cell responses have been investigated primarily 
in blood. There have been few studies that have looked at other compartments in the 
human body, such as lymphoid or mucosal tissues, due to the obvious difficulty of 
sampling these sites. Polyfunctional HIV-specific T cells were shown to be present at 
mucosal sites such as bronchoalveolar lavage (lung tissue) and the rectum in untreated 
individuals (Brenchley et al., 2007; Critchfield et al., 2007). 
 
In the first study, it was shown that both HIV-specific CD4+ and CD8+ polyfunctional 
T cells (cells producing IL-2, IFN-γ and TNF-α) were present at a higher frequency in 
lung tissue compared to blood, which may be due to less depletion of CD4+ T cells in 
the lung tissue, even though infection frequencies were similar to blood (Brenchley et 
al., 2007). Therefore, preservation of HIV-specific CD4+ T cells was associated with 
polyfunctionality. However, in rectal tissue, no differences were seen in Gag-specific 
polyfunctional CD8+ T cell responses (CD107a+IFN-γ+TNF-α+) compared to blood in 
chronic infection, even though there was a greater magnitude of CD8+ T cell 
responses in rectal tissue (Critchfield et al., 2007). This work was then extended to 
investigate two additional markers, IL-2 and MIP-1β, in a chronically infected cohort 
(Critchfield et al., 2008). Here, it was shown that rectal tissue in treated and untreated 
individuals had polyfunctional Gag-specific CD8+ T cell responses. These responses 
were also shown to inversely correlate with plasma viral load and positively with 
blood CD4+ counts.  These results indicate the presence of polyfunctional cells at 
mucosal sites.  
 
1.2.5.3 Polyfunctional T cells are superior effectors 
 
Why might polyfunctional cells be superior effectors? Recent studies have shown that 
polyfunctional T cells are capable of producing more cytokine per cell than a 











Kannanganat et al., 2007a; Duvall et al., 2008). This was determined by obtaining the 
median fluorescence intensity (MFI) of the cytokine population, since the 
fluorescence intensity is related to the amount of cytokine produced within an 
individual cell. Polyfunctional CD8+ T cell responses induced by vaccinia virus, the 
smallpox vaccine, secrete more cytokine per cell compared to monofunctional cells 
(Precopio et al., 2007).  In this study, the CD8+ IFN-γ MFI of four populations was 
determined (four+, three+, two+ and one+ cytokine producing cells). The MFI of IFN-γ 
was the highest in the three+ polyfunctional population and lowest in the 
monofunctional population. This suggests that these are superior effector cells that 
may be involved in viral control. This result was not observed for the other cytokines, 
IL-2 and TNF-α, and chemokine, MIP-1β.  
 
In agreement with these results, mice vaccinated with leishmania polyprotein 
generated polyfunctional CD4+ T cells that were producing more IFN-γ, IL-2 and 
TNF-α compared to single-cytokine secreting cells (Darrah et al., 2007). This was 
observed in the spleen, lymph node and lungs of these mice. The IFN-γ MFI inversely 
correlated with lesion size, thus supporting the idea that these polyfunctional cells are 
indeed superior in terms of function and controlling infection. The ability of 
polyfunctional CD4+ T cells to secrete more cytokine per cell was also found in 
healthy individuals that either had vaccinia virus, CMV or influenza responses 
(Kannanganat et al., 2007a). Additionally, HIV-2-specific CD4+ and CD8+ 
polyfunctional T cells (four+ and three+) were also capable of secreting more IFN-γ 
and TNF-α compared to monofunctional cells (Duvall et al., 2008). 
 
Interestingly, triple and dual-cytokine producing CD4+ T cells from healthy 
individuals that either had vaccinia virus, CMV or influenza responses showed 
increased levels of CD40 ligand (CD40L) compared to monofunctional cells 
(Kannanganat et al., 2007a). CD40L is a co-stimulatory molecule for CD8+ T cells 
(Bennett et al., 1998) and B cells (Foy et al., 1993). This indicates that multiple 













These studies demonstrate that polyfunctional T cells are important in protection of 
certain infections, and are superior in terms of their function as they are more efficient 
effectors compared to monofunctional T cells, due the fact that they secrete more 
cytokine per cell and may better activate CD8+ T and B cells.  
 
1.2.6 T cell differentiation in HIV infection 
 
Upon antigen stimulation, T cells proliferate and mature and differentiate into 
specialised subsets that can be identified by expression of different surface markers, 
as well as being defined by particular functions that they possess. Thus cellular 
phenotype is linked to function. Therefore it is relevant to investigate T cell 
differentiation in HIV infection to determine whether there are particular subsets of 
cells that are involved in viral control. 
 
1.2.6.1 What are Memory T cells? 
 
Memory T cells are cells that have differentiated and matured to perform their 
functions and hence are distinct from naïve (and effector) T cells. This differentiated 
state can be used to identify them based on expression of certain surface markers. 
Two major memory subsets have been defined (Sallusto et al., 1999), but recent work 
reveals that memory phenotypes are highly complex (as reviewed in Wherry and 
Ahmed, 2004). Different isoforms of CD45 are expressed when T cells differentiate 
(Michie et al., 1992). Naïve and terminally differentiated effector T cells express 
CD45RA+ (as reviewed by Esser et al., 2003), whereas memory T cells lose the 
expression of this marker to become CD45RA- and instead express CD45RO. The 
two major memory subsets are: central memory (Tcm) and effector memory (Tem) T 
cells which occur in both CD4 and CD8 compartments (Sallusto et al., 1999). 
Memory T cells form a unique subset due to the expression of specific markers, 
chemokines and adhesion molecules, and are responsible for a rapid and enhanced 
response upon subsequent encounter with antigen.  
 
Central memory cells are the long-lived memory cells and secrete IL-2 (as reviewed 
by Esser et al., 2003). They are found in lymph nodes due the expression of CD62L, 











expressing the chemokine receptor CCR7 to bind to secondary lymphoid tissue 
chemokine (SLC) and re-circulate between blood and lymph nodes (Sallusto et al., 
1999). It is well accepted that Tcm may be identified on the basis that they are 
CD45RA-/ CD62Lhi/CCR7+ (Figure 1.2)   
 
According to the linear model of T cell differentiation, at encounter with a respective 
antigen, Tcm differentiate into effector memory T cells (Tem) by losing the expression 
of CCR7 (and therefore the ability to migrate to lymph nodes) and become CD62Llo 
(Sallusto et al., 1999). Tem are thus identified as CD45RA-/ CD62Llo/CCR7- (Sallusto 
et al., 1999; Figure 1.2). Other markers that can be used to distinguish Tcm from Tem 
cells are CD28 and CD27 (as reviewed in Esser et al., 2003; Hamman et al., 1997). 
CD27 and CD28 are co-stimulatory receptors and the expression of CD28 and then 
CD27 are lost as T cells differentiate (Appay et al., 2002b). Effector and Tem cells are 
short lived and they perform a rapid effector function upon re-infection, and hence are 
found in peripheral blood sites of inflammation and in tissues. 
 
There are additional T cell markers that have been used to identify and characterise 
memory T cells, such as CD57 and CD127 (as reviewed in Ma et al., 2006). CD127 is 
a marker for long-term memory since it confers sensitivity to IL-7 and therefore 
homeostatic survival. CD57 is used to identify senescent T cells, i.e. cells that can no 
longer divide and are therefore short-lived (Brenchley et al., 2002). Telomeres are 
sequences at the ends of chromosomes, which shorten with each round of cell division 
(as reviewed in Akbar and Fletcher, 2005; Harley 1990), thus the length of telomeres 
in combination with phenotypic markers have been used to identify T cell 
differentiation subsets (Dunne et al., 2002), since the lengths of telomeres decrease as 














Figure 1.2: T cell differentiation from naïve to memory cells. The markers that are 
expressed for a particular subset are shown (taken from Akbar and Fletcher, 2005). 
 
1.2.6.2 Current literature on T cell differentiation in HIV infection  
 
In HIV infection, it appears that the immune system is constantly activated, which 
leads to exhaustion and dysfunction and ultimately progression to AIDS (Papagno et 
al., 2004). This link between exhaustion and disease progression is not clearly 
understood and studies have attempted to evaluate the differentiation status of T cells, 
particularly HIV-specific T cells, in HIV-infected individuals. This section will 
summarise the literature surrounding T cell differentiation in HIV infection. 
 
It was observed that during untreated HIV infection, HIV-specific CD8+ T cells were 
dominated by the effector memory phenotype (CD45RA-CCR7-) compared to CMV-
specific CD8+ T cells, which were terminally differentiated (CD45RA+CCR7-) 
(Champagne et al., 2001). This skewing towards an effector memory phenotype has 
also been observed for HIV-specific CD4+ memory T cells were (Tilton et al., 2007). 
These observations suggest that an incomplete maturation phenotype occurs for HIV-
specific T cells that may be dysfunctional. Furthermore, a greater frequency of HIV-
specific effector memory CD8+ T was observed in controllers compared to untreated 
progressors (Addo et al., 2007). An inverse correlation was observed between HIV-











set point associated with the presence of HIV-specific CD8+ T effector memory T 
cells (Northfield et al., 2007). Thus, the presence of these terminally differentiated 
cells is associated with a better disease outcome. 
  
It appears that the maintenance of Tcm may be a correlate of protection in HIV 
infection, as the percentage of HIV-specific CD4+ Tcm cells were greater in HIV 
controllers compared to viremic individuals or those on treatment, respectively (Potter 
et al., 2008).  This finding was also true for total CD4+ Tcm cells, where reduced 
levels of total CD4+ Tcm cells were associated with higher viral loads (Ladell et al., 
2008). Elite controllers were shown to have preserved total CD4+ Tcm cells compared 
to HIV-infected treated individuals (van Grevenynghe et al., 2008). Thus, in HIV 
infection, HIV-specific and total CD4+ Tcm cell phenotypes associated with HIV non-
progression.  
 
The relevance of SIV-specific and total CD4+ Tcm cells has also been investigated in 
SIV-infected (Ling et al., 2007) and vaccinated macaques (Sun et al., 2005; Letvin et 
al., 2006, Mattapalli et al., 2006; Manrique et al., 2008). SIV-specific CD4+ Tcm 
preservation can be induced through vaccination which leads to better survival and 
slower disease progression (Sun et al., 2005; Letvin et al., 2006, Mattapalli et al., 
2006; Letvin et al., 2006; Manrique et al., 2008). The preservation of SIV-specific 
CD8+ Tcm cells were also shown to be associated with delayed disease progression 
(Sun et al., 2006). Thus, these studies illustrate the importance of preservation of Tcm 
cells. 
  
In addition to memory markers, there are other markers that have been used to 
investigate T cell differentiation in HIV infection. Total CD4+ T cells that were 
CD127-/CD25- i.e. not long-lived cells, were related to the decline of total CD4+ naive 
and Tcm cells, and CD127-/CD25- CD4+ T cells correlated inversely with CD4+ counts 
(Dunham et al., 2007). Similarly, it was observed that HIV-specific CD8+ T cells 
express lower levels of CD127 compare to Flu, vaccinia and EBV-specific CD8+ T 
cells (Wherry et al., 2006), indicating impairment in HIV-specific CD8+ T cell 
differentiation. However, CD127 expression on HIV-specific CD8+ T cells can be 
maintained if individuals are treated early in infection, thus cells surviving long-term 











PD (programmed death)-1 is a receptor and upon binding with one of its ligands (PD-
L1 or PD-L2), inhibits T cell activation (Ishida et al., 1992). However, in HIV 
infection, PD-1 has been shown to be upregulated on HIV-specific CD8+ T cells in 
chronically infected individuals compared to CMV infection (Day et al; 2006; 
Trautman et al., 2006), and the PD-1 MFI of total HIV-specific CD8+ T cells 
positively correlates with viral load. Day et al. (2006) also showed that PD-1 MFI of 
total HIV-specific CD8+ T cells inversely correlates with CD4+ counts, as well as 
HIV-specific CD4+ T cells. Thus, the increased expression of PD-1 on HIV-specific T 
cells may render them unresponsive, which may be associated with disease 
progression. Blocking the PD-1/ligand pathway reversed this ‘exhausted’ phenotype 
of HIV-specific CD8+ T cells, so proliferative, cytokine and cytotoxic ability was 
restored (Day et al., 2006; Trautman et al., 2006). Similarly, CTLA-4 (cytotoxic T 
lymphocyte-associated antigen 4), which also functions to regulate T cell activation, 
has been shown to be upregulated on HIV-specific CD4+ T cells. Likewise, by 
blocking the CTLA-4 pathway, T cell function was restored in terms of IL-2 
production (Kaufmann et al., 2007). Thus, these studies illustrate a mechanism in 
which T cells are dysfunctional in HIV infection, but also very importantly 
demonstrate that this dysfunction may be reversible and hence provide a mechanism 
in which T cell exhaustion may be treated in chronic infection. 
 
In HIV infection, it appears that memory T cell differentiation is skewed. What might 
account for this observed dysfunction? It is becoming apparent that immune 
activation may drive HIV-specific T cell differentiation and hence dysfunction (Sousa 
et al., 2002; Papagno et al., 2004). Thus, HIV-specific CD8+ T cells are pushed to 





Since the discovery of HIV, there are constantly new insights into viral pathogenesis 
and interactions between HIV and the immune system that are being identified.  
Several T cell correlates of viral control have been identified, such as the preferential 
targeting of Gag, proliferative ability, polyfunctionality, and preservation of Tcm cells. 












replication, or merely reflect lower viral loads in individuals controlling viral 
replication. There are likely to be additional mechanisms, which may be involved in 
viral control, which have yet to be identified.  
 
1.4 Aims of thesis 
 
Studies have revealed the importance of investigating HIV-specific T cell responses 
in HIV infection using flow cytometry, and more recently, polychromatic flow 
cytometry, which allows the investigation of more than four markers. The first aim of 
this project was to establish a nine-colour polychromatic flow cytometry panel for use 
in the laboratory. The panel was to include five functional markers, namely IL-2, IFN-
γ, TNF-α, MIP-1β and CD107a. These were chosen since the expression of these 
markers simultaneously has been implicated with viral control. However, this 
association with viral control is not clear and further investigations are required. 
Therefore, the second aim of this project was to apply the panel to investigate HIV-
specific polyfunctional T cells in chronic and acute HIV infection, where individuals 
were followed for12 months post infection. Longitudinal investigations may provide 
different insights compared to cross-sectional studies. This study allowed a 
comparison between acute and chronic infection, and enabled patterns of 
polyfunctionality to be determined, adding to the body of data on the function of HIV-
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MATERIALS AND METHODS 
 
2.1 General laboratory operations and reagents 
 
All procedures with biohazardous material were performed in a Biosafety Class II 
hood with appropriate protective wear and procedures, including appropriate 
disinfection and disposal of waste. Table 2.1 lists commonly-used laboratory reagents, 
their composition and storage requirements. Fetal bovine serum (FBS; Invitrogen) is 
blood serum that is obtained from foetuses of cows. FBS is used to supplement 
culture media as it contains important growth factors and proteins, which are required 
by cells for growth and survival. Prior to use, it was heat inactivated for 30 min at 56 
°C in order to denature complement proteins to avoid cell lysis. RPMI (Invitrogen) 
media contains vitamins and amino acids and it is usually supplemented with 1-20 % 
FBS. Prior to use, Penicillin/ Streptomycin (Invitrogen; 1 unit/ml/ 1 µg/ml) was added 
to prevent bacterial contamination during cell culture. PBS (Invitrogen) is a buffer 
solution, and is used to maintain a constant pH when reagents were diluted.  
 
Table 2.1: Commonly used laboratory reagents  
 
Reagent Compo ition Storage Supplier 
Fetal Bovine Serum 
(FBS; 100 ml) 
- -20 °C Invitrogen 
RPMI-1640 Medium  
(1X) 
200 mM L-glutamine,  
25 mM HEPES, pH indicator 
4 °C Invitrogen  
 
Phosphate Buffered 
Saline (PBS; 1X) 
0.138M NaCl, 0.0027M KCl (pH 7.2) RT Invitrogen 
Penicillin/ Streptomycin 
(100 ml) 
100 units/ml penicillin,100 µg 
streptomycin 
-20 °C Invitrogen 
R1  1 % FBS in RPMI 4 °C * 
R10  10 % FBS in RPMI 4 °C * 
R20  20 % FBS in RPMI 4 °C * 













2.2 Ethical approval 
 
This study included participants in the acute and chronic stage of HIV infection. 
Ethical approval for individuals with chronic HIV infection was obtained from the 
Research Ethics Committee of the Faculty of Health Sciences, University of Cape 
Town (reference number is 106/2002). Inclusion criteria for participants were as 
follows:  HIV-infected, with CD4 counts >200 cells/mm3, and an age of greater than 
18 years old. Informed consent was obtained from each participant prior to 
participating in the study.   
 
HIV-uninfected individuals were longitudinally followed whilst enrolled in a vaccine 
preparedness study and individuals that seroconverted were recruited into an acute 
infection cohort funded by the International AIDS Vaccine Initiative. Ethical approval 
for this cohort was obtained from Research Ethics Committee of the Faculty of Health 
Sciences, University of Cape Town (reference number is 134/2006). Inclusion criteria 
included age between 16-40 years, and all participants gave informed consent.  
 
2.3 Peripheral Blood Mononuclear Cell (PBMC) processing 
 
HIV-uninfected blood samples were obtained from Western Province Blood 
Transfusion Service (WPBTS) donors. PBMCs from chronically infected participants 
were obtained from the Nyanga Day Clinic and acute samples from the Uluntu 
Centre, both sites in Gugulethu, Cape Town. All samples were processed on the day 
of collection. Briefly, PBMCs were processed using Ficoll-density gradient 
centrifugation, freezing media added and cryopreserved in vapour phase liquid 
nitrogen for long-term storage. Table 2.2 lists the reagents required for PBMC 
processing. 
 
2.3.1 PBMC isolation procedure 
 
Ficoll-Hypaque (Sigma Aldrich) is used for density gradient centrifugation and for the 
separation of peripheral mononuclear cells (PBMCs) from blood plasma, erythrocytes 
and granulocytes (Figure 2.1). Ficoll-Hypaque consists of ficoll, a carbohydrate 











Table 2.2: Reagents required for PBMC processing 
Reagent Composition Storage Supplier 
Ficoll-Hypaque Ficoll and metrizamide 4 °C Sigma Aldrich 
Dimethyl Sulfoxide (DMSO)  - RT Sigma Aldrich 
Freezing media  
 




ViaCount Reagent Nuclear and vibility dye, 
sodium azide 
4 °C Gauva Technologies 
Washing media  1 % FBS PBS RT * 
* Prepared in the laboratory 
 
solute and provides a higher density without increasing viscosity. Ficoll has a density 
higher than that of PBMCs and after centrifugation, plasma and platelets are located at 
the top of the gradient since they have a lower density compared to red blood cells, 
ficoll and PBMCs. The next layer formed is the PBMC layer which consists of 
lymphocytes and monocytes, and below the ficoll layer are the red blood cells which 




Figure 2.1: Diagrammatic representation of blood components as separated using 
ficoll-Hypaque density centrifugation (taken from McGukin et al., 2008). 
 
Initially, 30 ml of Ficoll-Hypaque solution (that was allowed to reach room 
temperature before use) was added to a 50 ml Leucosep tube (Greiner Bio-one) 
containing a filter disc. This was then centrifuged for 1 min at 1257 X g, to allow the 











blood samples were poured into the 50 ml Leucosep tubes and centrifuged as before 
for 15 min. The PBMC layer was then removed and washed with 1 % FBS in PBS. 
The cell pellet was resuspended in 5-40 ml R1 (Table 2.1) for counting.  
 
Samples were counted using an automated Gauva cell counter (Gauva Technologies) 
which counts the number of nucleated cells in a sample and tests the viability of the 
sample. For cell counting, a 1:20 dilution was made using the Gauva ViaCount 
reagent (10 µl of sample added to 190 µl of the ViaCount reagent; Gauva 
Technologies). This was incubated for 8 min at room temperature before counting. 
The Gauva ViaCount reagent consists of two dyes, a nuclear and viability dye. The 
nuclear dye stains nucleated cells and the viability dye stains dead cells. In this 
manner, viable and non-viable cells can be distinguished based on the differential 
permeabilities of the two dyes. This viability assay also allows for the exclusion of 
debris which is negatively stained by the nuclear dye. 
 
2.3.2 Cyropreservation of PBMCs 
 
Cryopreservation involves preserving cells at low temperatures in order to restore 
them with minimal damage for later analysis. Cyropreserved cells were stored in a 
vapour phase liquid nitrogen cryotank (Cryo 200, Forma Scientific). Cells were frozen 
in media containing the cryoprotectant reagent DMSO (Sigma Aldrich). It is a polar 
solvent that can penetrate membranes without damaging them during the freezing 
process and it protects cells from ice crystals that form. It also maintains the integrity 
of cell membranes during the freezing process, thereby limiting cell death. 
 
Isolated PBMCs were first resuspended in a volume of FBS (Invitrogen) and then 
freezing media (Table 2.2) was added drop-wise to the suspension to obtain a final 
concentration of 10-15 x106 cells/ml. One ml aliquots were dispensed into pre-cooled 
2 ml cryovials (Greiner Bio-one) and placed into pre-cooled “Mr Frosty” (Nalgene) 
containers. A “Mr Frosty” contains isopropanol and allows the temperature to 
gradually decrease at approximately -1 °C/minute, allowing samples to freeze slowly 
to limit cell death. “Mr Frosties” were stored in a -70 °C freezer overnight and 











2.4 Thawing of cryopreserved samples 
 
Frozen PBMC samples were thawed by being placed in a 37 °C waterbath for 1-2 min 
until a tiny ice crystal remained. Ten ml of pre-warmed R1 (Table 1) was added drop-
wise to the sample while gently swirling. To this suspension, a further 15 ml R1 was 
added and the sample was centrifuged at 289 X g for 10 min. The supernatant was 
decanted and the pellet was resuspended. DNAse I (0.002 %; Roche Diagnostics) was 
added to the sample. DNAse comes from bovine pancreas and it digests DNA by 
hydrolysing the phosphodiester linkages of double-stranded or single-stranded DNA 
to a mixture of oligo- and mononucleotides. Some inevitable cell death from 
cryopreservation leads to cell lysis and the release of viscous DNA in the sample, and 
DNAse treatment prevents cells from clumping. Samples were incubated at room 
temperature for 2 min. An additional 25 ml R1 was added to the sample and it was 
centrifuged as before. The pellet was resuspended in 3-5 ml (dependant on cell count, 
with 2-4 x106 cells/ml being optimal) of R20 (Table 2.1) and transferred into a 37 °C, 
5 % CO2 incubator overnight. Samples are rested overnight as this reduces 
background responses (Horton et al., 2007).  
 
2.5. Stimulation of thawed samples  
 
2.5.1. Peptides used in this study 
 
In order for an adaptive T cell immune response to develop or be detected, foreign 
bodies are phagocytised and proteins are processed to form peptides, small chains of 
amino acids. These peptides are presented to T cells by MHC molecules. To by-pass 
antigen-processing, peptides of 15 -18 amino acids in length were used to measure 
HIV-specific responses. All peptides were obtained lyophilised and resuspended in 
DMSO (Sigma Aldrich). Peptide pool stocks were then further dissolved in RPMI 
(Invitrogen) at a concentration of 40 μg/ml and stored at -80 °C. HIV peptides were 
assembled into Gag and Nef pools as listed in Table 2.3. These pools overlap by 10-
11 amino acids to ensure that no epitopes are lost. These peptides were based on the 
Du422 strain of HIV.  The Du HIV strains were used because they are close to a 











Table 2.3: HIV-1 subtype C peptide pools used in this study 
Peptide Pool * Number of peptides  
Gag 122 
Nef 50 
* Gag peptides were obtained from NIH Research and Reference Reagent Repository and Nef 
peptides were obtained from Clive Gray, National Institute of Communicable Diseases 
(NICD), Johannesburg. 
 
2.5.2 Additional stimulation reagents  
 
Whilst peptide stimuli were added to PBMC in order to stimulate cytokine production 
and therefore detect specific T cells, a number of additional reagents were included in 
the stimulation procedure. These are summarised Table 2.4 and their preparation and 
storage are listed in the Appendix. Co-stimulatory molecules anti-CD28 and anti-
CD49d (BD Biosciences) were included in the stimulation process to promote TCR 
recognition (Waldrop et al., 1997) by synergistically providing a distinct signal to 
induce transcription factors and thus cytokine gene induction (Udagawa et al., 1996). 
CD28 is a receptor for CD80 (B7.1) and CD86 (B7.2), which are expressed on antigen 
presenting cells. CD49d is the alpha 4 integrin subunit of the α4β1 lymphocyte 
homing receptor. It functions as an adhesion receptor and is expressed on 
lymphocytes, with an increased expression on activated cells. 
 
A positive control was included to ensure that the assay had worked and the cells were 
functional. Both PMA/Ionomycin (Sigma Aldrich) and SEB (Sigma Aldrich) were 
used. Phorbol Myristate Acetate (PMA) is a strong mitogen that stimulates the T cell 
receptor (Touraine et al., 1977). Ionomycin is an ionophore, which is produced by the 
bacterium Streptomyces conglobatus. It is involved in transferring ions across 
membranes (Beeler et al., 1979) and when used in conjunction with PMA it increases 
intracellular Ca2+ molecules, thereby inducing activation of a cell and production of 
cytokines (Kawanishi and Joseph, 1992). Staphylococcal enterotoxin B (SEB) is 
produced by Staphylococcus aureus and it is a toxin commonly causing food 
poisoning in humans. Similarly to PMA, it is also a strong stimulator of T cells by 











The benefit of using SEB instead of PMA is that it does not downregulate CD4 
expression (Pelchen-Matthews et al., 1993). 
 
In order to measure intracellular markers by flow cytometry, the protein secretory 
inhibitors Brefeldin A (BFA) and monensin (Sigma Aldrich) were both used. These 
substances prevent extracellular secretion and hence cytokines are confined 
intracellularly. BFA is a lactone antibiotic produced by the fungus Penicillium 
brefeldianum, and causes the endoplasmic reticulum and the golgi apparatus to merge, 
thereby forming a blockade (as reviewed in Klausner et al., 1992). Monensin is an 
antibiotic from the bacterium Streptomyces cinnamonensis and inhibits protein 
transport by de-acidifying the golgi layers (Fliesler and Basinger, 1987). 
 
Table 2.4: Reagents used for stimulation  
Reagent Storage Supplier 
anti-CD28 (1 μg/ml) 4 °C BD Biosciences 
anti-CD49d (1 μg/ml) 4 °C BD Biosciences 
Brefeldin A (BFA) 
(0.5 μg/ml) 
-20 °C Sigma Aldrich 
Monensin (10 μg/ml) -20 °C Sigma Aldrich 
Phorbol Myristate Acetate (PMA; 1 μg/ml) -20 °C Sigma Aldrich 
Ionomycin (0.5 μg/ml) -20 °C Sigma Aldrich 
SEB (2 μg/ml)   4 °C Sigma Aldrich 
 
2.5.3 Stimulation procedure  
 
After cells were rested overnight they were counted and washed in 15 ml of pre-
warmed R10 (Table 2.1) and centrifuged as before. The pellet was then resuspended 
in R10 stimulation mix. This mix consisted of 4.5 ml R10, 500 μl DNase I, anti-
CD49d (1 μg/ml), anti-CD28 (1 μg/ml) and BFA (0.5 μg/ml). An additional 5 μl of 












The cell suspension was then stimulated with either no peptide (unstimulated 
background control), the positive control PMA (1 μg/ml) and ionomycin (0.5 μg/ml) 
or SEB (50 μg/ml), or Gag and Nef peptide pools of HIV-1 subtype C, or specific 
peptides (used at 2 μg/ml). Included in each stimulation was 5 μl of anti-CD107a-
FITC (see section 3.2.2). Samples were stimulated for 16 h in a 37 °C, 5 % CO2 
incubator (Thermo Electron Corporation), while PMA/ionomycin tubes were 
incubated for 4 h. 
 
2.6 Surface and Intracellular Staining (ICS)  
 
 ICS involves staining for intracellular markers such as cytokines, and includes 
staining for surface markers that determine the phenotype of a cell. The term staining 
in this context refers to the use of antibodies that are conjugated to a fluorochrome 
that bind to markers of interest, which are then detected by a flow cytometer. Initially, 
cells were stained with antibodies that are expressed on the cell surface, thereafter 
were permeabilized allowing antibodies to enter and bind to intracellular markers of 
interest. The permeabilizing reagent consists of saponin, a plant derived antibiotic, 
which creates pores in the cell to allow antibodies to enter. This occurs by saponin 
binding to cholesterol molecules on cell membranes forming insoluble complexes, 
which results in rearrangement of lipids, hence producing a more permeable structure 
(Way, 1969). Samples were washed with a buffer containing saponin to maintain 
permeabilization, as this is a reversible process.  Cells were subsequently fixed to 
preserve the staining. Reagents used in the ICS protocol are listed in Table 2.5. 
 
Table 2.5: List of reagents for ICS 
Reagent Composition Storage Supplier 
FACS Wash Buffer  1 % FBS PBS, 0.001 % sodium azide 4 °C * 
Cytofix/Cytoperm (1X) Formaldehyde and saponin 4 °C BD Biosciences 
Perm/Wash (10X) FBS and saponin 4 °C BD Biosciences 
CellFIX (10X) Formaldehyde and sodium azide RT BD Biosciences 














2.6.1 Antibody staining procedure 
 
Table 2.6 contains a list of antibodies and the titrated volumes used for the 
polychromatic antibody assay. Once stimulations were complete, cells were washed 
with FACS wash buffer (Table 2.5) and centrifuged at 838 X g for 3 min at 4 ºC. All 
further centrifugation steps of 96 well microtiter plates were performed at this speed, 
time and temperature. The cell pellet was resuspended in 50 μl PBS containing a pre-
titered volume of violet viability reactive dye (“Vivid”; Invitrogen), and incubated for 
20 min at room temperature. Samples were washed with 150 μl FACS wash buffer 
and centrifuged, and this was repeated using 200 μl FACS wash buffer. A surface 
staining mix was prepared, which consisted of anti-CD19-Pacific Blue, anti-CD14-
Pacific Blue, anti-CD8-Qdot 605, anti-CD4-PerCP-Cy5.5 and PBS. A final volume of 
50 μl was added to each sample and the plate was incubated at room temperature for 
20 min. Samples were then washed twice with FACS wash buffer as before. The 
pellets were then resuspended in 100 μl Cytofix/Cytoperm (BD Biosciences) and 
incubated at room temperature for 20 min. Samples were washed twice using 150 μl 
and then 200 μl 1X Perm/Wash buffer (BD Biosciences). An intracellular staining 
mix of anti-CD3-APC-H7, anti-IFN-γ-Alexa fluor 700, anti-TNF-α-PE-Cy7, and anti-
APC-IL-2 was prepared in PBS and a final volume of 50 μl was added to each 
sample, followed by an incubation for 20 min at room temperature. Cells were washed 
as before with 1X Perm/Wash buffer and resuspended in 150 μl 1X CellFIX (BD 
Biosciences). 
 
2.6.2 Compensation  
 
2.6.2.1 What is compensation? 
 
During acquisition of samples from a flow cytometer there may be spectral overlap 
between fluorochromes in which fluorescence from one fluorochrome is detected in 
more than one detector, as indicated in red in the Figure 2.2. To correct for this, the 













Table 2.6: Anti-human antibodies used in multicolour flow cytometry panel 
Specificity* Fluorochrome** Clone Catalogue 
Number 
Titrated volume 
used in assay (µl)  
CD3 APC-H7 SP34.2 BD 641397 2.5 
CD14 Pacific Blue M5E2 BD 558121 5 
CD19 Pacific Blue SJ25-C1 MHCD1928 1.25 
CD8 Quantum dot 605 3BS Q10009 0.5 
CD4 Quantum dot 655 S3.5 Q10007 0.25 
CD4 PerCP-Cy5.5 L200 BD552838 1 
IFN- γ Alexa fluor 700 B27 BD 557995 2 
TNF-α PE-Cy7 MAB 11 BD 557647 1.25 
MIP1β PE D21-1351 BD 550078 0.625 











All antibodies were supplied by BD Biosciences except for both the Quantum dots (Invitrogen) and 
CD19 Pacific Blue (Caltag) 
* IFN-γ - Interferon gamma, TNF-α - Tumour necrosis factor alpha, MIP 1β -Macrophage inhibitory 
protein one beta, IL-2 – Interleukin two 
**  APC-H7 – allophycocyanin- H7, PerCP-Cy5.5 – Peridininchlorophyll protein-Cy5.5, PE-Cy7 – 
Phycoeryhrin-Cy7, PE-Phycoerythrin,  FITC – Fluorescein isothyocyanate, APC – allophycocyanin 
 
     
 
 
Figure 2.2: Emission spectra of two fluorochromes. Highlighted in red is the spectral 











This is accomplished by making a single stain of all antibodies used in the assay, i.e. 
one control for each fluorochrome. It is essential that each compensation control is as 
bright or brighter than staining on the cells of interest. This is to ensure that samples 
are compensated accurately so that the fluorescence spillover is corrected. 
Compensation controls which do not fluoresce at the same brightness as the sample 
will not be correctly compensated, as the fluorescent spillover of the compensation 
control will be less than the sample, therefore compensation will be inaccurate. All 
compensation was performed using FlowJo software version 8.1.3. (Treestar). 
 
In most cases, CompBeads (BD Biosciences) were used to compensate samples. With 
certain fluorochromes, however, cells were required for accurate compensation, as 
will be discussed in Chapter 3. 
 
2.6.2.2 Preparation of compensation beads 
 
CompBeads Set (BD Biosciences) consists of two microparticle populations, the 
CompBeads anti-mouse Ig,κ (positive) and the CompBeads negative control. The 
positive microparticles bind to mouse κ chain immunoglobulins (antibody), resulting 
in a positive population, whereas the CompBeads negative control has no binding 
ability, therefore cannot bind to an antibody and forms the unstained population. 
CompBeads anti-rat set (BD Biosciences) was also used. It functions in the same 
manner but is specific for rat κ chain immunoglobulins. Table 2.7 lists the details of 
CompBeads Sets used in the assays. 
 
To 5 ml Falcon tubes (BD Biosciences), 100 μl of Perm/Wash buffer (Table 2.5) was 
added. The CompBeads were vortexed thoroughly for 1 min to avoid aggregation. 
Subsequently, a drop of negative and positive beads was added to each tube. The 
corresponding volume of antibody that had been used during staining of samples was 
added to the tube. This was incubated at 4 °C for 15 min, and fixed by adding 100 μl 













Table 2.7: Reagents used for compensation and staining 
Compensation Kit Components Storage Supplier 
Anti-rat Ig,κ 
Compensation Beads  
Beads in buffered solution containing BSA 
(Bovine serum albumin)  and 0.09 % FBS 
4 °C BD Biosciences 
Anti-mouse Ig,κ 
Compensation Beads 
Beads in buffered solution containing BSA 
and 0.09 % FBS 
 4 °C BD Biosciences 
Live/Dead Fixable 
Violet Dead Cell Stain 
Kit 
5 vials of 25 μg lyophilised dye and 1 vial 
of 500 μl DMSO 
-20 °C Invitrogen 
Polymer Amine Beads 
(500 ml) 
Beads in DI water and 0.1 % SDS (sodium 
dodecyl sulphate) 




2.6.2.3 Preparation of Vivid dye and pre-labelled amine beads for ViVid 
compensation 
 
Live/Dead Fixable Violet Dead Cell Stain Kit (Invitrogen) (Table 2.8) was used to 
distinguish between viable and non-viable cells. It consists of a violet-fluorescent 
reactive dye that enters damaged cell membranes and reacts with the amine groups in 
the cytoplasm. The dye does react with surface amines but to a lesser extent, and 
cannot enter viable cells so doe  not enhance fluorescence significantly. In addition to 
violet, viability dyes are available in other colours, such as blue, aqua, green and red. 
These dyes are less problematic compared to other dead cell exclusion markers since 
they are not affected by permeabilization and fixing of cells (Perfetto et al., 2006). 
 
An aliquot of 40 μl of working stock (40 X 106 beads/ml) was added to 1660 μl PBS 
(Table 2.1) and centrifuged at 452 X g for 3 min. The bead pellet was resuspended in 
80 μl of PBS and 20 μl of the 1:40 working stock of the violet-fluorescent reactive 
dye was added to this. This was incubated for 20 min in the dark at room temperature. 
Subsequently, 20 μl of un-labelled polymer amine beads (40 X 106 beads/ml) was 













2.7 Flow Cytometry  
 
Flow cytometry is a powerful technique that can be used to investigate immune 
responses. Characteristics of an individual cell can be identified within a cell 
suspension, by detecting cell surface and intracellular markers. It requires a 
specialised instrument, a flow cytometer, in order to measure the fluorescence of each 
cell. 
 
A flow cytometer works by a pressurised fluidic system allowing cells in a suspension 
to be taken up through the flow cell (indicated by the arrow in Figure 2.3). During this 
process the cells pass the laser individually and the antibody-conjugated 
fluorochromes that are bound to a cell become excited by the laser and emit light at 
particular wavelengths, which are then directed by the mirrors and filters (optics) of 
the flow cytometer to detectors. These wavelengths are measured by photomultiplier 
tubes (PMT) or detectors that convert the optical signals into digital signals, thus 
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Figure 2.3: Diagrammatic representation of a flow cytometer, showing the three main 
characteristics of a flow cytometer, namely (A) fluidics, (B) optics and (C) electronics 













2.7.1 Data acquisition and gating strategy 
 
After staining, samples were stored at 4 ºC in the dark and acquired within 24 h. 
Samples were acquired on the LSRII (Becton Dickinson) with FACSDiva software 
version 6.0 (Becton Dickinson) was used. The number of events collected was 
between 200000 and 1000000.  
 
2.7.2 Analysis, including statistics 
 
All analyses were performed using FlowJo version 8.5.2 (Treestar). GraphPad Prism 
(version 5.0) and Pestle (version 1.5.4) and SPICE version 4.1.6 (both from Mario 
Roederer, Vaccine Research center, NIAID, NIH) were used to analyse data. 
Statistical analysis was performed on GraphPad, version 5.0. The non-parametric 
Mann-Whitney U test was used to determine if the medians between two groups were 
significantly different. Correlations were investigated by the non-parametric 
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CHAPTER 3  
OPTIMIZATION OF FLOW CYTOMETRY PANELS 
AND PROCEDURES 
 
This chapter describes the multiple steps required for development of a polychromatic 
flow cytometry panel, as well as optimization of the staining and stimulation 
procedures.  
 
3.1 Optimization of a polychromatic flow cytometry panel 
 
3.1.1 Initial considerations for development of a polychromatic flow cytometry 
panel 
 
The starting point for developing a panel is knowledge of the configuration of the 
flow cytometer to be used. It is important to know how many lasers the instrument has 
and how many channels are available in order to know how many markers can be 
included in the panel. The LSRII (BD Biosciences) that was used in this study has 
three lasers (blue, violet and red) and in total has 12 channels available, as shown in 
the Figure 3.1.  
 
3.1.1.1 Selection of markers 
 
The aim of this study was to establish a five functional panel to detect HIV-specific 
responses in cryopreserved PBMC in HIV infection. The panel required a viability 
marker, since dead cells in cryopreserved PBMC can bind antibodies non-specifically 
and increase background responses (Horton et al., 2007). Antibodies against CD14 
and CD19 were also included to exclude monocytes and B cells, in order to further 
reduce background responses, thereby increasing the sensitivity of the assay. Since 
this project was investigating T cell responses, a CD3 marker was required and both T 
cell subset markers, CD4 and CD8, were included. LSRII channels were limited, and 
thus no T cell differentiation markers could be included in the panel, which would 














                       
 
 
Figure 3.1: Configuration of the South African Tuberculosis Vaccine Initiative 
(SATVI) LSRII (BD Biosciences) showing the number of channels for each laser. (A) 
Blue laser, an octagon, and the 2 trigons (B) Violet, and (C) Red. 
 
 
Five functional markers were included, namely cytokines and a degranulation marker. 
The five functions that were to be investigated were IFN-γ, IL-2, TNF-α, MIP-1β and 
CD107a. As explained in Chapter 1 (section 1.2.1.), IFN-γ is an antiviral cytokine and 
has been implicated with control of diseases, IL-2 is required for T cell proliferation 
upon antigen stimulation, TNF-α production is required for the recruitment of 
neutrophils and monocytes, while MIP-1β is a chemokine, and is responsible for the 













1995). MIP-1β binds the HIV co-receptor CCR5, thus may compete with HIV for 
binding to CD4+ T cells expressing this molecule. CD107a is a surrogate marker for 
cytotoxicity. During the degranulation process, CD107a is transiently expressed on 
the inner membrane of the cytotoxic granule (Suni et al., 2005), which then becomes 
exposed during degranulation and it can be detected on the surface of the cell (Betts et 
al., 2003).  
 
3.1.1.2 Selection of fluorochromes 
 
Antibody selection is the next step in building a panel, as antibodies chosen should 
ideally be those that are bright, give the best separation, but also limit fluorescent 
spillover. One limiting factor in developing a panel is that not all markers are 
available commercially on all fluorochromes. 
 
In polychromatic flow cytometry, there is a greater choice of fluorochromes compared 
to those available for the FACS Calibur, since there are more lasers and hence more 
fluorescent channels available. However, even with a greater number of choices, 
LSRII configurations are different and panels are not readily transferable from one 
instrument to another. Taking this into account, one can try to include new 
fluorochromes, such as Quantam dots (Qdots) and tandem dyes that can’t be detected 
on a FACS Calibur. It is useful to use Qdots as the narrower emission spectra leads to 
less fluorescence being read in other detectors (see section 3.1.1.3) and hence reduced 
spillover. Tandem dyes have two fluorochromes bound together, and are excited by 
the wavelength of the first fluorochrome but emit at the wavelength of the second 
fluorochrome. For this reason, APC and APC-H7 can be used in the same panel. 
Tandem dyes can be unstable and degrade, thereby increasing fluorescent spillover, if 
exposed to light, high temperatures and paraformaldehyde-based fixatives 
(www.bdbiosciences.com). The H7 molecule is an analogue of Cy7 and APC-H7 has 
been engineered to be more stable than APC-Cy7.  
 
Once markers of interest have been chosen it is easier to then work from an existing, 
optimized panel and a list of proposed markers can then be made. Table 3.1 lists an 











laboratory that was used as a base to build a functional panel. Since the viability 
marker fluoresces in the Pacific Blue channel (and markers CD14 and CD19 were 
also placed on Pacific Blue), CD3 was moved to the APC-H7 channel. An attempt 
was made to include CD4 and CD8 on Qdots to maximise the use of the violet laser. 
CD107a was placed on the FITC fluorochrome as anti-CD107a-PE has been shown to 
have a higher background response in unstimulated CD8+ T cells (Betts et al., 2003), 
IL-2 was placed on APC, permitting MIP-1β to be in the PE channel, TNF-α in the 
PE-Cy7 channel, leaving IFN-γ on Alexa 700. 
 
Table 3.1: Antibodies of interest 
Detector Optimized Panel Proposed Panel 
SSC     
PE-Cy7 CD45RA-PE-Cy7 TNF-α-PE-Cy7 
PerCP-Cy5.5  CD8-PerCP-Cy5.5 CD8-PerCP-Cy5.5/CD4-PerCP-Cy5.5 
PE-Cy5, PerCP-Cy5  -  - 






FITC, Alexa 488, CFSE IL-2-FITC CD107a-FITC 
Qdots 705-525 -  - 
AmCyan  -   
Pacific Blue  CD3-Pacific Blue Vivid/CD14/CD19-Pacific Blue 
Cascade Blue  - CD4-Qdot 655 
or Qdots  - CD8-Qdot 605 
APC-Cy7, Alexa 750 - CD3-APC-H7 
Alexa 700 IFN-γ-Alexa 700 IFN-γ-Alexa 700 
APC, Alexa 647 CCR7-APC IL-2-APC 
or Qdots 705-640  -  - 
 
3.1.1.3 Spectral overlap between fluorochromes 
 
A critical factor to take into consideration when developing a polychromatic flow 
cytometry panel is the spectral overlap between fluorochromes. Since there are many 
antibodies that are used in a single sample, it is useful to choose, as far as possible, 
fluorochromes with minimal fluorescence spillover and hence compensation 
requirements. A useful website that shows the excitation and emission spectra of 
fluorochromes is the Invitrogen Spectraviewer (www.invitrogen.com). At this 
resource, five different fluorochromes can be plotted together to give an idea of 











selection. From this it can be seen that the use of APC and Qdot 655 may be highly 
problematic as their emission spectra completely overlap (Figure 3.2A). 
 
 
               
 
               
 
               
 
 
Figure 3.2: Emission spectra of fluorochromes using Spectraviewer (Invitrogen). (A) 
shows that Qdot 655 overlaps with APC and in (B) PerCP-Cy5.5 may be a better 
candidate to reduce this overlap. (C) shows the degree of Qdot 605 overlap between 
fluorochromes of interest.   
 
3.1.2 Titration of antibodies 
 
Titrations were performed in order to determine the optimum volume of antibody to 
use in the assays. It is crucial for titrations to be performed on all antibodies to ensure 
that they are used at a volume that provides the best separation and lowest 
background, the latter particularly important for antibodies binding to cytokines 
(Lamoreaux et al., 2006). Often the volume recommended by suppliers is not optimal. 
 
Every antibody is different in the sense that they each have different amounts of 
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affinities. Even high volumes may not provide the best separation between the 
negative and positive populations. The optimum volume to use in an assay is also 
dependent on the staining procedure, i.e. surface or intracellular staining. The optimal 
amount of antibody was determined by measuring the median fluorescent intensity 
(MFI) of the positive and negative population in a titration series. A titration curve 
was then drawn, plotting the MFI versus the antibody volume. The positive 
population curve was the one of interest, in order to observe when saturation occurs, 
shown by the curve levelling out. The optimum volume was taken as the volume just 
prior to saturation. Examples are described below. 
 
3.1.2.1 Titration of amine reactive dye (viability marker)  
 
The violet reactive fluorescent viability marker (‘Vivid’; Invitrogen) was chosen as 
the dead cell marker. Similar to all antibodies used in an assay, Vivid also required a 
titration. Figure 3.3 illustrates the titration of Vivid, where the positive population 
represents dead cells, and the negative population is the live cells. The 1:64 dilutions 
was chosen since there is a clear separation between positive and negative populations 
and the negative population is not too bright, as is apparent in lower dilutions. Vivid 
staining was performed, before surface staining, due to Vivid possibly binding to the 





Figure 3.3: Flow plots representing Vivid titration. A two-fold dilution series was 
prepared and PBMC were stained, permeabilized and fixed before acquisition took 
place. The value on the top right hand corner of each flow plot represents the dilution 
of Vivid and populations shown were gated on singlets. 
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3.1.2.2 Titration of cell surface markers 
 
Subsequent to viability staining, staining for cell surface markers is the next step in an 
ICS assay. Cells were stained with surface antibodies as described in chapter 2. As an 
example, titration of the CD8-Qdot 605 antibody is shown in Figure 3.4. At lower 
concentrations of the antibody no positive population could be identified. The MFI 




















Figure 3.4: CD8-Qdot 605 titration. (A) represents the flow plots, where the volume 
of antibody added is shown on the top right hand corner of each plot. A two-fold 
dilution series was performed and PBMC were surface-stained, permeabilized and 
fixed. Cells were gated on singlets and lymphocytes. (B) shows the titration curve in 


















3.1.2.3 Titration of intracellular markers 
 
Staining for intracellular markers requires the cells to first be permeabilized in order 
for the antibody to enter and bind to its corresponding marker, as described in chapter 
2. CD3 is a surface marker, however it was stained intracellularly due to 
internalization that may occur during stimulation (Luton et al., 1994). The titration 
results are shown in Figure 3.5. The optimum volume to use for staining of CD3 using 
anti-CD3-APC-H7 was chosen to be 2.5 µl. As can be seen from Figure 3.5, CD3 
separation was better at lower (1.25-5 µl) than higher amounts (10-20 µl) of antibody. 



















Figure 3.5: CD3-APC-H7 titration. (A) shows the flow plots with the volume of 
antibody added shown on the top right hand corner of each plot. A two-fold dilution 
series was performed and PBMC were permeabilized, intracellularly stained and 
fixed. Cells were gated on singlets and lymphocytes. (B) shows the titration curve in 















All cytokines were stained intracellularly, and the TNF-α-PE-Cy7 titration is shown 
as an example in Figure 3.6 (over the page). The MFI plot reveals that the optimum 
volume to use in a 50 µl staining mix is 2.5 µl. When titrating anti-cytokine 
antibodies, it is necessary also to take into account background responses (responses 
in unstimulated cells; Figure 3.6D), to ensure that the volume selected gives a low 
background response. 
 
3.1.2.4 Signal/noise ratio to determine the optimum antibody volume 
 
Another way in which the optimal antibody volume can be determined is by 
calculating the MFI ratio (Lamoreaux et al., 2006). In this case, the positive 
population is the signal and the negative population is the noise. The ratio is the signal 
(MFI positive population) divided by the noise (MFI negative population). The 
highest ratio value obtained is the optimum volume to use, as seen in the Figure 3.7, 
which was 2.5 µl, as obtained with the previous method.   
 














Figure 3.7: Signal/noise ratio titration curve of TNF-α-PE-Cy7. The ratio was 











                                                        












                             
                                                          






















Figure 3.6: TNF-α PE-Cy7 titration. Shown in (A) and (C) are the flow plots with the volume of antibody in the top right hand corner of each 
plot. A two-fold dilution series was performed and PMA/ionomycin and unstimulated PBMC respectively were permeabilized, intracellularly 
stained with anti-CD3-PE-Cy5 and TNF-α-PE-Cy7, and fixed. Cells were gated on singlets, lymphocytes and CD3+ T cells. (B) shows the 
titration curve in which the MFI was calculated for the negative (-) and positive (+) population for all volumes tested. (D) shows the percentage 






















3.1.3. Building a polychromatic flow cytometry panel 
 
Building a panel involves adding antibodies consecutively to determine whether 
populations stain optimally and whether particular fluorochromes can be used 
together on selected markers. This section discusses different antibodies and certain 
dyes that increase the accuracy of the results obtained, such as a viability marker. It 
also describes important controls (Fluorescence Minus One) for developing a 
polychromatic panel. Initially, a nine colour panel was to be optimised, but due to 
limitations of the LSRII that was used as well as time constraints, an eight colour 
panel incorporating the measurement of four functions was developed. 
 
3.1.3.1. Inclusion of a viability marker 
 
The violet fluorescent reactive dye (Vivid) was chosen to discriminate between dead 
and live cells. Since cryopreserved PBMC samples were used in this study, it was 
prudent to include such a dye to exclude dead cells and improve quality of data by 
reducing background. Figure 3.8 shows that the background responses were decreased 
for both CD4+ and CD8+ T cells when Vivid was included in the staining procedure. 
Typically the viability of cryopreserved PBMC used in this study ranged from 57 %-
94 % (median 74 %). 
 
                                  
            
 
 
Figure 3.8: A viability marker reduces non-specific background. The percentages of 
cytokines produced by unstimulated (A) CD8+ and (B) CD4+ T cells when Vivid is 








































3.1.3.2 Inclusion of a “dump” channel 
 
The Pacific Blue channel, which also includes the viability marker, was used as a 
dump channel, not only to exclude dead cells from the analysis, but also to exclude 
monocytes (CD14+ cells) and B cells (CD19+ cells; Figure 3.9). This also aided in 





Figure 3.9: Use of a dump channel. The different populations in the Pacific Blue 
channel were used to exclude B cells, monocytes and dead cells in the analysis. Cells 
were gated on singlets.  
 
3.1.3.3 Inclusion of Quantum dot fluorophores 
 
Quantum dots, commonly known as Qdots, are tiny inorganic crystals (nanoparticles) 
that consist of a semiconductor core coated with a zinc layer to stabilize the core 
(Chattopadhyay et al., 2006). The name of each Qdot refers to the centre emission 
wavelength. These fluorophores have a narrow emission wavelength and are more 
photostable compared to organic fluorophores and are therefore excellent candidates 
for polychromatic analysis to reduce spectral spillover (Figure 3.10). Qdots are best 
excited by the violet or UV laser, however they are excited by other lasers and their 
emission spectra remain the same. It is extremely important to titrate Qdot antibodies 
accurately, due to their brightness. Another important point when preparing a staining 
master mix including Qdots is to centrifuge the mixture to remove aggregates, which 
may appear very bright on the flow cytometry plot.  
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Figure 3.10: Emission wavelength of different Qdots (taken from Chattopadhyay et 
al., 2006). 
 
The LSRII that was used in this study had a trigon violet laser, and since Pacific Blue 
was used as the “dump channel”, two channels remained for Qdot use, namely Qdot 
605 and Qdot 655. These were included on the CD4 and CD8 markers, and staining is 
shown in Figure 3.11. Whilst the use of the two Qdots showed good separation 
between CD4 and CD8, and they were compatible for use with CD3-APC-H7 and the 
Pacific Blue channel, subsequent experience in the SATVI laboratory showed that 
Qdot 655 was incompatible with the APC channel due to a large degree of spillover 
with this LSRII configuration, and it had to be dropped from further development. 
 




Figure 3.11: Flow plots of Quantum dot staining. (A) CD8-Qdot 605 and (B) CD4-
Qdot 655 and (C) cells stained with both anti-CD4-Qdot 655 and anti-CD8-Qdot 605. 
A PBMC sample was surface stained (Vivid, CD4, and CD8, permeabilized, and 
intracellularly stained for CD3 and fixed. Flow plots represent cells gated on singlets, 
lymphocytes and then CD3+ viable cells.  
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3.1.3.4 Fluorescent Minus One (FMO) controls  
 
FMOs are used to determine whether the panel of fluorochromes chosen can be used 
in combination with one another. When developing a flow cytometry panel that 
includes many antibodies being used in conjunction, it is vital to make sure that there 
is no major spillage of one fluorochrome into another channel, thereby compromising 
its detection. This is achieved by performing FMOs (Figure 3.12A). Plotting the FMO 
channel versus all the other fluorochromes reveals any fluorescence spillover. To 
determine this experimentally, cells were stained with all antibodies in the panel 
excluding the one of interest. This is performed for all antibodies in the panel. FMOs 
are particularly important for cytokine markers, due to the fact that they are rare 
events, and phenotypic markers are brighter as they are highly expressed. Thus, it is 
vital to make sure that the fluorescence of bright phenotypic markers are not spilling 
into a cytokine channel so that there is optimal and accurate detection of cytokine 
markers. An example is shown here in Figure 3.12B, where there is no spillover of 




                        
   
 
Figure 3.12: Flow plots of FMOs. (A) CD8-Qdot 605 FMO, showing each channel 
plotted against FMO channel (B) IFN-γ-Alexa 700 and IL-2-APC FMOs, showing no 




























Another important use for an FMO is to distinguish between negative and positive 
populations that are not well separated due to continuous expression of markers, such 
as memory markers. In this way gates are set using the FMO, and then applied to the 
sample. 
 
3.1.3.5 Problems encountered during optimization 
 
Originally a nine colour panel, with five functions, was to be optimised. Cells 
expressing cytokines are rare events, therefore staining for these cells should be at 
optimum levels to allow for accurate and sensitive detection. To evaluate this 
experimentally, the frequency of cells expressing cytokines is compared with and 
without the addition of a new antibody, to determine whether it influences the 
response obtained. 
 
During this study, anti-MIP-1β-PE had to be removed from the panel as IL-2 
responses drastically decreased when stimulated with SEB, as illustrated in Figure 
3.13. This reduction in APC signal was not a result of compensation, as all 
compensation percentages were below 30 % as determined from analysis in FlowJo 
(Treestar). The amount of IL-2 detected did not differ substantially when IL-2 alone 
or three additional cytokine-specific antibodies were added (Figure 3.13A and B). 
However, addition of the MIP-1β PE-conjugated fluorochrome resulted in a near 
complete abrogation of the IL-2 response (Figure 3.13C). It is therefore vital to 
perform such analyses during development of a panel to detect incompatibility 
between markers a d fluorochromes. Due to time constraints, the nine colour 
functional panel could not be further optimized to include a MIP-1β antibody, and 





























Figure 3.13: Incompatibility of particular fluorochromes leads to a decrease in IL-2 
detection. (A) PBMC stained with CD3-APC-H7, CD4-PerCP-Cy5.5, CD8-Qdot 605 
and IL-2-APC antibodies. (B) Addition of IFN-γ-Alexa 700, CD107a-FITC and TNF-
α-PE-Cy7 antibodies. (C) Addition of MIP-1β-PE antibody. 
 
3.1.3.6 Validating the polychromatic flow cytometry panel (eight colours) 
 
MIP-1β-PE was dropped from the panel, leaving a four functional flow cytometry 
panel. It was then necessary to confirm that this eight colour panel was optimized in 
terms of cytokine detection. To determine whether percentages were influenced upon 
addition of fluorochromes, a sample was stimulated with SEB and stained with the 
full eight colour panel, or with all the surface markers and just one of the functional 
markers (Figure 3.14).  Results obtained from this analysis showed that percentages 
were similar in all panels compared to the full eight colour panel, and that no 
fluorochrome was influencing another channel in which responses were decreased 
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Figure 3.14: Optimisation of a four functional panel. Showed in (A) are CD8+ 
cytokine responses and in (B) CD4+ cytokine responses. PBMC were stained with 
Vivid, CD8, CD4 or both, and intracellularly stained with CD3 and cytokine 
antibodies, either individually or in combination.  
                                                                                                                  
3.1.3.7 Gating strategy 
 
Figure 3.15 shows the gating strategy for detecting cytokine responses using the 
optimized polychromatic panel. There are a number of ways in which gating can be 
performed, and it is important to establish a gating strategy for optimal analysis and 
visualisation of the data. For instance, T cells that produce cytokine may down-
regulate CD3 and CD8 expression, thereby becoming dim cells. It is important to bear 
this in mind since gating CD4+ cells versus CD8+ cells will exclude these dim cells 
from the CD8 gate and underestimate responses. To overcome this, surface markers 
were gated versus a cytokine to correct for these dim cells (as shown by the black 
arrow in Figure 3.15). 
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Figure 3.15: Gating scheme used for the polychromatic flow cytometry panel. Cells were first gated on singlets, live cells and then lymphocytes. 
From this gate, CD3+ cytokine-producing T cells were gated, and then further gated on CD4+ and CD8+ T cells. Gates for each of the four 
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Gating in this manner does not distinguish between CD4+ and CD8+ double positive T 
cells, as with a CD4+ versus CD8+ plot. Thus, gating on CD4- and CD8- (after the 
CD3+ gate) and then CD8+ and CD4+ respectively ensured that these two subsets were 
differentiated and double positive cells are excluded.  
 
Sometimes there may be interference in terms of bubbles or a small blockage in the 
flow cell during acquisition, which may not be noticed during this process. It is 
worthwhile to examine a time plot when analysing data to exclude any blocks which 
may have caused shifts in fluorescence. As illustrated in Figure 3.16, during the 
beginning of acquisition this occurred, which caused inconsistent acquisition.  A time 
gate was therefore included to exclude these events. 
 
                                         
 
 
Figure 3.16: A time plot to examine consistency during acquisition of sample. The 
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3.1.4 Determination of a cut-off value for positivity  
 
There are a number of ways of determining what constitutes a positive response. For 
this study, a threshold value was used. This was performed by analysing the 
background cytokine responses of 20 HIV-infected individuals (Figure 3.17). All 
medians were below 0.05 % for both CD4+ and CD8+ T cell subsets. This threshold 
was also obtained for the acute infected cohort. Therefore, a threshold of 0.05 % was 
chosen and a positive response was taken as net percentage (subtraction of the 
background unstimulated sample value) and > 0.05 %. All net responses that were ≤ 
0.05 % were set to zero. In polyfunctional analysis where cells producing more than 
one cytokine were measured, this threshold was reduced to 0.0 1%, since median 
background responses all fell below this value. 
 
 












































Figure 3.17: Establishment of a cut-off value for the determination of positive HIV-
specific responses. These graphs represent 20 HIV-infected unstimulated responses of 
the four functions examined for (A) CD8+and (B) CD4+ T cells. The solid black lines 
represent the median of responses for each cytokine and the dotted black line 
represents the cut-off chosen (0.05 %). 
 
3.1.5 Compensation requirements 
 
As mentioned in chapter 2, a compensation control consists of a sample (usually cells) 
stained with only one antibody conjugated to a fluorochrome (a single stain). 
However, compensation beads are available and can be used instead of cells, and are 












make note of the species of antibody in use. There are different compensation beads 
for each species of antibody, i.e. if your antibody is from mouse then, anti-mouse 
compensation beads are required.  
 
Compensation controls need to be brighter than stained samples, as described in 
chapter 2. To determine whether beads stain brighter than, or as bright, as cells, 
PBMC were stained singly with each antibody used in the panel, and single-stained 
beads were also prepared. The fluorescence of the cell and bead stain with the same 
antibody was plotted together to visualize fluorescence (Figure 3.18). The three 
antibodies that required cells for compensation were PE-Cy7, APC and Alexa 700, 
since the positive population of single stained cells (second peak) had a brighter 
fluorescence compared to beads. Thus, singly-stained cells were used for these 
fluorochromes for accurate compensation.  
 
                                                                                                        
  
 
        
 
Figure 3.18: Comparison of the fluorescence of single stained cells and single stained 
compensation beads for all 8 colours in polychromatic flow panel. Beads staining 
peaks are show in red and cells in blue. PE-Cy7, APC and Alexa 700 required cells 















3.2 Optimization of the stimulation protocol      
 
Cytokines are produced in response to a stimulus, and therefore it is important to 
ensure that the stimulation protocol is optimal. During the stimulation procedure, a 
number of reagents are added and the sample is incubated for a particular time period. 
Since there were five functions to be detected, and each with potentially different 
kinetics of production and intracellular transport, the stimulation process was 
optimized. 
 
3.2.1 Transport inhibitor selection: BFA versus Monensin      
 
The majority of studies use Brefeldin A (BFA) as the protein transport inhibitor, 
which blocks transport from the endoplasmic reticulum to the golgi apparatus (as 
reviewed in Klausner et al., 1992), hence trapping cytokines intracellularly. Since 
CD107a (a marker for degranulation) was included as one of the functions 
investigated, the addition of monensin was required (Betts et al., 2003). However, 
TNF-α detection is greater with BFA compared to monensin (O’Neil-Andersen and 
Lawrence, 2003). Therefore, a comparison between these two protein inhibitors was 
performed to investigate the effect on all five functions. 
 
The results revealed that the combination of both inhibitors increased MIP-1β and 
TNF-α detection, the latter substantially (Figure 3.19). However, IL-2 levels were 
decreased slightly whilst CD107a and IFN-γ remained fairly constant when one or 









































































Figure 3.19: The effect of BFA and monensin on cytokine detection. A PBMC 
sample was stained and gated on lymphocytes. Shown here are the CD3+ T cell 
frequencies of five functions investigated, when either one or both of the transport 
inhibitors were included in the stimulation assay.  
 
3.2.2 Determination of the incubation period for stimulations 
 
The duration of the incubation period is an important factor to be investigated as 
cytokines may be produced at different times in response to an antigen. For example, 
some may be produced early during stimulation period and remain at peak levels for a 
number of hours, whereas others may require more time before they can be detected. 
Since five functions wer  initially being investigated in this study, a 16 hour 
stimulation time course was performed and all five markers examined. Two HIV-
uninfected PBMC samples were incubated at 37 °C and every 2 h samples were 
stimulated and removed from the incubator and placed at 4 °C for staining and 
acquisition the following day. Samples were stimulated with immobilised anti-CD3 
monoclonal antibody (BD Biosciences) as described in Veenstra et al. (2007). BFA 
and monensin were added at the start of incubation period as well as anti-CD107a-
FITC antibody. It was necessary to include anti-CD107a-FITC antibody during 
stimulation as this marker is transiently expressed during stimulation (as reviewed in 
Fukuda, 1991) and a previous study showed that inclusion of a CD107a antibody 
during stimulation greatly increased detection compared to surface staining during 











The kinetics of five functions for both CD8+ and CD4+ T cells are shown in Figure 
3.20. IL-2 production peaked at 12 h and 10 h for CD8+ and CD4+ T cells, however 
the other functions peaked at 6 h for CD8+ T cells, and 16 h for CD4+ T cells. Thus, a 
16 h stimulation period was required, since the other cytokine levels did not decrease 
significantly at 16 h. It is important to note that CD107a levels were not significantly 
reduced during the 16 h stimulation process, thus it appears that an incubation of 
longer than 6 h does not affect the ability of the CD107a antibody to stain optimally. 
 
 











































Figure 3.20: Time course of cytokine production. Expression levels of cytokines 
produced by (A) CD8+ and (B) CD4+ T cells stimulated by anti-CD3 over various 

























The aim of this work was to develop a multicolour flow cytometry panel to 
investigate five different T cell functions. Several steps were followed to develop the 
panel. Initially, the markers of interest and then fluorochromes were chosen according 
to the LSRII that was to be used. The antibodies were titrated, and each antibody was 
added sequentially to the panel to ensure their compatibility and optimal staining. 
FMO controls were performed for all antibodies to confirm antibody compatibility 
and that there was no significant fluorescent spillover into other channels. During the 
development of the panel, the MIP-1β antibody had to be dropped due to reduction in 
IL-2 detection. The optimal incubation period for maximal induction of cytokine 
responses was determined to be 16 h.  The use of Brefeldin-A and monensin together 
was found to best inhibit cytokine transport. A gating strategy for optimal analysis 
was determined, and a threshold value for a positive response was set at >0.05 %, 
calculated from the median background cytokine production in unstimulated cells. 
Thus, an optimised stimulation protocol and an eight colour polychromatic flow 
cytometry panel were developed to apply to the investigation of HIV-specific T cell 
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INVESTIGATION OF T CELL RESPONSES IN 
CHRONIC AND ACUTE HIV INFECTION 
 
 
HIV-specific T cell responses were investigated in acute and chronic infection using 
an eight-colour flow cytometry panel.  The acute cohort was a longitudinal study, in 
which the individuals were followed one year post infection, and the chronic cohort 
was a cross-sectional study.  This chapter describes the magnitude and breadth of 
HIV-specific T cell responses in both these cohorts as well as a comparison between 
the two cohorts. Responses were measured by intracellular cytokine staining (ICS) 
using overlapping Gag and Nef peptides based on the HIV-1 subtype C genome.  
 
4.1 HIV-specific T cell responses in a chronic cohort 
 
HIV-specific T cell responses were investigated in 20 chronically infected 
individuals. The characteristics of the participants are listed in Table 4.1. Participants 
were recruited from the Nyanga Day Clinic, Cape Town, South Africa, and all 
participants were female. The median age of the cohort was 35. Four of the 20 
individuals had been on antiretroviral therapy (ART) for at least 1 year at the time of 
sample collection. Of these four individuals, three had CD4+ counts lower than the 
median CD4+ counts. Although the time of infection was not known, all participants 
had been HIV-infected for more than 1 year. The CD4+ cell counts of these 
individuals ranged from 188-1306 cells/ul (median = 619 cells/ul). Viral loads were 



















Table 4.1: Characteristics of 20 study participants 
Patient ID Age ART* CD4+ Count 
NY 017 36 Y 377 
NY 021 33 N 581 
NY 032 32 N 763 
NY 044 39 Y 1306 
NY 045 31 Y 530 
NY 062 28 N 624 
NY 066 26 N 908 
NY 074 36 N 390 
NY 076 36 N 640 
NY 167 31 N 302 
NY 168 35 N 567 
NY 217 32 N 783 
NY 219 37 N 642 
NY 224 47 N 672 
NY 234 35 N 943 
NY 240 26 N 188 
NY 263 35 Y 614 
NY 267 40 N 545 
NY 273 35 N 768 
NY 292 41 N 574 
* Antiretroviral therapy 
 
4.1.1 HIV-specific cytokine responses 
 
Single cytokine responses specific for HIV Gag and Nef peptide pools were 
investigated. Representative flow plots for two different study participants are shown 
in Figure 4.1. For each participant the negative control (unstimulated cells), Gag and 
Nef peptide pool stimulations are shown. The CD8+ T cell responses are shown for 
study participant NY 32, and the CD4+ T cell responses are for NY 292. Positive 
responses were observed for Gag-specific CD8+ T cells (CD107a, TNF-α and IFN-γ), 
Nef-specific CD8+ T cells (CD107a and IFN-γ), Gag-specific CD4+ T cells (CD107a, 
IL-2, TNF-α and IFN-γ) and Nef-specific CD4+ T cells (IL-2 and IFN-γ), after 
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Figure 4.1: Representative flow plots of Gag and Nef-specific responses as measured 
by polychromatic flow cytometry for two different study participants. Shown are 












The HIV-specific T cells responses from 20 chronically infected individuals are 
shown in Figure 4.2. Where positive responses were obtained, the proportion of cells 
that were producing each function was determined (Figure 4.2A). Approximately fifty 
percent of HIV-specific CD8+ T cell responses were due to CD107a expression, with 
the remaining 50 % being made of IFN-γ production.  Whilst not significant, there 
was a greater tendency towards degranulation than IFN-γ production. A striking 
observation was that Gag and Nef-specific CD8+ T cells produced no IL-2, and in 
only two individuals did a small proportion (<10 %) of the response consist of TNF-α 
production. In addition to the proportion of responses, the magnitude of HIV-specific 
CD8+ T cells were dominated by CD107a and IFN-γ (Figure 4.2B, left panel). HIV-
specific CD8+ CD107a and IFN-γ responses were significantly higher in magnitude 
compared to CD8+ TNF-α responses (P<0.0001 for both Gag and Nef). Gag and Nef 
were targeted in a similar manner, with CD107a dominating the response, followed by 
IFN-γ, as seen in Figure 4.4C. In contrast to CD8+ T cells, Gag-specific CD4+ T cells 
showed a broader range of proportion of cytokines secreted by individuals, with IFN-γ 
highest (approximately 35 %), followed by TNF-α (30 %) and only about 15 % of the 
response being IL-2 production (Figure 4.2A, right panel). This pattern was similar 
for Nef-specific CD4+ T cells. Analogous to CD8+ T cells, the magnitude of Gag and 
Nef-specific CD4+ T cells mirrored the proportion of responding CD4+ T cells, where 
HIV-specific CD4+ T cells showed a broader range of cytokine levels.  However, 
CD107a expression was rare in CD4+ cells and IFN-γ was of a lower magnitude than 
for CD8+ T cells (Figure 4.2B). In contrast, TNF-α and IL-2 were of a greater 
magnitude compared to CD8+ T cells. Gag- and Nef-specific CD4+ IFN-γ and TNF-α 
responses were significantly higher in magnitude than CD107a responses (p=0.001, 
p=0.0152 for Gag; p<0.0001 p=0.0002 for Nef respectively). Figure 4.4C summarises 
the magnitude of HIV-specific T cell cytokine responses. For CD4+ T cells, IFN-γ 
dominates the Gag-specific response, followed by TNF-α, IL-2 and then CD107a, 
whereas for Nef, TNF-α dominates, followed by IFN-γ, IL-2 and then CD107a. Thus, 
in chronic HIV infection, HIV-specific CD8+ T cell responses are characterised by 
CD107a and IFN-γ expression, while HIV-specific CD4+ T cells produce IFN-γ, TNF-
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Figure 4.2: Cross-sectional analysis of HIV-specific T cell responses in 20 chronically infected individuals. Shown in (A) is the proportion of 
responding cells, in (B) the magnitude of responses, and in (C), proportion of magnitude of responses represented by pie charts. Samples were 
stimulated with Gag or Nef peptide pools for 16 h, followed by staining and acquisition. Horizontal lines represent medians. Significant 











4.1.2 The total magnitude of HIV-specific T cell responses 
 
The magnitude of total cytokine responses i.e. all HIV-specific cells secreting one or 
any combination of cytokines or degranulating, were determined. The total magnitude 
of responses was calculated by adding all the boolean combinations, to give a total 
magnitude of response. Here, a less-stringent cut-off of 0.01 % was used for cells 
producing more than two functions, since median background responses were well 
below 0.01 %.  This is because non-specific binding of two cytokine antibodies to the 
same cell is rarer than non-specific binding of a single cytokine antibody.  A cut-off 
of 0.01 % also ensured that all positive responses were greater than 10 events. For the 
single cytokine-producing cells, (cells producing IFN-γ only, TNF-α only, etc.), the 
cut-off value of 0.05 % remained, since median background responses for these 
populations were 0.05 %. Total HIV-specific CD8+ T cell responses were 
substantially higher in magnitude than CD4+ T cell responses (median 0.045 % versus 
0 % for Gag, and 0.289 % versus 0.229 % for Nef), as shown in Figure 4.3A. There 
was no significant difference between Gag and Nef response magnitudes within either 
T cell compartment. When considering the frequency of responses, it was observed 
that all individuals mounted a CD8+ response, whilst 80 % (16/20) individuals 
mounted a CD4+ response. The frequency of Gag-specific CD8+ T cell responders 
was greater compared to Nef-specific CD8+ responders (20/20 and 15/20, 
respectively), and seventy five percent (15/20) of individuals had both a Gag and a 
Nef response (Figure 4.3B). Gag was also more highly targeted than Nef in the CD4+ 
compartment (15/20 and 9/20 responders, respectively). Many of these individuals 
(8/15) had both a Gag and Nef response. No correlations were observed with either 
the total HIV-specific CD8+ or CD4+ T cell responses and CD4+ counts, or between 
total HIV-specific CD8+ and CD4+ T cell responses (data not shown). Thus, the 
magnitude and frequency of total cytokine responses of HIV-specific CD8+ T cells 



































































                                                                                                                      






CD8+ CD4+  
 
Figure 4.3: The total magnitude of HIV-specific CD8+ T and CD4+ T cell responses, 
Shown in (A) are CD8+ (left panel) and CD4+ T cells (right panel). (B) shows the 
frequency of positive responders to either Gag, Nef or both peptides.  Samples were 
stimulated with Gag and Nef peptide pools for 16 h, stained and acquired. Horizontal 
lines represent medians. 
 
4.1.3 HIV-specific polyfunctional T cell responses     
 
The combinations of the four functions produced simultaneously were examined. 
Figure 4.4 shows HIV-specific CD8+ and CD4+ T cell responses. Both T cell 
compartments showed poor polyfunctionality towards Gag and Nef in chronic 
infection, with no cells det cted that produced the three cytokines and degranulated. 
HIV-specific CD8+ T cells showed similar functionality compared to HIV-specific 
CD4+ T cells, with tri-functional cells present in both compartments but at a low 
frequency (8/20 and 3/20 respectively). A common phenotype for both Gag and Nef 
were CD8+ T cells producing CD107a and IFN-γ simultaneously, whilst for CD4+ T 
cells two-functional cells were more diverse, reflecting the broader array of cytokines 
produced by CD4+ T cells. The proportion of response magnitudes are shown in pie 
charts (Figure 4.4A and 4.4B). Nef-specific CD8+ T cell responses were dominated by 
monofunctional cells, producing either CD107a or IFN-γ, whereas Gag-specific CD8+ 
T cell responses had a greater magnitude of dual-producing CD107a and IFN-γ cells. 
Tri- functional cells were present for Gag and Nef-specific CD8+ T cells, although at a 
very low magnitude and proportion of the response (Figure 4.4C). The proportion of 
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Figure 4.4: Gag and Nef polyfunctionality in chronic HIV infection. 
Shown in (A) are HIV-specific CD8+ and in (B) HIV-specific CD4+ 
responses for Gag and Nef. (C) shows the proportion of HIV-specific 
CD8+ responses. Samples were stimulated with Gag and Nef peptide 
pools for 16 h, stained and acquired. Gag responses are shown in blue 
dots and Nef in red dots. The pie charts for (A) and (B) summarise the 
magnitude of responses for each polyfunctional subset for Gag and Nef, 
and (C) summarises the proportion of the combinations of functions, i.e. 
4+, 3+, 2+ and 1+ producing cells. Note the difference in scale between 













































































































































































producers (p= 0.039; Figure 4.4C). Gag and Nef-specific CD4+ T cell responses were 
both dominated by monofunctional T cells (Figure 4.4.B). There was also no 
difference between Gag and Nef in the proportion of functions for CD4+ T cell 
responses (data not shown). The four individuals on ARVs did not shower a greater 
capacity for polyfunctionality compared to untreated individuals. Thus, HIV-specific 
T cells showed poor polyfunctionality in chronic HIV infection. 
 
4.1.4 HIV-specific polyfunctional T cells produce more cytokine per cell 
 
The median fluorescent intensity (MFI) was calculated to determine whether 
polyfunctional T cells (in this case 3+ cytokine producers) were producing more 
cytokine per cell compared to mono- or dual functional cells. Shown in Figure 4.5 is 
the IFN-γ MFI of Gag or Nef-specific CD8+ and CD4+T cells. Polyfunctional cells 
have a greater MFI compared to less functional cells, and this is true for CD8+ and 
CD4+ T cells. The difference is most striking between the most polyfunctional cells 
(3+) compared to monofunctional cells (p=0.0035) for IFN-γ MFI of CD8+ T cells 
(Figure 4.5A). Even though there were fewer CD4+ T cell polyfunctional responses, a 
similar trend for IFN-γ MFI was found. This trend was only examined for IFN-γ, 
since there were not sufficient responses to determine whether this trend was true for 
the other three functions investigated.  Thus, the amount of IFN-γ decreases with the 



































Figure 4.5:  Amount of IFN-γ produced decreases as polyfunctionality decreases. 
Shown in (A) is the CD8+ IFN-γ MFI and in (B) the CD4+ IFN-γ MFI. Samples were 
stimulated with Gag and Nef peptide pools for 16 h, stained and acquired. The 
horizontal line represents the median. The Mann Whitney non-parametric test, was 
used to determine statistical differences. G = IFN-γ; C = CD107a; T = TNF-α; I = IL-













4.2 HIV-specific responses in an acute longitudinal study 
 
Seven acutely infected individuals were recruited from a vaccine retention study and 
individuals were followed monthly for up to a year post infection. The characteristics 
of the study participants are listed in Table 4.2. Longitudinal analysis was only 
performed on five of these individuals, since two individuals left the study for 
unknown reasons, and for these two individuals only incident samples were analysed. 
The study participants were all female. Two individuals spontaneously controlled 
viral loads to < 5 000 copies/ml (001 and 008).  CD4+ counts were > 500 cells/μl for 
all participants, except for participant 007, who also had the highest viral load. 
Participants were evaluated for T cell responses to Gag and Nef peptide pools, as well 
as specific peptide responses that were determined by the IFN-γ ELISPOT assay.  The 
ELISPOT data was provided by Hoyam Gamieldien of the Division of Medical 
Virology, University of Cape Town.   
  
4.2.1 HIV-specific T cell total cytokine responses to peptide pools over time 
 
Due to the limited number of individuals in the acute cohort (n = 7), responses 
obtained were grouped according to incidence visit (containing a single time point), 
month 3-6 (M 3-6) and month 9-12 (M9-12), to determine any possible trends. Figure 
4.5 shows the HIV-specific T cell total cytokine responses over time. At a gross level, 
CD8+ T cell responses were initially high at incidence and decreased at M3-6 and 
increased again at 9-12 months post infection (Figure 4.6A). However, the difference 
between response magnitudes at the three different time points for CD8+ T cell 
responses was not significant. In contrast, a highly striking loss of CD4+ T cell 
responses was observed over time, where responses were highest at incidence and 
were then nearly completely lost over the period investigated. This was reflected in a 
significant difference between CD4+ T cell responses at incidence compared to M3-6 
(p=0.02). When only those individuals with longitudinal data were included in the 
analysis, the dynamics of responses are illustrated more clearly (Figure 4.4C and D). 
There was one individual (001) who showed an opposite trend compared to the other 
participants, in which Gag-specific CD4+ T cells were present at month 9-12. This 
data suggests that CD4+ responses are present initially, and are then lost as duration of 










Table 4.2: Characteristics of participants recruited during acute infection 

























001 19 548 NA 759 2020 555 6980 543 4890 - - 615 2420 
002 29 548 7480 592 4510 587 7410 - - - - - - 





























349a 34 - - - - - - - - - - - - 
420a 34 - - - - - - - - - - - - 
a Only incidence samples available for these participants   
NA- Not available 
 
          




















































   






















































Figure 4.6: HIV-specific CD8+ (A) and CD4+ T (B) cell responses over the first year of infection. Each dot represents either a Gag or Nef 
response. Samples were stimulated for 16 h with Gag or Nef peptide pools followed by ICS. Horizontal lines represent the median values for 
each data set. Significant difference was observed between time points as denoted by an asterisk, determined using the non-parametric Mann 











4.2.2 HIV-specific polyfunctional T cell responses over time 
 
The polyfunctional nature of the HIV-specific responses was investigated next. Figure 
4.7 illustrates HIV-specific polyfunctional T cell responses in the seven participants 
studied over the first year of infection. Gag and Nef-specific CD8+ T cell responses 
had similar profiles for both CD8+ and CD4+ T cells over the time period investigated, 
as shown in the pie charts. At incidence, CD8+ T cell responses consisted of one, two, 
three and four-functional cells (Figure 4.7A). CD8+ T cell responses showed a loss in 
polyfunctionality over the time investigated, where four-functional cells were present 
at incidence (Figure 4.7A) but were lost at month 3-6 and three-functional cells 
decreased substantially by month 3-6 in both magnitude and frequency (Figure 4.7B). 
By month 9-12, all CD8+ Nef-specific three-functional cells had disappeared (Figure 
4.7C). The three-functional cells present at incidence were simultaneously producing 
IFN-γ, TNF-α and degranulating, indicating the development of a strong effector-type 
HIV-specific CD8+ phenotype early on in infection, targeting both Gag and Nef.  Gag 
and Nef-specific CD4+ T cells showed a similar trend, where one, two, three and four-
functional cells were present at incidence, but functionality decreased over the first 
year of infection (Figure 4.7D-F). CD4+ three-functional T cells also comprised IFN-γ 
and TNF-α-producing cells, but differed from CD8+ T cells in that they produced IL-2 
and did not degranulate. There was a significant difference (p=0.008) between Gag 
and Nef-specific CD4+ T cell responses at month 3-6 due to the presence of three-
functional cells (IFN-γ, TNF-α, IL-2). Nef-specific CD4+ T cell polyfunctionality was 
lost earlier compared to Nef-specific CD8+ T cells, and a complete absence of CD4+ 
Nef-specific responses were observed (Figure 4.7F). The pie charts show the 
proportion of four, three, two or one cytokine producing cells, and it can be clearly 
seen that over time from infection, both CD8+ and CD4+ Gag and Nef responses lose 
functionality. Thus, in both T cell compartments, four-functional cells were only 



























                                                                                                                                           
               
       
 






Figure 4.7: Loss of polyfunctional T cell responses over time. Shown in (A)-(C) are CD8+ T cells and in (D)-(F) CD4+ T cells. Samples were 
stimulated for 16 h with Gag (blue dots) or Nef (red dots) peptide pools, followed by ICS and acquisition. Box charts represent median 
responses. Pie charts summarise the magnitude of responses for each combination of functions, 4+ (red), 3+ (dark blue), 2+ (green), and 1+ (light 
blue). Significant differences are shown by an asterisk. 
CD8+ 
CD4+ 
Incidence Month 3-6 Month 9-12 
A B C 























































































































































































































































































































































































































































4.2.3 Participant HIV-specific T cell cytokine responses over time 
 
The kinetics of HIV-specific T cell responses were investigated, to determine whether 
particular cytokine functions were preferentially lost over the course of HIV infection 
(Figure 4.8). Gag and Nef-specific CD8+ T cell responses were present initially, 
except for participant 001, and 004, which developed Gag and Nef-specific IFN-γ and 
CD107a responses only later. Frequently, Gag or Nef responses developed early (by 3 
months post infection). Interestingly, these cells appeared to maintain IFN-γ 
production and the ability to degranulate, but largely lost the ability, if it was 
detectable, to produce TNF-α, e.g. the Nef-specific responses in participants 004 and 
008 (Figure 4.8B). An exception was the Gag-specific CD8+ response in participant 
008, that maintained TNF-α production. All other responses consisted of only IFN-γ 
and CD107a, in line with results shown in Figure 4.7, where later time points were 
dominated by these two cytokines. There were few CD4+ responses detectable, but 
two participants maintained or developed CD4+ HIV-specific IL-2 responses 
(participants 001 and 008; Figure 4.8C and 4.8D), whilst participant 007 lost its IL-2 
responses.   
 
In summary, participants with a Gag or Nef-specific CD8+ T cell IFN-γ response also 
had a comparable CD107a response in terms of magnitude, and both of these were 
usually maintained or increased over time. IL-2 and TNF-α CD8+ T cell responses 
were rare and sub-dominant compared to IFN-γ and CD107a responses, and were not 
frequently maintained over time. HIV-specific CD4+ T cell responses consisted 
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Figure 4.8 e. Shown in (
Nef 007 008
007 008
: The magnitude of HIV-specific T A) and (B  CD8+ C) 
and (D) are CD4+ T cell Gag and Nef responses. Samples were stimulated with Gag and Nef peptide pools for 16 h stained and acquired. The 
number at the top left corner of each graph represents the participant ID. Time points represent months post infection whilst “0” represent the 
incidence visit. 











4.2.4. Changes in magnitude of CD8+ specific peptide responses over time   
 
Participants in this cohort were initially analysed for responses by the IFN-γ 
ELISPOT assay, which identified specific reactive peptides, thus allowing the use of 
those peptides in the ICS assay. Determining changes to specific peptide responses 
over time may give more accurate insights than tracking differences to peptide pools, 
since responses to pools will include multiple responses that may arise and decline 
over time. Figure 4.9 shows two participants that had detectable CD8+ responses to 
specific peptides (as outlined in Table 4.3). Both participants show a different pattern 
of responses over time even with respect to the same specific peptide (Nef 19). 
Participant 004 had Gag 38-specific CD8+ T cell responses producing IFN-γ and IL-2 
at a similar magnitude, which were only present at month 12. The IL-2 response was 
not detected in the Nef peptide pool (Figure 4.8A), but this may be because the 
response is borderline, being just above the cut-off threshold of 0.05 %. Nef 19-
specific CD8+ T cells consisted of IFN-γ and CD107a responses, corresponding with 
the data observed in Figure 4.8B in terms of these two functions. However, there was 
also a TNF-α CD8+ T cell response detected to the Nef pool which was probably due 
to another peptide and not Nef 19 (Figure 4.8B). The ELISPOT responses for Gag 38 
and Nef 19 were 260 and 100 s.f.u per 106 cells respectively, which are low but were 
still detectable with ICS (Table 4.3). It is also important to note that for both Gag 38 
and Nef 19 additional functions (IL-2 and CD107a, respectively) were observed, 
which were missed in the IFN-γ ELISPOT assay, which is limited to measuring IFN-
γ.    
 
Interestingly, there was a stepwise decrease in functionality observed for participant 
008 for both peptides tested.  There were CD8+ T cells producing all four functions at 
incidence, but at month 3, IL-2 responses were lost, and then at month 6 TNF-α was 
lost, but CD107a and IFN-γ responses were maintained (Figure 4.9B). This data 
largely confirms what was observed for the peptide pool responses in Figure 4.8. The 
TNF-α response was absent at month 6 (Figure 4.9B), however was still present in the 
peptide pool response, but this may be because it was secreted by T cells specific for 
another Gag peptide. CD107a and IFN-γ responses specific for Gag 19 and Nef 19 











probably due to other peptides that were also contributing to the overall response to 
Gag and Nef. 
 
 





















































































Gag 38 Nef 19 
Gag 19 Nef 19 
A
B
                         
Figure 4.9: The change in CD8+ T cell magnitudes of specific HIV peptide responses 
over time. Shown here are two participants, (A) 004, and (B) 008. Specific peptides 
for each participant are shown on the top left corner of each graph. Samples were 
stimulated with the respective peptide for 16 h, stained and acquired. The colours 
represent the different cytokine responses. 
 
The ELISPOT data reveals that there was an increase in IFN-γ responses for both Gag 
19 and Nef 19, from month 3 to month 6, however this increase in response was only 
observed in the Gag 19 IFN-γ ICS response, whereas the Nef 19 IFN-γ response 
decreased in magnitude (Table 4.3). 
 
Thus, specific detectable responses were rare, as determined by ICS, and did not 
always compare well with IFN-γ ELISPOT data.  This may be accounted for by the 
high threshold of 0.05 % that was used after background responses had been 
subtracted. This data also shows that it important to measure more than one function, 
as seen in these examples, since T cells are not only single cytokine producers. Thus, 
















Protein Peptide Sequenceb 
 
Phenotypec IFN-γ Net s.f.u 



































































































































a M= month; Inc= incidence 
b Obtained from the Los Alamos database 
c Phenotype identified by flow cytometry 
d Provided by Hoyam Gamieldien, Division of Medical Virology, University of Cape Town 















examining specific single peptide responses can provide more accurate information on 
kinetics compared to stimulating with peptide pools. 
 
4.3 Comparison of HIV responses in acute and chronic infection 
 
4.3.1 Magnitudes of single cytokine responses  
 
Cytokine response magnitudes and frequencies were compared between individuals in 
the acute phase of HIV infection (n = 7), and those chronically infected (n = 20) 
(Figure 4.10). The responses shown here for acute infection refer to any responses in 
the first three months of infection. Although low numbers of acutely-infected 
participants limits the conclusions that can be drawn from this analysis, several 
descriptive observations can be made. In the CD8+ T cell compartment, CD107a and 
IFN-γ tend to be greater in magnitude in chronic infection compared to acutely-
infected individuals. IL-2 CD8+ responses were completely absent in chronic infection 
but are found in acute infection (1/7 and 2/7 responders, for Gag and Nef, 
respectively). While there were few CD8+ TNF-α responses in both phases of 
infection, the frequency of responders was greater in acute infection compared to 
chronically infected individuals (e.g. 3/7 versus 1/20 for Nef). Although there were 
few CD4+ T cell responses in acute infection compared to chronic CD4+ T cell 
responses, when present they were in a similar range to each other. There was, 
however, a greater magnitude of CD4+ IFN-γ responses in chronic compared to acute 
HIV infection (p=0.0224). Even though Figure 4.7 illustrates a striking loss in CD4+ T 
cell responses over time, in a larger cohort of 20 chronically infected individuals, 



































































































































































































































Figure 4.10:  The magnitude of HIV-specific cytokine responses in chronic and acute 
HIV infection. Shown in (A) CD107a (B) IFN-γ (C) IL-2 and in (D) TNF-α responses 
for CD8+ and CD4+ T cells respectively. Samples were stimulated with Gag and Nef 
peptide pools for 16 h, stained and acquired. Significant differences are denoted by an 











4.3.2 Total cytokine production  
 
The magnitude of the total HIV-specific cytokine responses was compared in chronic 
and acutely-infected individuals (Figure 4.11). Acute infection here refers to any 
responses in the first three months of infection in the seven participants evaluated. In 
chronic infection, Gag and Nef-specific CD8+ T cell responses were higher in 
magnitude compared to acute infection, however this difference was not significant. 
However, the opposite was true for CD4+ T cells, where the magnitude of Gag and 
Nef-specific T cell responses were higher in acute infection. Similarly, there are a 
greater frequency of CD4+ responders in the acute phase of infection compared to 
chronically-infected individuals (4/7 versus 9/20 responders for Gag respectively).  
 























































Figure 4.11: The magnitude of total cytokine HIV-specific T cell responses in chronic 
and acute infection. Samples were stimulated with Gag and Nef peptide pools for 16 
h, stained and acquired.  
 
4.3.3 Polyfunctional T cell responses 
 
The polyfunctional responses in acute and chronic infection were compared next. 
Refer to Figure 4.4A and B and Figure 4.7. It can be clearly seen that early on in 
infection, both T cell compartments are polyfunctional (Figure 4.7A and D), with 4+ 
and 3+ cytokine-producing cells present. However, there is a loss in polyfunctionality 
over time (Figure 4.7). A few, low magnitude 3+ cytokine-producing cells were 
present in chronically infected individuals for both Gag and Nef in both T cell 
compartments, which was true only for Gag in the acute cohort, but this may be due to 
a smaller cohort evaluated. Thus, it appears that as duration of infection increases, 
polyfunctional T cell responses are largely lost, which was confirmed in the larger 














HIV-specific T cell responses were investigated in 20 chronically-infected individuals 
and 7 individuals with acute infection that were followed longitudinally over the first 
year of infection. HIV-specific CD8+ T cell responses were greater in magnitude than 
CD4+ responses and predominantly produced IFN-γ and degranulated (CD107a+), 
with a complete absence of IL-2 production in chronic infection. HIV-specific CD4+ 
T cells were of a lower magnitude and had a broader cytokine repertoire, producing 
IFN-γ, TNF-α and IL-2, but rarely degranulated.  There were poor polyfunctional 
CD8+ and CD4+ T cell responses in chronic infection. CD8+ T cells showed a similar 
capacity for polyfunctionality compared to CD4+ T cells, in which a small proportion 
of three functional were present and no four-functional cells were detected, but most 
responses were two and one-functional cells. Gag and Nef stimulated a similar 
magnitude and frequency of HIV-specific cells.  In acutely-infected individuals, there 
was a decline in polyfunctionality over time, as well as a striking loss of CD4+ T cell 
responses by 6 months post infection.  In comparison to chronic infection, there were 
greater CD4+ T cell responses in acute infection, and a greater CD8+ T cell response 
in chronic infection compared to acute infection.  In summary, it appears that HIV-
specific T cell polyfunctional responses are lost over time, and this is most striking in 













Several correlates of viral control have been identified in HIV infection, but it is still 
unclear whether they actually result in control of HIV replication, or are a 
consequence of lower viral loads that may be caused by as yet unidentified immune 
factors.  The advent of new technologies such as polychromatic flow cytometry have 
greatly enhanced our ability to try to determine correlates of control, including being 
able to investigate additional markers that traditionally were not evaluated.  
 
The major aim of this study was the development of a nine-colour polychromatic flow 
cytometry panel. The panel was to consist of a viability marker, CD3, CD8 and CD4 
and five functional markers, namely IFN-γ, IL-2, TNF-α, MIP-1β and CD107a. These 
five markers were chosen as they are commonly used to determine HIV-specific T 
cell responses (Almeida et al., 2007; Betts et al., 2006; Duvall et al., 2008; Streeck et 
al., 2008).  
 
During optimization of this panel, it was observed that upon addition of MIP-1β PE 
antibody, the signal in the IL-2-APC channel was drastically reduced. This loss in   
IL-2 detection was not expected as there is minimal fluorescent spillover of PE into 
the APC channel, as observed in the Invitrogen Spectraviewer (www.invitrogen.com). 
The compensation matrix in FlowJo also showed that all percentages were < 30 % 
and there was no apparent spillover of PE in the APC FMO. Thus, it was unclear as to 
what was the cause of this reduction in signal. It may be due to the LSRII 
configuration, since it consists of an octagon blue laser, and no green laser. The green 
laser provides better resolution compared to the blue laser since it increases 
immunofluorescence sensitivity (Perfetto and Roederer, 2007). All panels developed 
in the SATVI laboratory consist of a maximum of 8 markers, and no 9-colour panels 
have been developed to date, although attempts have been made. Thus, due to time 













Despite this result, a nine-colour panel may still be developed since there are further 
optimization steps that can be performed. When developing a polychromatic flow 
cytometry panel, it is essential to try markers on all available fluorochromes to 
observe which antibody combinations work well together, however, due to time and 
resource constraints, this was not possible. Thus, alternative optimization steps such 
as placing IL-2 on different fluorochromes may have resulted in obtaining a nine-
colour panel. One option may be to use IL-2-FITC, since this fluorochrome is bright 
and usually used for dim markers such as cytokines, and then transfer CD107a to 
APC, which is commercially available. This then leaves MIP-1β on PE. Since 
CD107a is a surface marker, and thus a brighter marker than intracellularly stained 
markers, the effect of the PE fluorochrome may not be so evident. An alternative 
would be to try transferring CD107a to APC, IL-2 could be placed on PE and MIP-1β 
on FITC. Another option is to try IL-2 on one of the fluorochromes that the other 
surface markers were on, such as PerCP-Cy5.5.  
 
Apart from optimizing a flow cytometry panel, the stimulation protocol was also 
optimized in terms of incubation period and transport inhibitor selection. In this study, 
two HIV-uninfected PBMC samples were stimulated with immobilised anti-CD3 
monoclonal antibody as previously shown in Veenstra et al. (2007), which non-
specifically stimulates the T cell receptor (TCR). It was found that the optimum 
incubation period for all five functions investigated was 16 hours, but a disadvantage 
of using a longer incubation period may be an increase in cell death (Waldrop et al., 
1997; Maino et al., 2008). The majority of studies use a 6 hour incubation to preserve 
cell viability, and some studies have shown that cytokine levels peak at 6 hours 
(Picker et al., 1995), but remain at peak levels until 18 hours (Horton et al., 2007). It 
has been documented that longer incubation periods do result in increased cell death, 
since incubations of 12 hours or longer were significantly different to shorter 
incubation times in terms of cell viability (Waldrop et al., 1997). Since cryopreserved 
samples were used, cell viability is of great concern, thus emphasizing the importance 
of including a viability marker in the staining procedure to ensure good quality data 












It would be of interest to observe whether the kinetic profile of cytokine secretion is 
similar with other stimuli, such as SEB, PMA/ionomycin or even viral peptides. 
Published studies show that the kinetics of SEB stimulated PBMC are similar to the 
results obtained in this study, where cytokines (IL-2, TNF-α, and IFN-γ) peaked 
around 6 hours and remained at that level till 15 hours (Sandberg et al., 2001). 
PMA/ionomycin stimulated cells, however, resulted in a more rapid expression of 
cytokines (IL-2, IL-4 and IFN-γ), which peaked at 4 hours, and drastically decreased 
at ten hours (Picker et al., 1995). However, in macaque PBMC stimulated with SIV 
peptides, IFN-γ and TNF-α were optimally detected at 6 hours, however the next time 
point investigated was 20 hours, so this does not clearly indicate whether responses 
increased for additional time and before responses started to wane at 20 hours 
(Gaudin et al., 2004).    
 
Protein transport inhibitors were evaluated for their effect on the cytokine and 
degranulation markers of interest. The majority of studies use Brefeldin A (BFA) as 
the protein transport inhibitor, which blocks transport from the endoplasmic reticulum 
to the golgi apparatus (as reviewed in Klausner et al., 1992). Since CD107a was 
included as one of the functions investigated, monensin was required, as it has been 
shown to enhance CD107a detection (Betts et al., 2003). Our analysis, however, 
revealed no difference in CD107a detection with either of the inhibitors.  For TNF-α, 
it was also found that detection was the same with BFA compared to monensin in the 
CD8+ T cell compartment. This lack of difference in TNF-α detection between 
monensin and BFA has been previously observed (O’Neil-Andersen and Lawrence, 
2002). Another finding with respect to TNF-α detection was that when both inhibitors 
were used together, this greatly increased TNF-α detection. Thus, both protein 
transport inhibitors were included in the optimized protocol. These findings, however, 
were based on a single HIV-uninfected PBMC sample, and this experiment would 
need to be repeated on at least two more samples to confirm the result. 
 
Besides the optimization to the stimulation protocols mentioned in this study, there 
are other variables during stimulation and ICS that could have been evaluated.  
Another contributing factor that may influence cytokine responses is the time of 











and monensin were added from the beginning of the incubation period, however there 
have been studies that added BFA 1-2 hours after stimulation (Suni et al., 1998; 
Waldrop et al., 1997). This variable was not tested in this study, due to time 
constraints. Co-stimulatory molecules anti-CD28 and anti-CD49d were added in our 
stimulation procedure. The use of co-stimulatory molecules has been investigated and 
it was found that they were beneficial in one study, with an increase in cytokine 
responses observed (Waldrop et al., 1997), whereas in another study results were 
inconclusive (Horton et al., 2007). The staining procedure in our protocol was 
performed in 96 well microtiter plates with incubations periods of 20 min at room 
temperature, as described in Lamoreaux et al. (2006).  However, other staining 
protocols use tubes and longer incubation periods at lower temperatures (Ramduth et 
al., 2005). The type of vessel used for ICS was shown not to affect cytokine responses 
(Horton et al., 2007). The benefit of using a plate versus tubes is that it is high 
throughput; if there are a large number of samples to stimulate and stain, it makes the 
procedure far easier working with one plate rather than a large number of tubes. 
 
It is also worthwhile to examine different gating strategies. When plotting different 
markers against each other, some combinations offer better separation compared to 
others, thus responses are not lost by inaccurate gating due to poor separation. This is 
especially important for cytokine responses.  It is also vital to evaluate surface down-
regulation of phenotypic markers, as observed in some samples in this study. CD3+ 
and/or CD8+ T cell cytokine+ populations may become dim due to down regulation of 
these markers. To account for this, CD3+ or CD8+ T cell populations were plotted 
versus a cytokine channel for initial gating, as described in Betts et al. (2006). 
 
Determination of what constitutes a positive response is an important issue.  This can 
be calculated in a number of ways, such as using a two to three-fold above 
background cutoff (Trigona et al., 2003), using a 90th percentile cut-off based on 
background responses (Duvall et al., 2008), using two standard deviations above 
background responses as a cut-off, as well as having a ten event cut-off for 
polyfunctional T cells (Betts et al., 2006), or using a threshold value (Shacklett et al., 
2003). Cut-off values may also be determined by evaluating cytokine responses in 
HIV-uninfected PBMC samples, and using the mean plus 4 times the standard 











rigorous statistical methods that offer stringent determination of positive responses, as 
shown in Trigona et al. (2003). Here, a threshold value of 0.05 % was used for single 
cytokine responses, determined by calculating the background responses of the four 
functions in the 20 chronically infected individuals. All net responses below 0.05 % 
were set to zero. For cells secreting more than one cytokine, this threshold was 
lowered to 0.01 % in the Spice analysis, which then included positive responses that 
were > 10 events, since these cells are unlikely to represent non-specific staining.  
This threshold was also used for calculating the total cytokine response for cells 
secreting >1 cytokine, since unstimulated background responses in the 2+, 3+ and 4+ 
cells were in the range 9.56 x 10-3 and 3.26 x 10-4. 
 
The second part of this study was to apply the polychromatic flow panel and 
optimized stimulation protocol to investigate T cell responses in acute and chronic 
HIV infection. Gag and Nef peptide pools only were used due to limited sample 
availability.  Many studies have shown that high frequencies of Gag and Nef CD8+ 
and CD4+ responses are detectable in HIV-infected individuals (Addo et al., 2003; 
Betts et al., 2001; Edwards et al., 2002; Kaufmann et al., 2004; Ramduth et al., 2005), 
thus these proteins were chosen as antigens. Using intracellular staining, it was found 
that in chronically infected individuals, cytokines responses are detectable for both 
CD4+ and CD8+ T cell responses. The cytokine profiles, however, differ between the 
two compartments, where CD8+ T cells predominantly produce IFN-γ and degranulate 
with little TNF-α production. This result agreed with previous literature, with the only 
difference observed was that MIP-1β (not tested here) was most frequently produced, 
followed by IFN-γ and CD107a expression (Betts et al., 2006). Similarly, our results 
confirm previous literature in which no IL-2 production from CD8+ T cells was 
detected (Betts et al., 2006), although others have shown that these cells can be 
present during chronic infection (Duvall et al., 2008). HIV-specific CD4+ T cells 
show a broader cytokine expression range, which was dominated by IFN-γ and TNF-
α, followed by IL-2, with little capacity to degranulate. There is evidence, though, 
that Gag-specific CD4+ T cells are capable of degranulating (Duvall et al., 2008). A 
likely reason for these discrepancies may be due to the fact that a small study cohort 
was used and individuals in the cohort were not chosen on their basis of having a high 











differences between cytokine expression by CD8+ and CD4+ cells likely reflects their 
different functional roles in HIV infection, were CD8+ cells are the effectors and are 
directly cytotoxic, while CD4+ cells are limited primarily to a helper response.  Our 
findings also show that the specificity of CD4+ and CD8+ T cell responses did not 
differ in their cytokine profiles between Gag and Nef proteins in terms of 
polyfunctionality, as previously shown (Betts et al., 2006). 
 
In terms of total magnitude of responses, Gag-specific CD8+ T cell responses were of 
a lower magnitude of responses compared to previous literature (medians were <0.5 
% and <2 % respectively) (Duvall et al., 2008). Similarly, Gag-specific CD4+ T cells 
were lower in total magnitude compared to previous literature (medians were 0 and 
0.25 % respectively) (Duvall et al., 2008). This may be due to the fact that an 
additional function, the chemokine MIP-1β, was included in this published study, and 
almost 100 % of HIV-specific CD8+ T cells are capable of producing MIP-1β, thus 
influencing the magnitude of the total response consid rably. HIV-specific CD8+ T 
cells have shown a vast breadth in response, capable of recognizing all HIV proteins 
(Betts et al., 2006). In this study, it was found that the magnitudes between Gag and 
Nef were similar in the CD8+ T cell compartment, however, the frequency of total 
cytokine responses differed between Gag and Nef. All 20 chronically infected 
individuals had a Gag-specific CD8+ response, as observed in Duvall et al. (2008). 
However, Gag-specific CD4+ T cells, showed a lower frequency of responders (15/20 
compared to 16/16; Duvall et al., 2008).  
 
A comparison between the ICS data obtained in this study and IFN-γ ELISPOT 
results showed that they did not always agree with one another. For instance, if an 
IFN-γ response was obtained using the ELISPOT assay, an ICS IFN-γ response may 
not have been detected. This was most likely due to low magnitude ELISPOT IFN-γ 
responses, which may have been undetectable in ICS due to the cut-off threshold, 
which may be more stringent than the ELISPOT cut-off, or background responses 
being higher in ICS (possibly from the addition of co-stimulatory molecules). It may 
also reflect a difference in sensitivity between the two assays. Previous studies have 
shown significant correlations between flow cytometry and ELISPOT (Asemissen et 











Results may also have differed based on the differentiation of the CD8+ and CD4+ T 
cell subsets in ICS, and their IFN-γ responses, compared to a bulk amount of T cell 
IFN-γ response obtained in the ELISPOT. The advantage of ICS is that cytokines in 
addition to IFN-γ can also be detected, and are indeed present. In addition to 
measuring more parameters, the phenotype of the responding cell is identified, thus 
distinguishing between CD4+ and CD8+ T cell responses. 
 
T cells are capable of exerting a number of functions, including the secretion of 
multiple cytokines, and expression of many cytokines simultaneously. Recently, it has 
been established that T cells that are polyfunctional have been associated with viral 
control or non-progression in HIV infection (Betts et al., 2006; Duvall et al., 2008; 
Kannanganat et al., 2007b). Thus, polyfunctional T cells were investigated in chronic 
and acute HIV infection. It was found that in chronic infection, both HIV-specific 
CD4+ and CD8+ T cell polyfunctionality were lower in frequency and in some cases, 
lower in magnitude, and 4+ producing cells were absent in chronic infection, 
compared to acute HIV infection. Previously, polyfunctional (5+ and 4+) HIV-specific 
T cells have been described in untreated chronic infection (Almeida et al., 2007; Betts 
et al, 2006; Duvall et al., 2008).. 
 
A major finding of this study, when comparing chronic and early HIV infection, was 
that there was a remarkable loss in polyfunctionality, which cannot be observed in a 
cross-sectional study. This illustrates the value of longitudinal studies. The loss in 
polyfunctionality reveals that specific cytokine responses over time decrease in terms 
of magnitude, and then become completely absent. For instance, this was observed for 
IL-2, which was the first cytokine response to diminish followed by TNF-α, but cells 
maintained the ability to degranulate and produce IFN-γ, suggesting an effector 
phenotype. This maintenance of an effector phenotype was confirmed in the chronic 
cohort. Our data clearly indicated that there was indeed a loss in polyfunctionality, 
where cells present early in infection (<3 months) were diminished in terms of 
polyfunctionality as duration of infection increased, which has been observed 













This loss in polyfunctionality in the CD4+ T cell compartment, as observed over time, 
was confirmed by showing that if polyfunctional (3+) HIV-specific CD4+ T cell 
responses were present in chronic infection, they were of a low frequency (3/20), 
whereas there was as dramatic loss in polyfunctionality observed in the smaller acute 
cohort. The decrease in functionality may be due to high viral loads (Streeck et al., 
2008). This seems unlikely in our study, since all the individuals who were followed 
for more than one time point in the acute cohort had decreasing viral loads from initial 
time point to last visit. Thus, it appears that high viral loads were not responsible for T 
cell functionality, although sustained viremia cannot be excluded as a reason for loss 
of polyfunctionality. However, all the individuals displayed decreasing CD4+ cell 
counts from the initial time point to the last visit. Thus, this loss in polyfunctionality 
may be accounted for by the loss of HIV-specific CD4+ T cells and hence loss in 
CD4+ T cell help for CD8+ T cells, which is important for the development of 
memory cells (Janssen et al., 2003; Shedlock et al., 2003; Sun et al., 2004). Why was 
there a loss in HIV-specific CD4+ T cells? A reason that may account for this is the 
fact that HIV-specific CD4+ T cells are preferentially targeted, and thus depleted in 
HIV infection (Douek et al., 2002). The connection between the depletion of CD4+ T 
cells and the loss in polyfunctional HIV-specific T cells has been observed in the 
bronchoalveolar lavage (BAL) of HIV infected individuals (Brenchley et al., 2007). It 
was shown that BAL had preserved CD4+ T cells, which were highly polyfunctional 
compared to the blood, where there were significantly fewer HIV-specific CD4+ T 
cells. It was also shown that polyfunctional HIV-specific CD8+ T cells were present 
more frequently in the BAL compared to blood. Hence, the loss of polyfunctionality 
may be due to the depletion of HIV-specific CD4+ T cells. 
 
During antigenic stimulation, T cells proliferate, mature and differentiate into 
specialised subsets of T cells. These subsets can be identified due to different surface 
expression markers as well as by the functions they play, thus phenotype is linked to 
function. This is of particular interest, since new functions may be acquired upon 
differentiation, and other functions may be lost. It was observed in this study that 
specific epitopes showed a loss in function over time. This loss in functionality could 
be a result of T cells differentiating, thus losing the ability to produce certain 
cytokines. An example in this study revealed that IL-2 was the first cytokine to be 











T cells, which primarily produce IFN-γ and have the capacity to be cytotoxic 
(Champagne et al., 2001). Furthermore, it has been shown with increased number of 
cell divisions, IL-2 production decreased, and IFN-γ production increased (Gett and 
Hodgkin, 1998).  Thus, sustained viremia may cause differentiation and increased cell 
division, resulting in certain functions being lost over time. 
 
Despite several studies showing polyfunctional cells associate with control of HIV 
and other infections, their function is still controversial.  HIV studies have shown the 
importance of polyfunctional T cells in individuals who naturally control virus, have 
low viral loads and do not progress to disease (Betts et al., 2006; Duvall et al., 2008; 
Kannanganat et al., 2007b). Thus, due to a limited amount of literature surrounding 
this topic, it is still unclear whether polyfunctionality controls viral replication or is 
the result of low viral loads. Recently, a study by Streeck et al. (2008) attempted to 
address the question of polyfunctionality as the cause or consequence of HIV control, 
by following acutely-infected individuals longitudinally. It was observed that 
persistent antigen recognition influenced functional profiles of CD8+ T cells, 
concluding that polyfunctionality (or the lack there of) was a consequence of viremia. 
Interestingly, it was observed that if a specific epitope escaped recognition, this 
resulted in a decrease in monofunctionality (or an increase in polyfunctionality), i.e. 
since there was no more persistent antigenic stimuli for these responses since the 
epitope had escaped, the response could possibly mature.  This finding (an increase in 
polyfunctionality) was not observed in the acutely-infected individuals in this study, 
but only a limited number of specific reactive peptides were examined over time, and 
these could be ones that did not induce escape. 
 
In spite of observing only a limiting number of polyfunctional responses in chronic 
infection, our data confirms previous findings that polyfunctional T cells secrete more 
cytokine per cell compared to a monofunctional cell, as determined by CD8+ T cell 
IFN-γ median fluorescent intensity (MFI) (Precopio et al., 2007; Darrah et al., 2007; 
Kannanganat et al., 2007a; Duvall et al., 2008). Due to few responses, this could not 
be determined for the other functions, although this has been shown to be true 
previously for IL-2 and TNF-α in vaccinated individuals, as well as for CD4+ T cells 











have enhanced effector functions due the secretion of more cytokine per cell, which 
may account for the protection that polyfunctional cells play in Leishmania major 
infection (Darrah et al., 2007), and their correlation with viral control (Betts et al., 
2006; Kannanganat et al., 2007b; Duvall et al., 2008) 
 
Although there have been great advances in flow cytometry allowing multiple 
functional markers to be investigated, thus enhancing the potential to discover 
correlates of control, the question still remains: what should be measured, and which 
immunological method should be used to provide the most relevant information? 
HIV-specific T cells are capable of producing a wide array of cytokines, including 
several that are rarely measured in the majority of HIV studies, such as IL-5, IL-8, IL-
13, and granulocyte-macrophage colony-stimulating factor (GM-CSF; Goonetilleke et 
al., 2006). Flow cytometry, is a powerful technique, allowing the measurement of a 
number of markers, however, the number of functional markers that can be included 
is still limited, and we do not necessarily know which are the most important 
cytokines or functions to measure. A further limitation is that many of the markers 
that are used are surrogates may not necessarily or accurately reflect direct T cell 
functioning. The panel developed in this study included IL-2 and CD107a markers to 
measure proliferative and cytotoxic activity indirectly. Are these markers true 
indicators of function? Markers such as granzyme A or B, perforin or even granulysin 
may be more reliable markers of cytotoxic activity. CD107a is a surface-expressed 
marker so it does not prove that degranulating cells can actually kill target cells, 
although CD107a expression has been shown to directly correlate with cytotoxic 
activity (Betts et al., 2003). Furthermore, T cell IL-2 responses have been shown to 
correlate with proliferative ability (Harari et al., 2004). Thus, verifying the use of 
surrogate markers is extremely important, and proliferation and viral suppression 
assays may be more biologically relevant to T cell functioning. 
 
In conclusion, the development of a polychromatic flow cytometry panel has led to an 
enhanced knowledge of T cell responses, and this is being applied to develop other 
panels in our laboratory, such as the investigation of memory differentiation and 
immune activation in HIV infection.  The major findings in this study, although 
limited by a small cohort, was the striking decrease of CD4+ T cell responses over the 












which was confirmed in the chronic cohort. It is still unknown whether 
polyfunctionality is the cause or consequence of viral control, emphasizing the 
importance of longitudinal studies to help resolve this issue. Thus, it is important to 
continue such investigations to further understand HIV-specific immunity and 













Addo, M.M., Yu, X. G., Rathod, A., Cohen, D., Eldridge, R. L., Strick, D., 
Johnston, M. N., Corcoran, C., Wurcel, A. G., Fitzpatrick, C. A., Feeney, M. E., 
Rodriguez, W. R., Basgoz, N., Draenert, R., Stone, D.R., Brander, C., Goulder, P. 
J. R., Rosenberg, E. S., Altfeld, M., Walker, B. D. 2003. Comprehensive epitope 
analysis of Human Immunodeficiency Virus type 1 (HIV-1)-specific T-cell responses 
directed against the entire expressed HIV-1 genome demonstrate broadly directed 
responses, but no correlation to viral load. Journal of Virology. 77: 2081–2092. 
 
Addo, M.M., Draenert, R., Rathod, A., Verrill C.L., Davis, B.T., Gandhi, R.T., 
Robbins, G.K., Basgoz, N.O., Stone, D.R., Cohen, D.E., Johnston, M.N., Flynn, 
T., Wurcel, A.G., Rosenberg, E.S., Altfeld, M., Walker, B.D. 2007. Fully 
differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in 
controlled than in progressive HIV-1 infection. PLoS One. 2: e321. 
 
Akbar, A.N., Fletcher, J.M. 2005. Memory T cell homeostasis and senescence 
during aging. Currrent Opinion in Immunology. 17: 480–485. 
 
Almeida, J.R., Price, D.A., Papagno, L., Arkoub, Z.A., Sauce, D., Bornstein, E., 
Asher, T.E, Samri, A., Schnuriger, A., Theodorou, I., Costagliola, D., Rouzioux, 
C., Agut, H., Marcelin, A., Douek, D., Autran, B., Appay, V. 2007. Superior 
control of HIV-1 replication by CD8+ T cells is reflected by their avidity, 
polyfunctionality, and clonal turnover. The Journal of Experimental Medicine. 204: 
2473-2485. 
 
Altfeld, M., Addo, M.M., Shankarappa, R., Lee, P.K., Allen, T.M., Yu, X.G., 
Rathod, A., Harlow, J., O’Sullivan, K., Johnston, M.N., Goulder, P.J.R., Mullins, 
J.I., Rosenberg, E.S., Brander, C., Korber, B., Walker, B,D. 2003. Enhanced 
detection of Human Immunodeficiency Virus type 1-specific T-cell responses to 
highly variable regions by using peptides based on autologous virus sequences. 
Journal of Virology. 77: 7330–7340. 
 
Andersson, J., Boasso, A., Nilsson, J., Zhang, R., Shire, N.J., Lindback, S., 
Shearer, G.M., Chougnet, C.A. 2005. Cutting Edge: The prevalence of regulatory T 
cells in lymphoid tissue is correlated with viral load in HIV-infected patients. The 
Journal of Immunology. 174: 3143–3147. 
 
Appay,V., Nixon, D.F., Donahoe, S.M., Gillespie, G.M.A., Dong, T., King, A., 
Ogg, G.S., Spiegel, H.M.L., Conlon, C., Spina, C.A., Havlir, D.V., Richman, D.D., 
Waters, A.,  Easterbrook, P., McMichael, A.J., Rowland-Jones, S.L. 2000. HIV-
specific CD8+ T cells produce antiviral cytokines but are impaired in cytolytic 
function. The Journal of Experimental Medicine. 192: 63–75. 
 
Appay, V., Zaunders, J., Papagno, L., Sutton, J., Jaramillo, A., Waters, A., 
Easterbrook, P., Grey, P., Smith, D., McMichael, A.J., Cooper, D.A., Rowland-
Jones, S.L., Kelleher, A.D. 2002a. Characterization of CD4 CTLs ex vivo. The 












Appay, V., Rowland-Jones, S.L. 2002b. Premature ageing of the immune system: 
the cause of AIDS? Trends in Immunology. 23: 580-585.  
 
Arens, R., Wang, P., Sidney, J., Loewendorf, A., Sette, A., Schoenberger, S.P., 
Peters, B., Benedict, C.A. 2008. Cutting Edge: Murine Cytomegalovirus induces a 
polyfunctional CD4 T cell response. The Journal of Immunology. 180: 6472– 6476. 
 
Aslan, N., Yurdaydin, C., Wiegand, J., Greten, T., Ciner, A., Meyer, M. F., 
Heiken, H., Kuhlmann, B., Kaiser, T., Bozkaya, H., Tillmann, H. L., Bozdayi, A. 
M., Manns, M. P., Wedemeyer, H. 2006. Cytotoxic CD4+ T cells in viral hepatitis.  
Journal of Viral Hepatitis. 13: 505–514. 
 
Asemissen, A.M., Nagorsen, D., Keilholz, U., Letsch, A., Schmittel, A., Thiel, E., 
Scheibenbogen, C. Flow cytometric determination of intracellular or secreted IFNγ 
for the quantification of antigen reactive T cells. Journal of Immunological Methods. 
251: 101–108. 
 
Aziz, N., Nishanian, P., Mitsuyasu, R., Detels, R., Fahey, J.L. 1999. Variables that 
affect assays for plasma cytokines and soluble activation markers. Clinical and 
Diagnostic Laboratory Immunology. 6: 89–95. 
 
Bansal, A., Jackson, B., West, K., Wang, S., Lu, S., Kennedy, J.S., Goepfert, P.A. 
2008. Multifunctional T cell characteristics induced by a polyvalent DNA prime/ 
protein boost HIV-1 vaccine regimen given to healthy adults are dependant upon the 
route and dose of administration. Journal of Virology. 82: 6458–6469 
 
Beeler, T.J., Jona, I., Martonosi, A. 1979. The effect of ionomycin on calcium 
fluxes in sarcoplasmic reticulum vesicles and liposomes. The Journal of Chemistry. 
254: 6229-6231. 
 
Betts, M.R., Ambrozak, D. R., Douek, D.C., Bonhoeffer, S., Brenchley, J.M., 
Casazza, J. P., Koup, R. A., Picker, L. J. 2001. Analysis of total Human 
Immunodeficiency Virus (HIV)-specific CD4+and CD8+ T-cell responses: 
relationship to viral load in untreated HIV infection. Journal of Virology. 75: 11983–
11991. 
 
Betts, M.R., Brenchley, J.M., Price, D.A., De Rosa, S.C., Douek, D.C., Roederer, 
M., Koup, R.A. 2003. Sensitive and viable identification of antigen-specific CD8+ T 
cells by a flow cytometric assay fro degranulation. Journal of Immunological 
Methods. 281: 65-78. 
 
Betts, M.R., Nason, M.C.,  West, S.M., De Rosa, S.C., Migueles, S.A.,  Abraham, 
J., Lederman, M.M. Benito, J.M., Goepfert, P.A., Connors, M., Roederer, M., 
Koup, R.A. 2006. HIV nonprogressors preferentially maintain highly functional HIV-
specific CD8+ T cells. Blood. 107: 4781-4789. 
 
Bennett, S.R.M., Carbone, F.R., Karamalis, F., Flavell, R.A., Miller, J. F.A.P., 
Heath, W.R. 1998. Help for cytotoxic-T-cell responses ismediated by CD40 












Beveridge, N.E., Price, D.A., Casazza, J.P., Pathan, A.A., Sander, C.R., Asher 
T.E., Ambrozak, D.R., Precopio, M.L., Scheinberg. P., Alder, N.C., Roederer, 
M., Koup, R.A., Douek, D.C., Hill, A.V., McShane, H. 2008. Immunisation with 
BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium 
tuberculosis-specific CD4+ memory T lymphocyte populations. European Journal of 
Immunology. 37: 3089-100 
 
Biancotto, A., Grivel, J., Iglehart, S.J., Vanpouille,  C., Lisco, A.,Sieg, S.F., 
Debernardo,  R., Garate, K., Rodriguez, B., Margolis, L.B.,., Lederman, M.M. 
2007. Abnormal activation and cytokine spectra in lymph nodes of people chronically 
infected with HIV-1. Blood. 109: 4272-4279. 
 
Boaz, M. J., Waters, A., Murad, S., Easterbrook, P. J., Vyakarnam, A. 2002. 
Presence of HIV-1 Gag-specific IFN-γ+ IL-2+ and CD28+IL-2+ CD4 T cell responses 
is associated with nonprogression in HIV-1 infection. The Journal of Immunology. 
169: 6376–6385. 
 
Boritz, E., Palmer, B.E., Wilson1, C.C. 2004. Human Immunodeficiency Virus type 
1 (HIV-1)-specific CD4+T cells that proliferate in vitro detected in samples from most 
viremic subjects and inversely associated with plasma HIV-1 levels. Journal of 
Virology. 78: 12638–12646. 
 
Bossi, G., Griffiths, G.M. 1999. Degranulation plays an essential part in regulating 
cell surface expression of Fas ligand in T cells and natural killer cells. Nature 
Medicine. 5: 90-96. 
 
Boulet, S., Ndongala, M, L., Peretza, Y., Boisvert, M., Boulassel, M., Tremblay, 
C., Routy, J., Sekaly, R.P., Bernard, N.F. 2007. A dual color ELISPOT method for 
the simultaneous detection of IL-2 and IFN-γ HIV-specific immune responses. 
Journal of Immunological Methods. 320: 18–29. 
 
Brenchley, J.M., Karandikar, N.J., Betts, M.R., Ambrozak, D.R., Hill, B.J., 
Crotty, L.E., Casazza, J.P., Kuruppu, J., Migueles,  S.A., Connors, M., Roederer, 
M. Douek, D.C., Koup, R.A. 2002. Expression of CD57 defines replicative 
senescence and antigen-induced apoptotic death of CD8+ T cells. Blood. 101: 2711-
2720. 
 
Brenchley, J.M., Schacker, T.W., Ruff, L.E., Price, D.A., Taylor, J.H.,  Beilman, 
G.J.,  Nguyen, P.L., Khoruts, A., Larson, M., Haase, A.T., Douek, D.C. 2004. 
CD4 T cell depletion during all stages of HIV disease occurs predominantly in the 
gastrointestinal tract. The Journal of Experimental Medicine. 200: 749–759. 
 
Brenchley, J.M., Knox , K.S., Asher, A.I., Price, D.A., Kohli, L.M.,Gostick , E., 
Hill, B.J., Hage, C.A., Brahmi, Z., Khoruts, A., Twigg III, H.L.,Shacker, W.T., 
Douek, D.C. 2007.  High frequencies of polyfunctional HIV-specific T cells are 
associated with preservation of mucosal CD4 T cells in bronchoalveolar lavage. 












Cantin, E., Tanamachi, B., Openshaw, H. 1999. Role for gamma interferon in 
control of herpes simplex virus type 1 reactivation. Journal of Virology. 73: 3418–
3423. 
 
Carrington, M., Nelson, G.W., Martin, M.P., Kissner, T., Vlahov, D., Goedert, 
J.J., Kaslow, R., Buchbinder, S., Hoots, K., O’Brien, S.J. 1999. HLA and HIV-1: 
Heterozygote advantage and B*35-Cw*04disadvantage. Science. 283: 1748-1752. 
 
Champagne, P., Ogg, G.S., King, A.S., Knabenhans, C., Ellefsen, K., Nobile, M., 
Appay, V., Rizzardi, G.P., Fleury, S., Lipp, M., Förster, R., Rowland-Jones, S., 
Sékaly, R.P., McMichael, A.J., Pantaleo, G. 2001. Skewed maturation of memory 
HIV-specific CD8 T lymphocytes. Nature. 410: 106-11. 
 
Chattopadhyay, P.K., Price, D.A., Harper, T.F., Betts, M.R., Yu,  J., Gostick, E., 
Perfetto, S.P., Goepfert, P., Koup, R.A., De Rosa, S.C., Bruchez, M.P., Roederer, 
M. 2006. Quantum dot semiconductor nanocrystals forimmunophenotyping by 
polychromatic flow cytometry. Nature Medicine. 12: 972-977. 
 
Chesler, D.A., Reiss, C.S. 2002. The role of IFN-γ in immune responses to viral 
infections of the central nervous system. Cytokine & Growth Factor Reviews. 13: 
441–454. 
 
Chung, C., Lee, W., Loffredo, J.T., Burwitz, B., Friedrich, T.C., Vela, J.P.G., 
Napoe, G., Rakasz, E.G., Wilson, N.A. Allison, D.B., Watkins, D.I. 2007. Not all 
cytokine-producing CD8+ T cells suppress Simian Immunodeficiency Virus 
replication. Journal of Virology.  81: 1517–1523 
 
Ciuffreda, D., Comte, D., Cavassini, M., Giostra, E., Bühler, L., Perruchoud, M., 
Heim, M.H., Battegay, M., Genné, D., Mulhaupt, B., Malinverni, R., Oneta, C., 
Bernasconi, E., Monnat, M., Cerny, A., Chuard, C., Borovicka, J., Mentha, G., 
Pascual, M., Gonvers, J.J., Pantaleo, G., Dutoit, V. 2008. Polyfunctional HCV-
specific T-cell responses are associated with effective control of HCV replication. 
European Journal of Immunology. 38: 2665-2677. 
 
Clore, G.M., Gronenborn, A.M. 1995. Three dimensional structure of α and β 
chemokines. The Federation of American Societies for Experimental Biology. 9: 57-
62. 
 
Critchfield, J.W., Lemongello, D., Walker, D.H., Garcia, J.C., Asmuth, D.M., 
Pollard, R.B., Shacklett, B.L. 2007. Multifunctional Human Immunodeficiency 
Virus (HIV) Gag-specificCD8+ T-cell responses in rectal mucosa and peripheral blood 
mononuclear cells during chronic HIV type 1 infection. Journal of Virology. 81: 
5460–5471. 
 
Critchfield, J.W., Young, D.H., Hayes, T.L., Braun, J.V., Garcia, J.C., Pollard, 
R.B., Shacklett, B.L. 2008. Magnitude and complexity of rectal mucosa HIV-1-
specific CD8+ T-cell responses during chronic infection reflect clinical status. PLoS 












Darrah, P.A., Patel, D.T., De Luca, P.M., Lindsay, R.W.B., Davey, D.F., Flynn, 
B.J., Hoff , S.T., Andersen, P., Reed, S.G., Morris, S.L., Roederer, M., Seder, 
R.A. 2007. Multifunctional TH1 cells define a correlate of vaccinemediated 
protection against Leishmania major. Nature Medicine. 13: 843-850. 
 
Day, C.L.,  Kaufmann, D.E., Kiepiela, P., Brown, J.A., Moodley, E.S., Reddy, S., 
Mackey, E.W., Miller, J.D., Leslie, A.J., DePierres, C., Mncube, Z., Duraiswamy, 
J., Zhu, B., Eichbaum, Q., Altfeld, M., Wherry, E.J., Coovadia, H.M., Goulder, 
P.J.R., Klenerman, P., Ahmed, R., Freeman, G.J., Walker, B.D. 2006. PD-1 
expression on HIV-specific T cells is associated with T-cell exhaustion and disease 
progression. Nature. 443: 350:354 
 
Day, C.L., Kiepiela, P., Leslie, A.J., van der Stok, M., Nair, K., Ismail, N., 
Honeyborne, I., Crawford, H., Coovadia, H.M., Goulder, P.J.R., Walker, B.D., 
Klenerman, P. 2007. Proliferative capacity of epitope-specific CD8 T-cell responses 
is inversely related to viral load in chronic Human Immunodeficiency Virus type 1 
infection. Journal of Virology. 81: 434–438. 
 
Day, C.L., Mkhwanazi, N., Reddy, S., Mncube, Z., van der Stok, M., Klenerman, 
P., Walker, B.D. 2008. Detection of polyfunctional Mycobacterium tuberculosis-
specific T cells and association with viral load in HIV-1–infected persons. The 
Journal of Infectious Diseases.197: 990 –999. 
 
Dorak, M.T., Tang, J., Tang, S., Penman-Aguilar, A., Coutinho, R.A., Goedert, 
J.J., Detels, R., Kaslow, R.A. 2003. Influence of Human Leukocyte Antigen–B22 
alleles on the course of Human Immunodeficiency Virus Type 1 infection in 3 cohorts 
of white men. The Journal of Infectious Diseases. 188: 856–863. 
 
Douek, D.C., Brenchley, J.M., Betts, M.R., Ambrozak, D.R.,. Hill, B.J., 
Okamoto, Y., Casazza, J.P., Kuruppu, J., Kunstmank, K., Wolinsky, S., 
Grossman, Z., Dybul, M., Oxenius, A., Price, D.A., Connors, M., Koup. R.A. 
2002. HIV preferentially infects HIV-specific CD4+ T cells. Nature. 417: 95-98. 
 
Draenert, A., Altfeld, M., Brander, C., Basgoz, N., Corcoran, C., Wurcel, A.G., 
Stone, D.R., Kalams, S.A, Trocha, A., Addo, M.M., Goulder, P.J.R., Walker, 
B.D. 2003. Comparison of overlapping peptide sets for detection of antiviral CD8 and 
CD4 T cell responses. Journal of Immunological Methods. 275: 19– 29. 
 
Dunham, R.M., Cervasi, B., Brenchley, J.M., Albrecht, H., Weintrob, A., 
Sumpter, B., Engram, J., Gordon, S., Klatt, N.R., Frank, I., Sodora, D.L., Douek, 
D.C., Paiardini, M., Silvestri, G. 2007. CD127 and CD25 expression defines CD4+ T 
cell subsets that are differentially depleted during HIV infection. The Journal of 
Immunology.  180: 5582–5592. 
 
Dunne, P.J., Faint, J.M., Gudgeon, N.H., Fletcher, J.M., Plunkett, F.J., Soares, 
M.V.D., Hislop, A.D., Annels,  N.E., Rickinson, A.B., Salmon, M., Akbar, A.N. 
2002. Epstein-Barr virus-specific CD8+ T cells that re-express CD45RA are 












duPont, N.C., Wang, K., Wadhwa, P.D., Culhane, J.F., Nelson, E.L. 2005. 
Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: 
Determinations of a panel of nine cytokines in clinical sample culture supernatants. 
Journal of Reproductive Immunology. 66: 175–191 
 
Duvall, M.G, Precopio, M.L., Ambrozak, D.A., Jaye, A., McMichael, A.J., 
Whittle, H.C., Roederer, M., Rowland-Jones, S.L., Koup, R.A. 2008. 
Polyfunctional T cell responses are a hallmark of HIV-2 infection. European Journal 
of Immunology. 38: 350–363. 
 
Edwards B.H., Bansal, A., Sabbaj, S., Bakari, J., Mulligan, M.J., Goepfert,  P.A. 
2002. Magnitude of functional CD8+ T-cell responses to the Gag protein of Human 
Immunodeficiency Virus type 1 correlates inversely with viral load in plasma. Journal 
of Virology. 76: 2298–2305. 
 
Esser, M.T., Marchese, R.D., Kierstead, L.S., Tussey, L.G., Wang, F., Chirmule, 
N., Washabaugh, M.W. 2003. Memory T cells and vaccines. Vaccine. 21: 419–430. 
Fliesler, S.J., Basinger, S.F. 1987. Monensin stimulates glycerolipid incorporation 
into rod outer segment membranes. Journal of Biological Chemistry. 262: 17516-
7523.  
Flores-Villanueva, P., Hendel, H., Caillat-Zucman, S., Rappaport, J., Burgos-
Tiburcio, A., Bertin-Maghit, S., Ruiz-Morales, J.A., Teran, M.E., Rodriguez-
Tafur, J., Zagury, J. 2003. Associations of MHC ancestral haplotypes with 
resistance/susceptibility to AIDS disease development. The Journal of Immunology. 
170: 1925–1929. 
 
Foy, T. M., D. M. Shepherd, F. H. Durie, A. Aruffo, J. A. Ledbetter, and R. J. 
Noelle. 1993. In vivo CD40-gp39 interactions are essential for thymus-dependent 
humoral immunity. II. Prolonged suppression of the humoral immune response by an 
antibody to the ligand for CD40, gp39. Journal of Experimantal Medicine. 178:1567–
1575. 
 
Fuhrmann, S., Streitz, M., Reinke, P., Volk, H., Kern, F. 2008. T cell response to 
the Cytomegalovirus major capsid protein (UL86) is dominated by helper cells with a 
large polyfunctional component and diverse epitope recognition. The Journal of 
Infectious Diseases. 197: 1455– 1458. 
 
Fukuda, M. 1991. Lysosomal membrane glycoproteins. Structure, biosynthesis, and 
intracellular trafficking. The Journal of Biological Chemistry. 266: 21327-21330 
 
Gauduin, M., Kaur, A., Ahmad, S., Yilma, T., Lifson, J.D., Johnson, R.P. 2004. 
Optimization of intracellular cytokine staining for the quantitation of antigen-specific 
CD4+ T cell responses in rhesus macaques. Journal of Immunological Methods. 288: 
61– 79. 
 
Geldmacher, C., Currier, J.R., Herrmann, E., Haule, A., Kuta, E., McCutchan, 
F., Njovu, L., Geis, S., Hoffmann, O., Maboko, L., Williamson, C., Birx, D., 











epitopes within specific Gag regionsi associated with maintenance of a low steady-
state viremia in Human Immunodeficiency Virus Type 1-seropositive patients. 
Journal of Virology.  81: 2440–2448.  
 
Geldmacher, C., Gray, C., Nason, M., Currier, J.R., Haule, A., Njovu, L., Geis, 
S., Hoffmann, O., Maboko, L., Meyerhans, L., Cox, J., Hoelscher, M. 2007b. A 
high viral burden predicts the loss of CD8 T-cell responses specific for subdominant 
Gag epitopes during chronic Human Immunodeficiency Virus Infection. Journal of 
Virology. 81:13809–13815. 
 
Genesca`, M., Rourke, T., Li, J., Bost, K., Chohan, B., McChesney, M.B.,  Miller, 
C.J. 2007. Live attenuated lentivirus infection elicits polyfunctional Simian 
Immunodeficiency Virus Gag-specific CD8+ T cells with reduced apoptotic 
susceptibility in rhesus macaques that control virus replication after challenge with 
pathogenic SIVmac239. The Journal of Immunology. 179: 4732–4740. 
 
Gett, A.V., Hodgkin, P.D. 1998. Cell division regulates the T cell cytokine 
repertoire, revealing a mechanism underlying immune class regulation. Proceedings 
of  the National Academy of Sciences. 95: 9488–9493. 
 
Goonetilleke, N., Moore, S., Dally, L., Winstone, N., Cebere, I., Mahmoud, A., 
Pinheiro, S., Gillespie, G., Brown, D., Loach, V., Roberts, J., Guimaraes-Walker, 
A., Hayes, P., Loughran, K., Smith, C., De Bont, J., Verlinde, C., Vooijs, D., 
Schmidt, C., Boaz, M., Gilmour, J., Fast, P., Dorrell, L., Hanke, T., McMichael, 
A.J. 2006. Induction of multifunctional Human Immunodeficiency Virus type 1 
(HIV-1) specific T cells capable of proliferation in healthy subjects by using a prime-
boost Regimen of DNA- and modified Vaccinia virus ankara-vectored vaccines 
expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. Journal of Virology. 80: 
4717-4728. 
 
Goulder, P.J.R., Phillips, R.E., Colbert, R.A., McAdam, S., Ogg, G., Nowak, 
M.A., Giangrande, P., Luzzi, G., Morgan, B., Edwards, A., McMichael, A.J., 
Rowland-Jones, S. 1997. Late escape from an immunodominant cytotoxic T-
lymphocyte response associated with progression to AIDS. Nature. 3: 212-217. 
 
Goulder, P.J.R., Brander, C., Tang, Y,. Trembley, C,. Colbert, R.A.,. 
Addo, M.M., Rosenberg, E.S., Nguyen, T., Allen, R., Trocha, A., Altfeld, M.,; 
He, S., Bunce, M., Funkhouser, R., Pelton, S.I., Burchett, S.K., McIntosh, K., 
Korber, B.T.M., Walker, B.D. 2001. Evolution and transmission of stable CTL 
escape mutations in HIV infection. Nature. 412: 334-338. 
 
Gray, C.M., Mlotshwa, M., Riou, C., Mathebula, T., de Assis Rosa, D., Mashishi, 
T., Seoighe, C., Ngandu, N., van Loggerenberg, F., Morris, L., Mlisana, K., 
Williamson, C., Karim , A.S. on behalf of the CAPRISA 002 Acute Infection 
Study Team. 2008. HIV-specific IFNγ-ELISPOT responses targeting  specific 
regions of the proteome during primary subtype C infection are poor predictors of the 
course of viraemia and set point. Journal of Virology. 83: 470-478 
 
van Grevenynghe, J., Procopio, F.A., He, Z., Chomont, N., Riou, C., Zhang, Y., 











Trautmann, L.,El Far., M., Balderas, R.S., Boulassel, M. Routy, J., Haddad, 
E.K., Sekaly, R. 2008. Transcription factor FOXO3a controls the persistence of 
memory CD4+ T cells during HIV infection. Nature Medicine. 4: 266-274. 
 
Hamann, D., Baars, P.A., Rep, M.H.G., Hooibrink, B., Kerkhof-Garde, S.R., 
Klein, M.R., van Lier, R.A.W. 1997. Phenotypic and functional separation of 
memory and effector human CD8  T cells. Journal of Experimantal Medicine. 186: 
1407–1418. 
 
Harari, A., Petitpierre, S., Vallelian, F.,Pantaleo, G. 2004. Skewed representation 
of functionally distinct populations of virus-specific CD4 T cells in HIV-1–infected 
subjects with progressive disease: changes after antiretroviral therapy. Blood. 103: 
966-972. 
 
Harari, A., Cellerai, C., Enders, F.B., Ko¨ stler, J., Codarri, L., Tapia, G., 
Boyman, O., Castro, E., Gaudieri, S., James, I., John, M., Wagner, R., Mallal, S., 
Pantaleo G. 2008.  Skewed association of polyfunctional antigen-specific CD8+  T 
cell populations with HLA-B genotype. Proceedings of  the National Academy of 
Sciences. 104: 16233–16238. 
 
Harley, C.B., Futcher, A.B., Greider, C.W. 1990. Telomeres shorten during ageing 
of human fibroblasts. Nature. 345: 458-460. 
 
Hendel, H., Caillat-Zucman, S., Lebuanec, H., Carrington, M., O’Brien, S., 
Andrieu, J., Scha¨chter, F., Zagury, D., Rappaport, J., Winkler, C., Nelson, 
G.W., Zagury, J. 1999. New class I and II HLA alleles strongly associated with 
opposite patterns of progression to AIDS. The Journal of Immunology.162: 6942–
6946. 
 
Hickling, J.K. 1998. Measuring human T-lymphocyte function. Expert Reviews in 
Molecular Medicine. 1:1-20. 
 
Horton, H., Thomas, E.P., Stucky, J.A., Frank, I., Moodie, Z., Huang, Y., Chiu, 
Y., McElrath, M.J., De Rosa, S.C. 2007. Optimization and validation of an 8-color 
intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced 
by vaccination. Journal of Immunological Methods. 323: 39–54. 
 
Ishida, Y., Agata, Y., Shibahara, K., Honjo, T. 1992. Induced expression of PD-1, 
a novel member of the immunoglobulin gene superfamily, upon programmed cell 
death. The European Molecular Biology Organization Journal. 11: 3887 – 3895. 
 
Itescu, S., Rose, S., Dwyer, E., Winchester, R. 1994. Certain HLA-DR5 and -DR6 
major histocompatibility complex class II alleles are associated with a CD8 
lymphocytic host response to human immunodeficiency virus type 1 characterized by 
low lymphocyte viral strain heterogeneity and slow disease progression. Proceedings 
of  the National Academy of Sciences. 91:11472-11476. 
 
Iyasere, C., Tilton, J.C., Johnson, A.J., Younes, S.,Yassine-Diab, B.,Sekaly, R., 
Kwok, W.W., Migueles, S.A, Laborico, A.C., Shupert, W.L., Hallahan, C.W., 











proliferation of Human Immunodeficiency Virus-specific CD4+ T cells is associated 
with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2. 
Journal of Virology. 77: 10900–10909. 
 
Janssen, E.M., Lemmens, E.E., Wolfe, T., Christen, U., von Herrath, M.G., 
Schoenberger, S.P. 2003. CD4 T cells are required for secondary expansion and 
memory in CD8 T lymphocytes. Nature. 421: 852-856. 
 
Jenkinson, E.J., Kingston, R., Smith, C.A., Williams, G.T., Owen, J.J. 1989.    
Antigen-induced apoptosis in developing T cells: a mechanism for negative selection 
of the T cell receptor repertoire. European Journal of Immunology. 19: 175-177.    
 
Kalams, S.A., Buchbinder, S.B., Rosenberg, E.S., Billingsley, J.M., Colbert, D.S., 
Jones, N.G., Shea, A.K., Trocha, A.K., Walker, B.D. 1999. Association between 
virus-specific cytotoxic T-lymphocyte and helper responses in Human 
Immunodeficiency Virus type 1 infection. Journal of Immunology. 73: 6715–6720. 
 
Kannanganat, S., Ibegbu, C., Chennareddi, L., Robinson, H.L., Amara, R.R. 
2007a.  Multiple-cytokine-producing antiviral CD4 T cells are functionally superior 
to single-cytokine-producing cells. Journal of Virology. 81: 8468–8476. 
 
Kannanganat, S., Kapogiannis, B.G., Ibegbu, C., Chennareddi, L., Goepfert, P., 
Robinson, H.L., Lennox, J., Amara, R.R. 2007b. Human Immunodeficiency Virus 
Type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three 
cytokines. Journal of Virology. 81: 12071–12076. 
 
Karlsson, A.C., Martin, J.N., Younger, S.R., Bredt, B.M., Epling, L., Ronquillo, 
R., Varma, A., Deeks, S.G., McCune, J.M., Nixon, D.F., Sinclair, E. Comparison 
of the ELISPOT and cytokine flow c tometry assays for the enumeration of antigen-
specific T cells. Journal of Immunological Methods. 283: 141–153. 
 
Kaufmann, D.E., Bailey, P.M., Sidney, J., Wagner, B., Norris, P.J., Johnston, 
M.N.,Cosimi, LA., Addo, M.M., Lichterfeld, M., Altfeld, M.,  Frahm, N., 
Brander, C., Sette, A., Walker, B.D., Rosenberg, E.S. 2004. Comprehensive 
analysis of Human Immunodeficiency Virus Type1-specific CD4 responses reveals 
marked immunodominance of gag and nef and the presence of broadly recognized 
peptides. Journal of Virology. 78: 4463-4477. 
 
Kaufmann, D.E., Kavanagh, D.G., Pereyra, F., Zaunders, J.J., Mackey, E.W., 
Miura, T., Palmer, S., Brockman, M., Rathod, A., Piechocka-Trocha, A., Baker, 
B., Zhu, B., Le Gall, S., Waring, M.T., Ahern, R., Moss, K., Kelleher, A.D., 
Coffin, J.M., Freeman, G.J., Rosenberg, E.S., Walker, B.D. 2007. Upregulation of 
CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and 
defines a reversible immune dysfunction. Nature Immunology. 8: 1246-54.  
 
Kawanishi, H., Joseph, K. 1992. Effects of phorbol myristate and ionomycin on in 
vitro growth of aged Peyer's patch T and B cells. Mechanism of Ageing and 












Kiepiela, P., Ngumbela1, K., Thobakgale, C., Ramduth, D., Honeyborne, I., 
Moodley, E., Reddy, S., de Pierres, C., Mncube, Z., Mkhwanazi, N., Bishop, K., 
van der Stok, M., Nair, K., Khan, N., Crawford, H., Payne, R., Leslie, A., Prado, 
J., Prendergast, A., Frater, J., McCarthy, N., Brander, C., Learn, G.H., Nickle, 
D., Rousseau, C., Coovadia, H., Mullins, J.I., Heckerman, D., Walker, B.D., 
Goulder, P. 2007. CD8+ T-cell responses to different HIV proteins have discordant 
associations with viral load. Nature Medicine. 13: 46-53. 
 
Kimberlin, D.W., Spector, S.A., Hill, E.L., Biron, K.K., Hay, A.L., Mayers, D.L., 
Whitley, R.J. 1995. Assays for antiviral drug resistance. Antiviral Research. 26: 403-
413. 
 
Klausner, R.D., Donaldson, J.G., Schwartz, J.L. 1992. Brefeldin A: Insights into 
the control of membrane traffic and organelle structure. The Journal of Cell Biology, 
116:1071-1080. 
 
Koup, R.A., Safrit, J.T., Cao, Y., Andrews, C.A., McLeod, G., BorkowskyY, W., 
Farthing, C., Ho, D.D. 1994. Temporal association of cellular immune responses 
with the initial control of viremia in primary Human Immunodeficiency Virus type 1 
syndrome. Journal of Virology. 68: 4650-4655. 
 
Krensky, A.M., Clayberger, C. 2005. Granulysin: A novel host defense molecule. 
American Journal of Transplantation. 5: 1789–1792. 
 
Kuerten, S., Nowacki, T.M., Kleen, T.O., Asaad, R.J., Lehmann, P.V., Tary-
Lehmann, M. 2008. Dissociated production of perforin, granzyme B, and IFN-γ by 
HIV-specific CD8+ cells in HIV infection. AIDS Research and Human Retroviruses. 
24: 62-71. 
 
Ladell, K., Hellerstein, M.K., Cesar, D., Busch, R., Boban, D., McCune, J.M. 
2008.  Central memory CD8+ T cells appear to have a shorter lifespan and reduced 
abundance as a function of HIV disease progression. The Journal of Immunology. 
180: 7907–7918. 
 
Lamoreaux, L., Roederer, M., Koup, R. 2006. Intracellular cytokine optimization 
and standard operating procedure. Nature protocols. 3: 1507-1516.  
 
Leslie, A.J., Pfafferott, K.J., Chetty, P. l. Dreanert, R., Addo. M.M., Feeney, M., 
Tang, Y.,  Holmes, E.C., Allen, T., Prado, J.G., Altfeld, M., Brander, C., Dixon, 
C., Ramduth, D.,  Jeena, P.,  Thomas, S.A., St John, A., Roach, TA., Kupfer, B., 
Luzzi, G.,  Edwards, A.,  Taylor, G., Lyall, H.,  Tudor-Williams, G., Novelli, V.,  
Martinez-Picado, J., Kiepiela, P., Walker, B.D., Goulder, P.J.R., 2004. HIV 
evolution: CTL escape mutation and reversion after transmission. Nature Medecine. 
10: 282-289. 
 
Letvin, N.L. 2005. Progress toward an HIV vaccine. Annual Review of Medicine.  56: 
213–23. 
 
Letvin, N.L., Mascola, J.R., Sun, Y., Gorgone, D.A., Buzby, A.P., Xu, L., Yang, 











Bookstein, F.L., Nabel, G.J. 2006. Preserved CD4+ central memory T cells and 
survival in vaccinated SIV-challenged monkeys. Science. 312- 1530-1533. 
 
Lichterfeld, M., Kaufmann, D.E., Yu, X.G., Mui, S.K., Addo, M.M., Johnston, 
M.N., Cohen, D., Robbins, G.K., Pae, E., Alter, G., Wurcel, A., Stone, D., 
Rosenberg, E.S., Walker, B.D., Altfeld, M. 2004. Loss of HIV-1–specific CD8 T 
cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-
1-specific CD4 T cells. The Journal of Experimental Medicine. 200: 701–712. 
 
Li, C.K., Wu, H., Yan, H., Ma, S., Wang, L., Zhang, M., Tang, X., Temperton, 
N.J., Weiss, R.A., Brenchley, J.M., Douek, D.C., Mongkolsapaya, J., Tran, B., 
Lin, C.S., Screaton, G.R., Hou, J., McMichael, A.J., Xu, X. 2008. T Cell 
Responses to Whole SARS Coronavirus in Humans. The Journal of Immunology. 181: 
5490–5500. 
 
Ling, B.,Veazey, R.S.,Hart,  M., Lackner, A.A., Kuroda, M., Pahar, B., Marx, 
P.A. 2007. Early restoration of mucosal CD4 memory CCR5 T cells in the gut of 
SIV-infected rhesus predicts long term non-progression. AIDS. 21:2377–2385. 
 
Luton, F., Buferne, M., Davoust, J., Schmitt-Verhulst, A., Boyer, C. 1994. 
Evidence for protein tyrosine kinase involvement in ligand-induced TCR/CD3 
internalization and surface redistribution. The Journal of Immunology. 153: 63-72. 
 
Ma, A., Koka, R., Burkett, P. 2006. Diverse Functions of IL-2, IL-15, and IL-7 in 
Lymphoid Homeostasis. The Annual Review of Immunology. 24: 657–679. 
 
MacDonald, K.S., Fowke, K.I., Kimani, J., Dunand, V.A., Nagelkerke, N.J.D., 
Ball, T.B., Oyugi, J., Njagi, E., Gaur, L.K., Brunham, R.C., Wade, J., Luscher, 
M.A., Krausa, P., Rowland-Jones, S., Ngugi, E., Bwayo, J.J., Plummer, F.A. 
2000. Influence of HLA supertypes on susceptibility and resistance to Human 
Immunodeficiency Virus Type 1 infection. The Journal of Infectious Diseases. 
181:1581–1589. 
 
Maino, V.C., Maecker, H.T. 2004. Cytokine flow cytometry: a multiparametric 
approach for assessing cellular immune responses to viral antigens. Clinical 
Immunology. 110: 222-231. 
 
Manrique, M., Micewicz, E., Kozlowski, P.A., Wang, S., Aurora, D., Wilson, 
R.L., Ghebremichael, M., Mazzara, G., Montefiori, D., Carville, A., Mansfield, 
K.G., Aldovini, A. 2008. DNA-MVA vaccine protection after X4 SHIV challenge in 
macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity 
levels and postchallenge preservation of CD4+ T cell memory. AIDS Research and 
Human Retroviruses. 24: 505- 519. 
 
Masemola, A., Mashishi, T., Khoury, G., Mohube, P.,Mokgotho, P., Vardas, E., 
Colvin, M., Zijenah, L., Katzenstein, D., Musonda, R., Allen, S., Kumwenda, N., 
Taha, T., Gray, G., McIntyre, J., Karim, S.A., Sheppard, H.W. Gray, C.M., 
HIVNET 028 Study Team. 2004. Hierarchical Targeting of subtype C Human 
Immunodeficiency Virus type 1 proteins by CD8+ T cells: correlation with viral load 











Mattapallil, J.J., Douek, D.C., Buckler-White, A., Montefiori, D., Letvin, N.L., 
Nabel, G.J., Roederer, M. 2006. Vaccination preserves CD4 memory T cells during 
acute simian immunodeficiency virus challenge. The Journal of Experimental 
Medicine. 203: 1533–1541 
McGukin, C., Jurga, M., Ali, H., Strbad, M., Forraz. 2008. Culture of embryonic-
like stem cells from human umbilical cord blood and onward differentiation to neural 
cells in vitro. Nature Protocols. 3: 1046-1055. 
 
McNeil, A.C., Shupert, W.L., Iyasere, C.A., Hallahan, C.W., Mican, J., Davey, 
R.T., Connors, M. 2001. High-level HIV-1 viremia suppresses viral antigen-specific 
CD4+ T cell proliferation. Proceedings of  the National Academy of Sciences. 98: 
13878–13883. 
 
Melby, P.C., 2002. Recent developments in leishmaniasis. Current Opinion in 
Infectious Diseases. 15: 485-490. 
 
Michie, C.A., McLean, A., Alcock, C., Beverley, P.C.L. 1992.  Lifespan of human 
lymphocyte subsets defined by CD45 iso-forms. Nature. 360: 264–265. 
 
Migueles, S.A., Laborico, A.C., Shubert, W.L., Sabbaghian, M.S., Rabin, R., 
Hallahan, C.W., Van Baarle, D., Kontense, S., Miedema, F., McLaughlin, M., 
Ehler, L., Metcalf, J., Liu, S., Connors, M. 2002. HIV-1-specific CD8 T cell 
proliferation is coupled to perforin expression and is maintained in nonprogressers. 
Nature Immunology. 3: 1061-1068. 
 
Norris, P.J., Moffett, H.F., Yang, O.O., Kaufmann, D.E., Clark, M.J., Addo, 
M.M., Rosenberg, E.S. 2004. Beyond help: Direct effector functions of Human 
Immunodeficiency Virus type 1-specific CD4+ T cells. Journal of Virology. 78: 8844–
8851. 
 
Northfield, J.W., Loo, C.P., Barbour, J.D., Spotts, G., Hecht, F.M., Klenerman, 
P., Nixon, D.F., Michaëlsson, J. 2007. Human immunodeficiency virus type 1 (HIV-
1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 
viremia and predict the subsequent viral load set point. Journal of Virology. 81:5759-
65.  
 
O’Neil-Andersen, N.J., Lawrence, D.A. 2002. Differential Modulation of Surface 
and Intracellular Protein Expression by T Cells after Stimulation in the Presence of 
Monensin or Brefeldin A. Clinical and Diagnostic Laboratory Immunology. 9: 243–
250. 
 
Owen, R.E., Sinclair, E., Emu, B., Heitman, J.W., Hirschkorn, D.F., Epling, C.L., 
Tan, Q.X., Custer, B., Harris, J.M., Jacobson, M.A., McCune, J.M., Martin, J.N., 
Hecht, F.M., Deeks, S.G., Norris, P.J. 2007. Loss of T cell responses following 
long-term cryopreservation. The Journal of Immunological Methods. 326: 93-115. 
 
Palmer, B.E., Boritz, E., Blyveis, N., Wilson, C.C. 2002. Discordance between 
frequency of Human Immunodeficiency Virus type 1 (HIV-1)-specific gamma 











infected subjects with active viral replication. The Journal of Immunology .76: 5925–
5936. 
 
Papagno, L., Spina, C.A., Marchant, A., Salio, M., Rufer, N., Little, S., Dong, T., 
Chesney, G., Waters, A., Easterbrook, P., Dunbar, P.R., Shepherd, D., 
Cerundolo, V., Emery, V., Griffiths, P., Conlon, C., McMichael, A.J., Richman, 
D.D., Rowland-Jones, S.A, Appay, V. 2004. Immune activation and CD8+ T-cell 
differentiation towards senescence in HIV-1 infection. PLoS Biology. 2: 173- 185. 
 
Pelchen-Matthews, A., Parsons, I.J., Marsh, M. 1993. Phorbol Ester-induced 
downregulation of CD4 is a multistep process involving dissociation from p56lck, 
increased association with clathrin-coated pits, and altered endosomal sorting. Journal 
of Experimental Medicine. 178: 1209-1222. 
 
Perfetto, S.P., Chattopadhyay, P.K., Roederer, M. 2004. Seventeen-colour flow 
cytometry: unravelling the immune system. Nature Reviews. 4: 648-655. 
 
Perfetto, S.P., Chattopadhyay, P.K., Lamoreaux, L., Nguyen, R., Ambrozak, D., 
Koup, R.A., Roederer, M. 2006. Amine reactive dyes: An effective tool to 
discriminate live and dead cells in polychromatic flow cytometry. Journal of 
Immunological Methods. 313: 199–208. 
 
Perfetto SP, Roederer M. 2007. Increased immunofluorescence sensitivity using 532 
nm laser excitation. Cytometry A.71: 73–9. 
 
Peters, P.J., Borst, J., Oorschot, V., Fukuda, M., Krahenbuhl, O., Tschopp, J., 
Slot, J.W., Geuze, H.J. 1991. Cytotoxic T lymphocyte granules are secretory 
lysosomes, containing both perforin and granzymes. Journal of Immunological 
Experimental Biology. 173: 1099-1109. 
 
Picker, L.J., Singh, M.K., Zdraveski, Z., Treer, J.R., Waldrop, S.L., 
Bergstresser, P.R., Maino, V.C. 1995. Direct demonstration of cytokine synthesis 
heterogeneity among human memory/effector T cells by flow cytometry. Blood. 86: 
1408-1419. 
 
Potter, S.J., Lacabaratz, C., Lambotte, O., Perez-Patrigeon, S., Vingert, B., Sinet, 
M., Colle, J., Urrutia, A., Scott-Algara, D., Boufassa, F., Delfraissy, J., The`ze, J., 
Venet, A., Chakrabarti, L.A. 2008. Preserved Central Memory and Activated 
effector memory CD4+ T-cell subsets in Human Immunodeficiency Virus controllers: 
an ANRS EP36 study. Journal of Virology. 81: 13904–13915. 
 
Precopio, M.L., Betts, M.R., Parrino, J., Price, D.A., Gostick, E., Ambrozak, 
D.R., Asher, T.E., Douek, D.C., Harari, A., Pantaleo, G., Bailer, R., Graham, 
B.S., Roederer, M., Koup, R.A. 2007. Immunization with vaccinia virus induces 
polyfunctional and phenotypically distinctive CD8+ T cell responses. The Journal of 
Experimental Medicine. 204: 1405–1416. 
 
Ramduth, D., Chetty, P., Mngquandaniso, N.C., Nene,N., Harlow, J.D., 
Honeyborne, I., Ntumba, N., Gappoo, S., Henry, C., Jeena, P., Addo, M.M., 











Walker, B. 2005. Differential immunogenicity of HIV-1 clade C proteins in eliciting 
CD8+ and CD4+ cell responses. The Journal of Infectious Diseases. 192: 1588–1596. 
 
Rehr, M., Cahenzli, J., Haas, A., Price, D.A., Gostick, E., Huber, M., Karrer, U., 
Oxenius, A. 2008. Emergence of polyfunctional CD8+ T cells after prolonged 
suppression of Human Immunodeficiency Virus replication  by antiretroviral therapy. 
Journal of Virology. 82: 3391–3404 
 
Rosenberg, E.S., Billingsley, J.M., Caliendo, A.M., Boswell, S.L., Sax, P.E., 
Kalams, S.A., Walker, B.D. 1997. Vigorous HIV-1–specific CD4 T cell responses 
associated with control of viremia. Science. 278: 1447-1450. 
 
Sabbaj, S., Heath, S.L., Bansal, A., Vohra, S., Kilby, J.M., Zajac, A.J., Goepfert, 
P.A. 2007. Functionally competent antigen-specific CD127hi memory CD8+ T cells 
are preserved only in HIV-infected individuals receiving early treatment. The Journal 
of Infectious Diseases. 195: 108–117. 
 
Sadagopal, S., Amara, R.R., Montefiori, D.C., Wyatt, L.S., Staprans, S.I., Kozyr, 
N.L., McClure, H.M., Moss, B., Robinson1, H.L. 2005. Signature for long-term 
vaccine-mediated control of a Simian and Human Immunodeficiency Virus 89.6P 
challenge: Stable low-breadth and low-frequency T-cell response capable of 
coproducing gamma interferon and interleukin-2. The Journal of Virology. 79: 3243–
3253. 
 
Sallusto, F., Lenig, D., Fo¨ rster, R., Lipp, M., Lanzavecchia, A. Two subsets of 
memory T lymphocytes with distinct homing potentials and effector functions. 
Nature. 401: 708-712. 
 
Sandberg, J.K., Fast, N.M., Nixon, D.F. 2001. Functional heterogeneity of 
cytokines and cytolytic effector molecules in human CD8+ T lymphocytes. The 
Journal of Immunology. 167: 181–187. 
 
Schmitz, J.E., Kuroda, M.J., Santra, S., Sasseville, V.G., Simon, M.A., Lifton, 
M.A., Racz, P., Tenner-Racz, K., Dalesandro, M., Scallon, B.J., Ghrayeb, J., 
Forman, M.A., Montefori, D.C., Rieber, E.B., Letvin, N.L. Reimann, K.A. 1999. 
Control of viremia in Simian ImmunodeÞciency Virus infection by CD8+ 
lymphocytes. Science. 283: 857-860. 
 
Schroder, K., Hertzog, P.J., Ravasi, T., Hume, D.A. Interferon-γ: an overview of 
signals, mechanisms and functions. Journal of Leukocyte Biology. 75: 163–189. 
Shacklett, B.R., Yang, O., Hausner, M.A., Elliott, J., Hultin, L., Price, C., Fuerst, 
M., Matud, J., Hultin, P., Cox, C., Ibarrondo, J., Wong, J.T., Nixon, D.F., Anton, 
P.A., Jamieson, B.D. 2003. Optimization of methods to assess human mucosal T-cell 
responses to HIV infection.  Journal of Immunological Methods. 279: 17-31. 
Shedlock, D.J., Shen, H. 2003. Requirement for CD4 T cell help in generating 












Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. 
2002. CD4 T cell depletion is linked directly to immune activation in the pathogenesis 
of HIV-1 and HIV-2 but only indirectly to the viral load. Journal of Immunology. 169: 
3400-3406. 
 
Starr, E., Sarr, M., Campbell, D.E., Wilson, C.M., Douglous S.D. 2002. Increased 
proliferation within T lymphocyte subsets of HIV-infected adolescents. AIDS 
Research and human retroviruses. 18: 1301–1310. 
 
Streeck, H., Brumme1, Z.L., Anastario, M., Cohen, K.W., Jolin, J.S., Meier, A., 
Brumme1, C.J., Rosenberg, E.S., Alter, G., Allen, T.M., Walker, B.D., Altfeld, 
M. 2008. Antigen load and viral sequence diversification determine the functional 
profile of HIV-1–specific CD8+ T cells. PLoS Medicine. 5: 1-15. 
 
Sun, J.C., Williams, M.A., Bevan, M.J. 2004. CD4+ T cells are required for the 
maintenance, not programming of CD8+ T-cells after acute infection. Nature 
Immunology. 5: 927-933.   
 
Sun, Y., Schmitz, J.E., Acierno, P.M., Santra, S., Subbramanian, R.A., Barouch, 
D.H., Gorgone, D.A., Lifton, M.A., Beaudry, K.R., Manson, K., Philippon, V., 
Xu, L., Maecker, H.T., Mascola, J.R., Panicali, D., Nabel, G.J., Letvin, N.L. 2005. 
Dysfunction of Simian Immunodeficiency Virus/Simian Human Immunodeficiency 
Virus-induced IL-2 expression by central memory CD4+ T lymphocytes. The Journal 
of Immunology. 174: 4753–4760. 
 
Sun, Y., Santra, S., Schmitz, J.E., Roederer, M., Letvin, N.L. 2008. Magnitude 
and quality of vaccine-elicited T cell responses in the control of Immunodeficiency 
Virus replication in rhesus monkeys. Journal of Virology. 82: 8812-8819. 
 
Suni, M.A., Picker, L.J., Maino, V.C. 1998. Detection of antigen-specific T cell 
cytokine expression in whole blood by flow cytometry. Journal of Immunological 
Methods. 212: 89-98. 
 
Suni, M.A., Maino, V.C., Maecker, H.T. 2005. Ex vivo analysis of T-cell function. 
Current Opinion in Immunology. 17: 434–440. 
 
Tang, J., Tang, S., Lobashevsky, E., Myracle, A.D., Fideli, U., Aldrovandi, G., 
Allen, S., Musonda, R., Kaslow, R.A., Zambia-UAB HIV Research Project. 2002. 
Favorable and unfavorable HLA Class I alleles and haplotypes in Zambians 
predominantly infected with clade C Human Immunodeficiency Virus Type 1. 
Journal of Virology. 76: 8276–8284.  
 
Tilton, J.C., Luskin, M. R., Johnson, A. J., Manion, M., Hallahan, C. W., 
Metcalf, J.A.,  McLaughlin, M.,  Davey, R.T., Connors, M. 2007. Changes in 
paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine 
secretion of Human Immunodeficiency Virus-Specific CD4 T cells are a consequence 












Touraine, J., Hadden, J.W., Touraine, F., Hadden, E.M., Estensen, R., Good, 
R.A. 1977. Phorbol myristate acetate: a mitogen selective for a T-lymphocyte 
subpopulation. The Journal of Experimental Medicine. 145: 460-465.  
 
Trautmann, L., Janbazian, L., Chomont, N., Said , E.A., Gimmig, S., Bessette, B., 
Boulassel, M., Delwart, E., Sepulveda, H., Balderas, R.S., Routy, J., Haddad, 
E.K., Sekaly, R. 2006. Upregulation of PD-1 expression on HIV-specific CD8+ T 
cells leads to reversible immune dysfunction. Nature Medicine. 12: 1198: 1202. 
 
Trigona, W.L., Clair, J.H., Persaud, N., Punt, K., Bachinsky, M., Sadasivan-
Nai,r U., Dubey, S., Tussey, L., Fu, T.M,, Shiver, J. 2003. Intracellular staining for 
HIV-specific IFN-gamma production: statistical analyses establish reproducibility and 
criteria for distinguishing positive responses. Journal of Interferon Cytokine 
Research. 23: 369-377. 
 
Udagawa, T., Woodside, D.G., Mclntyre, B.W. 1996. α4β1 (CD49d/CD29) lntegrin 
costimulation of human T cells enhances transcription factor and cytokine induction 
in the absence of altered sensitivity to anti-CD3 stimulation. The Journal of 
Immunology. 157: 1965-1972. 
 
Veenstra,  H., Crous, I., Brahmbhatt, S., Lukey, P., Beyers, N., van Helden, P.D., 
Walzl, G. 2007. Changes in the kinetics of intracellular IFN-γ production in TB 
patients during treatment. Clinical Immunology. 124: 336–344. 
 
Younes, S.A., Diab, B.Y., Dumont, A.R., Boulassel, M.R., Grossman, Z., Routy, 
J.P., Sékaly, R.P. 2003. HIV-1 viremia prevents the establishment of interleukin 2–
producing HIV-specific memory CD4+T cells endowed with proliferative capacity. 
The Journal of Experimental Medicine. 198: 1909–1922. 
 
Waldrop, S.L., Pitcher, C.J., Peterson, D.M., Maino, V.C., Picker, L.J. 1997. 
Determination of antigen-specific memory/effector CD4 T cell frequencies by flow 
cytometry. Evidence for a novel, antigen-specific homeostatic mechanism in HIV-
associated Immunodeficiency. Journal of Clinical Investigations. 99: 1739–1750. 
 
Way, H.J. I969. Enhancement of Encephalomyocarditis Plaques by Saponin. Journal 
of General Virology. 5: 57-559. 
 
Wherry, E.J., Ahmed, R. 2004. Memory CD8 T-cell differentiation during viral 
infection.  Journal of Virology. 78: 5535–5545. 
 
Wherry , E.J., Day, C.L., Draenert, R., Miller, J.D., Kiepiela, P., Woodberry, T., 
Brander, C., Addo, M., Klenerman, P., Ahmed, R., Walker, B.D. 2006. HIV- 
specific CD8 T cells express low levels of IL-7Rα: Implications for HIV-specific T 
cell memory. Virology. 353: 366–373. 
 
Williamson, C., Morris, L., Maughan, M.F., Ping, L., Dryga, S.A., Thomas, R., 
Reap, E.A.., Cilliers, T., van Harmelen, J., Pascual, A., Ramjee, G., Gray, G., 
Johnston, R., Karim, S.A., Swanstrom, R. 2003. Characterization and selection of 













Zheng, C.F., Ma, L.L., Jones, G.J., Gill, M.J., Krensky, A.M., Kubes, P., Mody, 
C.H. 2007. Cytotoxic CD4+ T cells use granulysin to kill Cryptococcus neoformans, 
and activation of this pathway is defective in HIV patients. Blood. 109: 2049-2067. 
 
Zuniga, R., Lucchetti, A., Galvan, P., Sanchez, S., Sanchez, C., Hernandez, A., 
Sanchez, H., Frahm, N., Linde, C.H., Hewitt, H.S., Hildebrand, W., Altfeld, M., 
Allen, T.M., Walker, B.D., Korber, B.T., Leitner, T., Sanchez, J., Brander, C. 
2006. Relative Dominance of Gag p24-specific cytotoxic T lymphocytes ss associated 












Preparation and storage of reagents 
 
 
DNAse (Roche Diagnostics) 
Working stocks of 0.2 μg/ml (500 μl) in R1 were stored at -20 °C. A 1:10 dilution 
was made with 4.5 ml R1 and 500 μl of this dilution was added to each sample. 
 
Brefeldin A (Sigma Aldrich) 
Stock solutions of 5 μg/ml were prepared with 100 % ethanol and stored at -20 °C. 
These were further diluted 1:10 with PBS for use at final concentration of 0.5 μg/ml. 
 
Monensin (Sigma Aldrich) 
10 mg/ml stocks were prepared with 100 % ethanol and stored at -20 °C. It was used 
at a final concentration of 10 μg/ml. 
  
Phorbol Myristate Acetate (PMA) (Sigma Aldrich) 
0.1 mg/ml stocks of PMA were prepared with DMSO and stored at -20 °C. A 1:100 
dilution was made with PBS for a final concentration of 1 μg/ml. 
 
Ionomycin (Sigma Aldrich) 
5 μg/ml stocks of ionomycin were prepared with 100 % ethanol and stored at -20 °C. 
A 1:10 dilution with PBS was made for a final concentration of 0.5 μg/ml. 
 
Staphylococcal enterotoxin B (SEB) 
0.5 mg/ml aliquots in PBS were stored at -80 °C. An aliquot was further diluted 1:10 
using PBS to make 50 μg/ml working stocks and stored at 4°C. 
 
Violet viability reactive dye (Invitrogen) 
50 μl of DMSO was added to a vial of Violet viability reactive dye (25 μg/ml), which 
was stored at -20 °C. This was further diluted in a 1:40 dilution with dH2O, and 2.5 μl 
of this dilution was used to stain samples, as determined by a titration. 
 
Polymer Amine Beads (Bangs Laboratories) 
Beads were diluted to a final concentration of 40 X 106 beads/ml with PBS and stored 
at 4 °C. 40 μl of this stock was used for compensation. 
 
Perm/Wash Buffer (BD Biosciences) 
A 1:10 dilution was prepared with dH2O to make a 1 X stock solution and stored at 4 
°C, with a shelf life of 3 weeks. 
 
CellFIX (BD Biosciences) 
A 1:10 dilution with dH20 (1X stock) was prepared and stored at 4 ºC, with a shelf life 
of 1 month. 
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